NZ791720A - Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers - Google Patents
Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancersInfo
- Publication number
- NZ791720A NZ791720A NZ791720A NZ79172017A NZ791720A NZ 791720 A NZ791720 A NZ 791720A NZ 791720 A NZ791720 A NZ 791720A NZ 79172017 A NZ79172017 A NZ 79172017A NZ 791720 A NZ791720 A NZ 791720A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- peptide
- cell
- peptides
- cells
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 172
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 172
- 201000011510 cancer Diseases 0.000 title claims abstract description 154
- 238000009169 immunotherapy Methods 0.000 title abstract description 12
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 title description 30
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 title description 30
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 title description 30
- 210000004027 cells Anatomy 0.000 claims abstract description 277
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 142
- 102000004965 antibodies Human genes 0.000 claims abstract description 128
- 108090001123 antibodies Proteins 0.000 claims abstract description 128
- 108091008153 T cell receptors Proteins 0.000 claims abstract description 122
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 122
- 210000001744 T-Lymphocytes Anatomy 0.000 claims abstract description 111
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims abstract description 103
- 230000027455 binding Effects 0.000 claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 46
- 229960005486 vaccines Drugs 0.000 claims abstract description 32
- 230000014509 gene expression Effects 0.000 claims description 161
- 239000000427 antigen Substances 0.000 claims description 74
- 108091007172 antigens Proteins 0.000 claims description 72
- 102000038129 antigens Human genes 0.000 claims description 72
- 241000282414 Homo sapiens Species 0.000 claims description 70
- 210000001519 tissues Anatomy 0.000 claims description 65
- 206010006187 Breast cancer Diseases 0.000 claims description 63
- 150000001413 amino acids Chemical class 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 52
- 239000011780 sodium chloride Substances 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 40
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 39
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 201000004101 esophageal cancer Diseases 0.000 claims description 33
- 201000001441 melanoma Diseases 0.000 claims description 33
- 206010025650 Malignant melanoma Diseases 0.000 claims description 32
- 206010060862 Prostate cancer Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 206010046766 Uterine cancer Diseases 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 25
- 230000000240 adjuvant Effects 0.000 claims description 25
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims description 24
- 201000011231 colorectal cancer Diseases 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 23
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 22
- 201000009030 carcinoma Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 229920002395 Aptamer Polymers 0.000 claims description 20
- 206010004593 Bile duct cancer Diseases 0.000 claims description 20
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 20
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 206010017758 Gastric cancer Diseases 0.000 claims description 18
- 201000010175 gallbladder cancer Diseases 0.000 claims description 18
- 201000011549 stomach cancer Diseases 0.000 claims description 18
- -1 or dy Proteins 0.000 claims description 17
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 15
- 230000002018 overexpression Effects 0.000 claims description 15
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 14
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 14
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 13
- 230000000875 corresponding Effects 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 201000005216 brain cancer Diseases 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 102000037240 fusion proteins Human genes 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 8
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 8
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 229940035295 Ting Drugs 0.000 claims description 6
- 231100000765 Toxin Toxicity 0.000 claims description 6
- 238000004166 bioassay Methods 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 108020003112 toxins Proteins 0.000 claims description 6
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 5
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 5
- 108010028930 invariant chain Proteins 0.000 claims description 5
- 230000002147 killing Effects 0.000 claims description 5
- 238000002659 cell therapy Methods 0.000 claims description 4
- 239000001963 growth media Substances 0.000 claims description 4
- 230000003211 malignant Effects 0.000 claims description 4
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 3
- 230000001413 cellular Effects 0.000 claims description 3
- 239000000568 immunological adjuvant Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000001571 immunoadjuvant Effects 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241001446467 Mama Species 0.000 claims 3
- 235000013601 eggs Nutrition 0.000 claims 3
- 238000010195 expression analysis Methods 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 101700045658 A332 Proteins 0.000 claims 1
- 241000270311 Crocodylus niloticus Species 0.000 claims 1
- 235000002723 Dioscorea alata Nutrition 0.000 claims 1
- 235000007056 Dioscorea composita Nutrition 0.000 claims 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 claims 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 claims 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 claims 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 claims 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 claims 1
- 240000005760 Dioscorea villosa Species 0.000 claims 1
- 241000271571 Dromaius novaehollandiae Species 0.000 claims 1
- 210000004693 NK cell Anatomy 0.000 claims 1
- 206010038776 Retching Diseases 0.000 claims 1
- 240000005499 Sasa Species 0.000 claims 1
- 235000006350 apichu Nutrition 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 235000004879 dioscorea Nutrition 0.000 claims 1
- 101700022472 egg-6 Proteins 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 102000014187 peptide receptors Human genes 0.000 claims 1
- 108010011903 peptide receptors Proteins 0.000 claims 1
- 239000001415 potassium malate Substances 0.000 claims 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 24
- 230000000259 anti-tumor Effects 0.000 abstract description 11
- 230000001024 immunotherapeutic Effects 0.000 abstract description 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 230000001105 regulatory Effects 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 53
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 43
- 150000002500 ions Chemical class 0.000 description 43
- 235000002639 sodium chloride Nutrition 0.000 description 40
- 230000004083 survival Effects 0.000 description 31
- 239000003550 marker Substances 0.000 description 28
- 102100008616 G3BP1 Human genes 0.000 description 25
- 101700081169 G3BP1 Proteins 0.000 description 25
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 25
- 102100008644 KRT6A Human genes 0.000 description 25
- 101710017745 KRT6A Proteins 0.000 description 25
- 102100004653 LGALS7 Human genes 0.000 description 24
- 101710015839 LGALS7B Proteins 0.000 description 24
- 206010027476 Metastasis Diseases 0.000 description 24
- 210000004881 tumor cells Anatomy 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 102100008641 KRT5 Human genes 0.000 description 20
- 101710005529 KRT5 Proteins 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 102100019730 TP53 Human genes 0.000 description 18
- 101710026335 TP53 Proteins 0.000 description 18
- 230000001965 increased Effects 0.000 description 18
- 206010033128 Ovarian cancer Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000004048 modification Effects 0.000 description 17
- 238000006011 modification reaction Methods 0.000 description 17
- 230000002829 reduced Effects 0.000 description 17
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000002596 correlated Effects 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 16
- 229920000023 polynucleotide Polymers 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 210000003128 Head Anatomy 0.000 description 15
- 101710005525 KRT1 Proteins 0.000 description 15
- 102100019501 KRT1 Human genes 0.000 description 15
- 210000004072 Lung Anatomy 0.000 description 15
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 206010005003 Bladder cancer Diseases 0.000 description 14
- 101700011770 PDK1 Proteins 0.000 description 14
- 102100012905 PKP1 Human genes 0.000 description 14
- 101700050742 PKP1 Proteins 0.000 description 14
- 101700049386 PKP2 Proteins 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 14
- 230000011664 signaling Effects 0.000 description 14
- 102100005705 CDH15 Human genes 0.000 description 13
- 101710032686 CDH15 Proteins 0.000 description 13
- 101710035601 CDH3 Proteins 0.000 description 13
- 102100012342 CLCA2 Human genes 0.000 description 13
- 101700083678 CLCA2 Proteins 0.000 description 13
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 description 13
- 102100019269 KRT15 Human genes 0.000 description 13
- 101710026208 KRT15 Proteins 0.000 description 13
- 102100001769 LAP3 Human genes 0.000 description 13
- 101700065453 LAP3 Proteins 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 13
- 101700043277 SSL13 Proteins 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 230000029578 entry into host Effects 0.000 description 13
- 206010008943 Chronic leukaemia Diseases 0.000 description 12
- 101710038727 F2RL1 Proteins 0.000 description 12
- 101710004324 SLC52A2 Proteins 0.000 description 12
- 238000003197 gene knockdown Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 201000005202 lung cancer Diseases 0.000 description 12
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000022983 regulation of cell cycle Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 230000001225 therapeutic Effects 0.000 description 12
- 102100006400 CSF2 Human genes 0.000 description 11
- 102000018358 Immunoglobulins Human genes 0.000 description 11
- 108060003951 Immunoglobulins Proteins 0.000 description 11
- 102100019266 KRT13 Human genes 0.000 description 11
- 108020004999 Messenger RNA Proteins 0.000 description 11
- 101700063429 NID1 Proteins 0.000 description 11
- 102000037168 SLC7A1 Human genes 0.000 description 11
- 108091006209 SLC7A1 Proteins 0.000 description 11
- 230000035492 administration Effects 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 238000005755 formation reaction Methods 0.000 description 11
- 229920002106 messenger RNA Polymers 0.000 description 11
- 206010059512 Apoptosis Diseases 0.000 description 10
- 102100007873 CDH23 Human genes 0.000 description 10
- 101710032824 CDH23 Proteins 0.000 description 10
- 102100010864 DSG1 Human genes 0.000 description 10
- 101700017882 DSG1 Proteins 0.000 description 10
- 102100017427 DSG3 Human genes 0.000 description 10
- 101700058212 DSG3 Proteins 0.000 description 10
- 102100004832 DST Human genes 0.000 description 10
- 101710031749 DST Proteins 0.000 description 10
- 102100002588 F2RL1 Human genes 0.000 description 10
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 10
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 10
- 102100011310 KLK6 Human genes 0.000 description 10
- 101700058468 KLK6 Proteins 0.000 description 10
- 101710026211 KRT13 Proteins 0.000 description 10
- 101700024956 MCM4 Proteins 0.000 description 10
- 102100014033 MCM4 Human genes 0.000 description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- 210000003932 Urinary Bladder Anatomy 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229960004316 cisplatin Drugs 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 241000701806 Human papillomavirus Species 0.000 description 9
- 102100000311 KLHL21 Human genes 0.000 description 9
- 101710042650 KLHL21 Proteins 0.000 description 9
- 102100008646 KRT6B Human genes 0.000 description 9
- 101710017751 KRT6B Proteins 0.000 description 9
- 101710017746 KRT6C Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010038807 Oligopeptides Proteins 0.000 description 9
- 102000015636 Oligopeptides Human genes 0.000 description 9
- 101710042732 PPL Proteins 0.000 description 9
- 102100000334 PPL Human genes 0.000 description 9
- 102100003564 SUDS3 Human genes 0.000 description 9
- 101710042966 SUDS3 Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 108010045030 monoclonal antibodies Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- 230000001131 transforming Effects 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 101700054888 FAT1 Proteins 0.000 description 8
- 102100008327 FAT1 Human genes 0.000 description 8
- 210000000232 Gallbladder Anatomy 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100020458 HLA-A Human genes 0.000 description 8
- 108010075704 HLA-A Antigens Proteins 0.000 description 8
- 210000000987 Immune System Anatomy 0.000 description 8
- 210000001165 Lymph Nodes Anatomy 0.000 description 8
- 206010061289 Metastatic neoplasm Diseases 0.000 description 8
- 102100007098 PARP9 Human genes 0.000 description 8
- 101700001687 PARP9 Proteins 0.000 description 8
- 101710005331 RPL7A Proteins 0.000 description 8
- 101710027132 RPL8 Proteins 0.000 description 8
- 102100018145 RPL8 Human genes 0.000 description 8
- 230000036952 cancer formation Effects 0.000 description 8
- 231100000504 carcinogenesis Toxicity 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000003247 decreasing Effects 0.000 description 8
- 230000001419 dependent Effects 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000001394 metastastic Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 210000000349 Chromosomes Anatomy 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 7
- 101710012658 FAM160A1 Proteins 0.000 description 7
- 102100018305 FAM160A1 Human genes 0.000 description 7
- 102100011162 FANCE Human genes 0.000 description 7
- 101700063275 FAT3 Proteins 0.000 description 7
- 102100008326 FAT3 Human genes 0.000 description 7
- 108010077898 Fanconi Anemia Complementation Group E Protein Proteins 0.000 description 7
- 201000000143 Fanconi anemia complementation group E Diseases 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 7
- 102100010041 KRT75 Human genes 0.000 description 7
- 101710016576 KRT75 Proteins 0.000 description 7
- 206010024324 Leukaemias Diseases 0.000 description 7
- 102100016861 ODC1 Human genes 0.000 description 7
- 101700071555 ODC1 Proteins 0.000 description 7
- 229920000272 Oligonucleotide Polymers 0.000 description 7
- 101710026531 SLC25A21 Proteins 0.000 description 7
- 210000003491 Skin Anatomy 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000002443 helper T lymphocyte Anatomy 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000002062 proliferating Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- 208000009956 Adenocarcinoma Diseases 0.000 description 6
- 229920001405 Coding region Polymers 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 101700049666 KDM5B Proteins 0.000 description 6
- 102100010210 KDM5B Human genes 0.000 description 6
- 102100005750 KRT16 Human genes 0.000 description 6
- 101710026198 KRT16 Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 102100017155 PROM2 Human genes 0.000 description 6
- 101700033955 PROM2 Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100010201 XIRP1 Human genes 0.000 description 6
- 101700075540 XIRP1 Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 108091006028 chimera Proteins 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000004936 stimulating Effects 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 230000002485 urinary Effects 0.000 description 6
- 102100014197 BTBD11 Human genes 0.000 description 5
- 101710030803 BTBD11 Proteins 0.000 description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 description 5
- 102100002974 CDKN1A Human genes 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960004397 Cyclophosphamide Drugs 0.000 description 5
- 102100003967 EMC7 Human genes 0.000 description 5
- 108060002540 EMC7 Proteins 0.000 description 5
- 102100007400 FHAD1 Human genes 0.000 description 5
- 101700013785 FHAD1 Proteins 0.000 description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 102100001473 ITGB4 Human genes 0.000 description 5
- 101710006665 ITGB4 Proteins 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 102100019270 KRT14 Human genes 0.000 description 5
- 101710026207 KRT14 Proteins 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 210000002540 Macrophages Anatomy 0.000 description 5
- 210000000214 Mouth Anatomy 0.000 description 5
- 229960001592 Paclitaxel Drugs 0.000 description 5
- 102000035443 Peptidases Human genes 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 5
- 229950010550 Resiquimod Drugs 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 230000001580 bacterial Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 230000004059 degradation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229960002751 imiquimod Drugs 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 210000004962 mammalian cells Anatomy 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 229930003347 taxol Natural products 0.000 description 5
- 230000002103 transcriptional Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101700010938 APC Proteins 0.000 description 4
- 102100007788 APC Human genes 0.000 description 4
- 102100017054 ATP5MC1 Human genes 0.000 description 4
- 101710042432 ATP5MC1 Proteins 0.000 description 4
- 102100017057 ATP5MC2 Human genes 0.000 description 4
- 101710042430 ATP5MC2 Proteins 0.000 description 4
- 102100017058 ATP5MC3 Human genes 0.000 description 4
- 101710042426 ATP5MC3 Proteins 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- 108090000206 Autoantibodies Proteins 0.000 description 4
- 102000003852 Autoantibodies Human genes 0.000 description 4
- 210000000481 Breast Anatomy 0.000 description 4
- 102100009811 CNGB1 Human genes 0.000 description 4
- 108060002033 CNGB1 Proteins 0.000 description 4
- 102000036640 Cullin Ring E3 Ligases Human genes 0.000 description 4
- 108091006941 Cullin Ring E3 Ligases Proteins 0.000 description 4
- 241000668709 Dipterocarpus costatus Species 0.000 description 4
- 102100020194 ESRP2 Human genes 0.000 description 4
- 101700072614 ESRP2 Proteins 0.000 description 4
- 108060003090 GAR1 Proteins 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 230000036499 Half live Effects 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 101700061400 PRKDC Proteins 0.000 description 4
- 102100003225 PRKDC Human genes 0.000 description 4
- 102000033170 PRNP Human genes 0.000 description 4
- 101710024107 PRNP Proteins 0.000 description 4
- 101700067963 RIPK4 Proteins 0.000 description 4
- 102100014267 RIPK4 Human genes 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 210000003079 Salivary Glands Anatomy 0.000 description 4
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 4
- 101710036345 TENM2 Proteins 0.000 description 4
- 102100017265 TENM2 Human genes 0.000 description 4
- 102100012317 TGM5 Human genes 0.000 description 4
- 101700026773 TGM5 Proteins 0.000 description 4
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 4
- 102100014238 ZBED6 Human genes 0.000 description 4
- 101700033312 ZBED6 Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 102000015735 beta Catenin Human genes 0.000 description 4
- 108060000903 beta Catenin Proteins 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 230000004709 cell invasion Effects 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000002246 oncogenic Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 108091008117 polyclonal antibodies Proteins 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 230000001737 promoting Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 230000000391 smoking Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 102000002689 toll-like receptors Human genes 0.000 description 4
- 108020000411 toll-like receptors Proteins 0.000 description 4
- 102000003995 transcription factors Human genes 0.000 description 4
- 108090000464 transcription factors Proteins 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000003612 virological Effects 0.000 description 4
- 102100015488 ALOX12B Human genes 0.000 description 3
- 101710030791 ALOX12B Proteins 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 210000000941 Bile Anatomy 0.000 description 3
- 210000000013 Bile Ducts Anatomy 0.000 description 3
- 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 3
- 102100004728 CDH1 Human genes 0.000 description 3
- 101700016900 CDH1 Proteins 0.000 description 3
- 102100010221 CKAP4 Human genes 0.000 description 3
- 101700076376 CKAP4 Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100000790 DSP Human genes 0.000 description 3
- 101710011613 DSP Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 210000001508 Eye Anatomy 0.000 description 3
- 101700086098 FAT2 Proteins 0.000 description 3
- 102100008328 FAT2 Human genes 0.000 description 3
- 102100004358 GFER Human genes 0.000 description 3
- 101710004784 GFER Proteins 0.000 description 3
- 208000005017 Glioblastoma Diseases 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 210000002510 Keratinocytes Anatomy 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 102100015262 MYC Human genes 0.000 description 3
- 101700075357 MYC Proteins 0.000 description 3
- 210000001616 Monocytes Anatomy 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 229940055729 Papain Drugs 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 206010057056 Paraneoplastic pemphigus Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 101710002300 RNASE7 Proteins 0.000 description 3
- 102100014854 RNASE7 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100007182 SLC25A3 Human genes 0.000 description 3
- 108091006625 SLC25A3 Proteins 0.000 description 3
- 102000005020 SLC6A11 Human genes 0.000 description 3
- 108060007750 SLC6A11 Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 101710026354 TP63 Proteins 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- DTMHTVJOHYTUHE-UHFFFAOYSA-N Thiocyanogen Chemical compound N#CSSC#N DTMHTVJOHYTUHE-UHFFFAOYSA-N 0.000 description 3
- 210000001541 Thymus Gland Anatomy 0.000 description 3
- 210000001685 Thyroid Gland Anatomy 0.000 description 3
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102400000757 Ubiquitin Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 241001672648 Vieira Species 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000035572 chemosensitivity Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000010192 crystallographic characterization Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940020899 hematological Enzymes Drugs 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002055 immunohistochemical Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001771 impaired Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 230000001617 migratory Effects 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000002797 proteolythic Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000001177 retroviral Effects 0.000 description 3
- 101710040918 shg Proteins 0.000 description 3
- 230000001743 silencing Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229960001322 trypsin Drugs 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102100003649 ACP3 Human genes 0.000 description 2
- 102100010270 AHCTF1 Human genes 0.000 description 2
- 101710024198 AHCTF1 Proteins 0.000 description 2
- 101710016019 ANKRD17 Proteins 0.000 description 2
- 102100011290 ANKRD17 Human genes 0.000 description 2
- 101710034857 ATIC Proteins 0.000 description 2
- 208000002517 Adenoid Cystic Carcinoma Diseases 0.000 description 2
- 210000000577 Adipose Tissue Anatomy 0.000 description 2
- 210000004100 Adrenal Glands Anatomy 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 208000010029 Ameloblastoma Diseases 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 208000000934 Autosomal Recessive 12 Deafness Diseases 0.000 description 2
- 102000036638 BRCA1 Human genes 0.000 description 2
- 108010042977 BRCA1 Protein Proteins 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 241000283699 Bos indicus Species 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 208000000409 Breast Neoplasms Diseases 0.000 description 2
- 102100005859 CCNA1 Human genes 0.000 description 2
- 101700074919 CCNA1 Proteins 0.000 description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 2
- 101700073164 CH63 Proteins 0.000 description 2
- LYQFWZFBNBDLEO-UHFFFAOYSA-M Caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 2
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
- 108009000097 DNA Replication Proteins 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 101700083062 EVPL Proteins 0.000 description 2
- 102100011020 EVPL Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 210000003238 Esophagus Anatomy 0.000 description 2
- 101710015181 FAA2 Proteins 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- 102100006231 GJB5 Human genes 0.000 description 2
- 101710007397 GJB5 Proteins 0.000 description 2
- 210000003714 Granulocytes Anatomy 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 210000004209 Hair Anatomy 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 210000003284 Horns Anatomy 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- 108020004391 Introns Proteins 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N Iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 102100004464 KLK10 Human genes 0.000 description 2
- 101700050384 KLK10 Proteins 0.000 description 2
- 102000001399 Kallikreins Human genes 0.000 description 2
- 108060005987 Kallikreins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000134253 Lanka Species 0.000 description 2
- 210000000867 Larynx Anatomy 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 210000000088 Lip Anatomy 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M Lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 208000010085 Loose Anagen Hair Syndrome Diseases 0.000 description 2
- 102100008857 MLANA Human genes 0.000 description 2
- 102100018882 MYCN Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 208000006178 Malignant Mesothelioma Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M Monopotassium phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 108010010748 N-Myc Proto-Oncogene Protein Proteins 0.000 description 2
- 102100012131 NOTCH1 Human genes 0.000 description 2
- 101710036042 NOTCH1 Proteins 0.000 description 2
- 101700044442 NR1I2 Proteins 0.000 description 2
- 210000000282 Nails Anatomy 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- 210000003300 Oropharynx Anatomy 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108009000578 Oxidative Stress Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 101710007178 PGLYRP4 Proteins 0.000 description 2
- 102100004668 PGLYRP4 Human genes 0.000 description 2
- 102100002479 PLEC Human genes 0.000 description 2
- 101700037174 PLEC Proteins 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 108010061219 Panitumumab Proteins 0.000 description 2
- 208000003154 Papilloma Diseases 0.000 description 2
- 210000002990 Parathyroid Glands Anatomy 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- 210000004303 Peritoneum Anatomy 0.000 description 2
- 102000011755 Phosphoglycerate kinases Human genes 0.000 description 2
- 108020004454 Phosphoglycerate kinases Proteins 0.000 description 2
- 239000004698 Polyethylene (PE) Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 210000000173 Precursor Cells, T-Lymphoid Anatomy 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 101710037934 QRSL1 Proteins 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 210000003705 Ribosomes Anatomy 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101710004327 SLC52A1 Proteins 0.000 description 2
- 102100010800 SLC52A1 Human genes 0.000 description 2
- 101700038338 SNAI2 Proteins 0.000 description 2
- 101710044667 SPOCK1 Proteins 0.000 description 2
- 102100001271 SPOCK1 Human genes 0.000 description 2
- 101710009384 SRC Proteins 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M Sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 241000713880 Spleen focus-forming virus Species 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 102100009727 TRBC1 Human genes 0.000 description 2
- 101700083255 TRBC1 Proteins 0.000 description 2
- 102100000176 TRDC Human genes 0.000 description 2
- 101700045303 TRDC Proteins 0.000 description 2
- 102000004591 Telomerase Human genes 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- 210000002105 Tongue Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 101700063261 UVRAG Proteins 0.000 description 2
- 210000000626 Ureter Anatomy 0.000 description 2
- 241001442055 Vipera berus Species 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 102100003351 YBX1 Human genes 0.000 description 2
- 230000001594 aberrant Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- PAAZCQANMCYGAW-UHFFFAOYSA-N acetic acid;2,2,2-trifluoroacetic acid Chemical class CC(O)=O.OC(=O)C(F)(F)F PAAZCQANMCYGAW-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 102000003802 alpha-Synuclein Human genes 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000011420 autosomal recessive nonsyndromic deafness 12 Diseases 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 108091005593 modified peptides Proteins 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 230000001817 pituitary Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N pyruvic aldehyde Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 229960002530 sargramostim Drugs 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- UATJOMSPNYCXIX-UHFFFAOYSA-N symmetric Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 description 2
- 108091006091 transcriptional repressors Proteins 0.000 description 2
- 230000001960 triggered Effects 0.000 description 2
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000008190 vulva squamous cell carcinoma Diseases 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N (18)F Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 1
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2S,3R,4S,5S,6R)-2-[(2R,4R,5R,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- 229910019670 (NH4)H2PO4 Inorganic materials 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-Ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical class CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-Trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical class OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- KFTHUBZIEMOORC-UHFFFAOYSA-N 2-methylbut-2-enamide Chemical compound CC=C(C)C(N)=O KFTHUBZIEMOORC-UHFFFAOYSA-N 0.000 description 1
- MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
- HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 1
- DRHZYJAUECRAJM-UHFFFAOYSA-N 6-{[8a-({[3-({5-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl)oxy]-3,4-dihydroxy-6-methyloxan-2-yl}oxy)-5-({5-[(5-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxy-6-methyloctanoyl)oxy]-3-hydroxy-6-methyloctanoyl}o Chemical compound O1C(CO)C(O)C(O)C1OC(C(C)CC)CC(O)CC(=O)OC(C(C)CC)CC(O)CC(=O)OC(C(C1OC2C(C(O)C(OC3C(C(OC4C(C(O)(CO)CO4)O)C(O)CO3)O)C(C)O2)O)O)C(C)OC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(C=O)C)O)CCC(C)(C)CC1C2=CCC3C4(C)CCC5OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(C(O)=O)C(O)C1OC1OCC(O)C(O)C1O DRHZYJAUECRAJM-UHFFFAOYSA-N 0.000 description 1
- 101700065985 ACAD9 Proteins 0.000 description 1
- 102100006004 ACAD9 Human genes 0.000 description 1
- 102100019082 ACP7 Human genes 0.000 description 1
- 101700083762 ACP7 Proteins 0.000 description 1
- 102100019707 ADAMTS2 Human genes 0.000 description 1
- 108091005654 ADAMTS2 Proteins 0.000 description 1
- 101700014023 AFP Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 102100001248 AKT1 Human genes 0.000 description 1
- 101700006234 AKT1 Proteins 0.000 description 1
- 101710038340 ARHGEF19 Proteins 0.000 description 1
- 102100009055 ARHGEF19 Human genes 0.000 description 1
- 102100003698 ATG9B Human genes 0.000 description 1
- 101700004042 ATG9B Proteins 0.000 description 1
- 208000009621 Actinic Keratosis Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 208000002075 Adenoameloblastoma Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229940060265 Aldara Drugs 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- 208000008524 Alveolar Soft Part Sarcoma Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 108009000447 Amino Acid metabolism Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N Ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 108010002367 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108009000409 Autophagy Proteins 0.000 description 1
- 208000000734 Autosomal Recessive Deafness Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N BAY 38-9456 Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100011377 BCL6 Human genes 0.000 description 1
- 101700024247 BCL6 Proteins 0.000 description 1
- 101700038591 BDH1 Proteins 0.000 description 1
- 102100010710 BDH1 Human genes 0.000 description 1
- 102100007326 BIRC5 Human genes 0.000 description 1
- 102100009542 BMS1 Human genes 0.000 description 1
- 108060008496 BMS1 Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 101710038672 Ba71V-067 Proteins 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 201000011497 Barrett's esophagus Diseases 0.000 description 1
- 206010004137 Barrett's oesophagus Diseases 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- OQALFHMKVSJFRR-UHFFFAOYSA-N Bityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100005851 C4orf36 Human genes 0.000 description 1
- 101710031627 C4orf36 Proteins 0.000 description 1
- 102100013017 C6orf132 Human genes 0.000 description 1
- 101710025620 C6orf132 Proteins 0.000 description 1
- 108060001088 CAMSAP1 Proteins 0.000 description 1
- 102100015339 CAMSAP1 Human genes 0.000 description 1
- 101700072178 CCNA2 Proteins 0.000 description 1
- 102100005858 CCNA2 Human genes 0.000 description 1
- 102100008136 CCNB3 Human genes 0.000 description 1
- 101700007425 CCNB3 Proteins 0.000 description 1
- 102100016489 CCNE2 Human genes 0.000 description 1
- 101700041341 CCNE2 Proteins 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100013075 CDC27 Human genes 0.000 description 1
- 101710003762 CDC42BPG Proteins 0.000 description 1
- 102100004738 CDC42BPG Human genes 0.000 description 1
- 101700048555 CDK2 Proteins 0.000 description 1
- 101700008359 CDK4 Proteins 0.000 description 1
- 102100019398 CDK4 Human genes 0.000 description 1
- 101700084813 CEBPB Proteins 0.000 description 1
- 102100019343 CEBPB Human genes 0.000 description 1
- 101710033307 CELSR2 Proteins 0.000 description 1
- 102100016584 CELSR2 Human genes 0.000 description 1
- 210000003996 CFU-GM Anatomy 0.000 description 1
- 101710015564 CHEK1 Proteins 0.000 description 1
- 101700066277 COS-1 Proteins 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 102100014050 CUL3 Human genes 0.000 description 1
- 101700002039 CUL3 Proteins 0.000 description 1
- 102100014003 CYBRD1 Human genes 0.000 description 1
- 101710023964 CYBRD1 Proteins 0.000 description 1
- 102000000905 Cadherins Human genes 0.000 description 1
- 108050007957 Cadherins Proteins 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 description 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 210000002230 Centromere Anatomy 0.000 description 1
- 208000007951 Cervical Intraepithelial Neoplasia Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N Chloramine-T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 229940047120 Colony stimulating factors Drugs 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241000723655 Cowpea mosaic virus Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- XVOYSCVBGLVSOL-UHFFFAOYSA-N Cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 102000003844 DNA Helicases Human genes 0.000 description 1
- 108090000133 DNA Helicases Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004536 DNA copy number loss Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100018208 DNMT1 Human genes 0.000 description 1
- 101700070526 DNMT1 Proteins 0.000 description 1
- 102100015153 DNMT3B Human genes 0.000 description 1
- 101710038366 DNMT3B Proteins 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 101700080548 DPP9 Proteins 0.000 description 1
- 102100012457 DPP9 Human genes 0.000 description 1
- 102100017428 DSG2 Human genes 0.000 description 1
- 101700079527 DSG2 Proteins 0.000 description 1
- 102100005669 DTX3L Human genes 0.000 description 1
- 101700077369 DTX3L Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229950006137 Dexfosfoserine Drugs 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-M Diammonium phosphate Chemical compound [NH4+].[NH4+].[O-]P([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-M 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N Diethylpyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 229950009791 Durvalumab Drugs 0.000 description 1
- 101700035153 EER5 Proteins 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 108091007936 ERK family Proteins 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 229940066758 Endopeptidases Drugs 0.000 description 1
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102100012318 F3 Human genes 0.000 description 1
- 101710038055 FAM83A Proteins 0.000 description 1
- 102100017675 FAM83A Human genes 0.000 description 1
- 102100017673 FAM83D Human genes 0.000 description 1
- 101710038069 FAM83D Proteins 0.000 description 1
- 102100008871 FAM83F Human genes 0.000 description 1
- 101710038077 FAM83F Proteins 0.000 description 1
- 102100008329 FASN Human genes 0.000 description 1
- 101710008102 FASN Proteins 0.000 description 1
- 102100017788 FBXO22 Human genes 0.000 description 1
- 101710027159 FBXO22 Proteins 0.000 description 1
- 102100008648 FHL2 Human genes 0.000 description 1
- 101700061856 FHL2 Proteins 0.000 description 1
- 101700010580 FLO11 Proteins 0.000 description 1
- 102100002018 FSCN1 Human genes 0.000 description 1
- 102100008632 FTSJ1 Human genes 0.000 description 1
- 101710042349 FTSJ1 Proteins 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108090000786 Fascin Proteins 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 230000008051 G1/S transition checkpoint Effects 0.000 description 1
- 102000017700 GABRP Human genes 0.000 description 1
- 108060004401 GABRP Proteins 0.000 description 1
- 102100012859 GADD45G Human genes 0.000 description 1
- 101710037024 GADD45G Proteins 0.000 description 1
- 102100010305 GLI2 Human genes 0.000 description 1
- 101700036688 GLI2 Proteins 0.000 description 1
- 102100014511 GNA13 Human genes 0.000 description 1
- 101700021123 GNA13 Proteins 0.000 description 1
- 102100014519 GPNMB Human genes 0.000 description 1
- 102100007058 GRHL1 Human genes 0.000 description 1
- 101700025972 GRHL1 Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006093 GTPases Proteins 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229960002449 Glycine Drugs 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060005986 Granzymes Proteins 0.000 description 1
- 102000001398 Granzymes Human genes 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 101710007246 H3-3A Proteins 0.000 description 1
- 102100010141 HAS3 Human genes 0.000 description 1
- 101710016604 HAS3 Proteins 0.000 description 1
- 102100002572 HDAC1 Human genes 0.000 description 1
- 101700036927 HDAC1 Proteins 0.000 description 1
- 102100020036 HEPHL1 Human genes 0.000 description 1
- 101710017483 HEPHL1 Proteins 0.000 description 1
- 101700009603 HIS3 Proteins 0.000 description 1
- 102100020459 HLA-B Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010008553 HLA-B*07 antigen Proteins 0.000 description 1
- 102100020457 HLA-C Human genes 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 210000003780 Hair Follicle Anatomy 0.000 description 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 102000003964 Histone deacetylases Human genes 0.000 description 1
- 108090000353 Histone deacetylases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 102100004115 ICAM1 Human genes 0.000 description 1
- 102100005117 IGF2 Human genes 0.000 description 1
- 101700070236 IGF2 Proteins 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 102100013277 IRF1 Human genes 0.000 description 1
- 101700001416 IRF1 Proteins 0.000 description 1
- 102100013278 IRF2 Human genes 0.000 description 1
- 101700001385 IRF2 Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 101700025474 ISP2 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 229940117681 Interleukin-12 Drugs 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 102100012899 JUP Human genes 0.000 description 1
- 101710014170 JUP Proteins 0.000 description 1
- 101700038758 KIFC1 Proteins 0.000 description 1
- 102100006550 KIFC1 Human genes 0.000 description 1
- 102100007829 KLF10 Human genes 0.000 description 1
- 101700061257 KLF10 Proteins 0.000 description 1
- 102100006525 KLF4 Human genes 0.000 description 1
- 101700048573 KLF4 Proteins 0.000 description 1
- 102100011309 KLK5 Human genes 0.000 description 1
- 101700077195 KLK5 Proteins 0.000 description 1
- 102100011312 KLK7 Human genes 0.000 description 1
- 101700079133 KLK7 Proteins 0.000 description 1
- 102100005749 KRT17 Human genes 0.000 description 1
- 101710026199 KRT17 Proteins 0.000 description 1
- 102100013426 KRT78 Human genes 0.000 description 1
- 101710016566 KRT78 Proteins 0.000 description 1
- 108010065070 Keratin-13 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 102100009095 LAMC2 Human genes 0.000 description 1
- 101700017755 LAMC2 Proteins 0.000 description 1
- 102100005613 LDHA Human genes 0.000 description 1
- 101700041404 LDHA Proteins 0.000 description 1
- 102100009633 LGALS1 Human genes 0.000 description 1
- 108020000524 LGALS1 Proteins 0.000 description 1
- 102100015816 LNX2 Human genes 0.000 description 1
- 101700004960 LNX2 Proteins 0.000 description 1
- 229960001021 Lactose Monohydrate Drugs 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 210000003171 Lymphocytes, Tumor-Infiltrating Anatomy 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- 102000038027 MAP kinase family Human genes 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 102100016823 MAPK1 Human genes 0.000 description 1
- 101700083887 MAPK1 Proteins 0.000 description 1
- 101710029789 MAPK6 Proteins 0.000 description 1
- 102100016821 MAPK6 Human genes 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 101700064880 MBD2 Proteins 0.000 description 1
- 102100008691 MBD2 Human genes 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 101710012533 MLANA Proteins 0.000 description 1
- 102100014894 MMP2 Human genes 0.000 description 1
- 101700060512 MMP2 Proteins 0.000 description 1
- 101700052154 MPK1 Proteins 0.000 description 1
- 101700035337 MPK7 Proteins 0.000 description 1
- 102100014007 MPZL2 Human genes 0.000 description 1
- 101700069183 MPZL2 Proteins 0.000 description 1
- 102100015411 MROH6 Human genes 0.000 description 1
- 101700052685 MROH6 Proteins 0.000 description 1
- 102100009175 MTCL1 Human genes 0.000 description 1
- 101700043477 MTCL1 Proteins 0.000 description 1
- 102100006037 MUC1 Human genes 0.000 description 1
- 101700052761 MUC1 Proteins 0.000 description 1
- 102100015091 MYCNOS Human genes 0.000 description 1
- 101710006257 MYCNOS Proteins 0.000 description 1
- 229940057948 Magnesium stearate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010073087 Malignant sweat gland neoplasm Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 1
- 210000002752 Melanocytes Anatomy 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 206010027195 Meningiomas benign Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004388 MicroRNAs Proteins 0.000 description 1
- 229920002393 Microsatellite Polymers 0.000 description 1
- 229920001899 Mir-143 Polymers 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 102000008789 N-cadherin Human genes 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 101700072946 NEDD1 Proteins 0.000 description 1
- 102100000573 NEDD1 Human genes 0.000 description 1
- 102100007978 NFE2 Human genes 0.000 description 1
- 101700064339 NFE2 Proteins 0.000 description 1
- 101710043084 NLRP10 Proteins 0.000 description 1
- 102100000664 NLRP10 Human genes 0.000 description 1
- 101710044526 NLRP2 Proteins 0.000 description 1
- 102100018734 NLRP2 Human genes 0.000 description 1
- 102100000797 NOC4L Human genes 0.000 description 1
- 101700004594 NOC4L Proteins 0.000 description 1
- 102100017833 NUP205 Human genes 0.000 description 1
- 101710017536 NUP205 Proteins 0.000 description 1
- 101700049878 NWD1 Proteins 0.000 description 1
- 102100010900 NWD1 Human genes 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 210000001989 Nasopharynx Anatomy 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 208000004296 Neuralgia Diseases 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010019706 Nivolumab Proteins 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- VXAPDXVBDZRZKP-UHFFFAOYSA-N O[N+]([O-])=O.OP(O)(O)=O Chemical compound O[N+]([O-])=O.OP(O)(O)=O VXAPDXVBDZRZKP-UHFFFAOYSA-N 0.000 description 1
- 206010073310 Occupational exposure Diseases 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 229940099990 Ogen Drugs 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100014579 PARP1 Human genes 0.000 description 1
- 102100019629 PARP14 Human genes 0.000 description 1
- 101710021100 PARP14 Proteins 0.000 description 1
- 102100018806 PDPN Human genes 0.000 description 1
- 101700039373 PDPN Proteins 0.000 description 1
- 101700037337 PIGA Proteins 0.000 description 1
- 102100012341 PIGA Human genes 0.000 description 1
- 101700050065 PKP3 Proteins 0.000 description 1
- 102100012901 PKP3 Human genes 0.000 description 1
- 102100010401 PLA2G4E Human genes 0.000 description 1
- 101710029803 PLA2G4E Proteins 0.000 description 1
- 101700042133 PMP22 Proteins 0.000 description 1
- 102100011787 PMP22 Human genes 0.000 description 1
- 101710027911 PNPLA1 Proteins 0.000 description 1
- 102100013356 PNPLA1 Human genes 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 102000030063 POZ domain binding proteins Human genes 0.000 description 1
- 108091013809 POZ domain binding proteins Proteins 0.000 description 1
- 101700082309 PRDM2 Proteins 0.000 description 1
- 102100004028 PRDM2 Human genes 0.000 description 1
- 102100008799 PTEN Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102100006335 PTGS1 Human genes 0.000 description 1
- 101710040931 PTGS1 Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- 102100017873 PTK2 Human genes 0.000 description 1
- 101700086523 PTK2 Proteins 0.000 description 1
- 101700013176 PXMP2 Proteins 0.000 description 1
- 210000001983 Palate, Hard Anatomy 0.000 description 1
- 210000001584 Palate, Soft Anatomy 0.000 description 1
- 210000002741 Palatine Tonsil Anatomy 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 210000003695 Paranasal Sinuses Anatomy 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101800001442 Peptide pr Proteins 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N Phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000004224 Pleura Anatomy 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940069338 Potassium Sorbate Drugs 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M Potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M Potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 208000003055 Prion Disease Diseases 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 229950008679 Protamine sulfate Drugs 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 102100003126 RAD54B Human genes 0.000 description 1
- 101710002793 RAD54B Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 102100008731 RHOV Human genes 0.000 description 1
- 101700075814 RHOV Proteins 0.000 description 1
- 102100012118 RIOX1 Human genes 0.000 description 1
- 101700068671 RIOX1 Proteins 0.000 description 1
- 102100005395 RIOX2 Human genes 0.000 description 1
- 101700025374 RIOX2 Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100014855 RNASE8 Human genes 0.000 description 1
- 101710002294 RNASE8 Proteins 0.000 description 1
- 102100018787 RPS19 Human genes 0.000 description 1
- 101710007829 RPS19 Proteins 0.000 description 1
- 102100012979 RPSA Human genes 0.000 description 1
- 101710024037 RPSA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102100017877 S100A7 Human genes 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 102100019586 SERPINB5 Human genes 0.000 description 1
- 102100016624 SERPINH1 Human genes 0.000 description 1
- 101710025898 SERPINH1 Proteins 0.000 description 1
- 102100016701 SH3D21 Human genes 0.000 description 1
- 101710016242 SH3D21 Proteins 0.000 description 1
- 101700058417 SIRT2 Proteins 0.000 description 1
- 102100000596 SIRT2 Human genes 0.000 description 1
- 102000012986 SLC1A7 Human genes 0.000 description 1
- 108060002243 SLC1A7 Proteins 0.000 description 1
- 102100005308 SLC44A5 Human genes 0.000 description 1
- 108091007275 SLC44A5 Proteins 0.000 description 1
- 102000005031 SLC6A15 Human genes 0.000 description 1
- 108060007754 SLC6A15 Proteins 0.000 description 1
- 102100017668 SMAD3 Human genes 0.000 description 1
- 101700079713 SMAD3 Proteins 0.000 description 1
- 102100017680 SMAD4 Human genes 0.000 description 1
- 101700062085 SMAD4 Proteins 0.000 description 1
- 102100017511 SPN Human genes 0.000 description 1
- 101710018229 SPN Proteins 0.000 description 1
- 102100004015 SPRR3 Human genes 0.000 description 1
- 101700047167 SPRR3 Proteins 0.000 description 1
- 102100014920 SREBF1 Human genes 0.000 description 1
- 101710043414 SREBF1 Proteins 0.000 description 1
- 102100019667 STAT3 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102220460541 SVBP T47D Human genes 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 208000000649 Small Cell Carcinoma Diseases 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 229940084026 Sodium Valproate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M Sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M Sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000003915 Spermatocytes Anatomy 0.000 description 1
- 210000002921 Spermatogonia Anatomy 0.000 description 1
- 208000001016 Spinal Injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000002536 Stromal Cells Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102100003993 TGFBR1 Human genes 0.000 description 1
- 102100008284 TGFBR3 Human genes 0.000 description 1
- 101700070494 THP1 Proteins 0.000 description 1
- 102100012087 TLR4 Human genes 0.000 description 1
- 101700022711 TLR4 Proteins 0.000 description 1
- 101700025666 TLR5 Proteins 0.000 description 1
- 102100006352 TLR5 Human genes 0.000 description 1
- 102100002548 TMEM222 Human genes 0.000 description 1
- 101710009631 TMEM222 Proteins 0.000 description 1
- 101710044695 TMPRSS3 Proteins 0.000 description 1
- 102100001067 TMPRSS4 Human genes 0.000 description 1
- 101710044691 TMPRSS4 Proteins 0.000 description 1
- 102100002197 TNRC18 Human genes 0.000 description 1
- 101710022559 TNRC18 Proteins 0.000 description 1
- 102100019854 TP63 Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 102100000184 TRIM26 Human genes 0.000 description 1
- 101710021280 TRIM26 Proteins 0.000 description 1
- 102100005372 TSKU Human genes 0.000 description 1
- 101710039957 TSKU Proteins 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102000008208 Toll-Like Receptor 8 Human genes 0.000 description 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 1
- 229950007217 Tremelimumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 108060005989 Tryptase family Proteins 0.000 description 1
- 102000001400 Tryptase family Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000007962 Type II Keratins Human genes 0.000 description 1
- 108010089374 Type II Keratins Proteins 0.000 description 1
- 102100017819 UBE4B Human genes 0.000 description 1
- 101700009561 UBE4B Proteins 0.000 description 1
- 102100011110 USP10 Human genes 0.000 description 1
- 108060005929 USP10 Proteins 0.000 description 1
- 101710043446 USP17L2 Proteins 0.000 description 1
- 102100004158 USP17L24 Human genes 0.000 description 1
- 101710044602 USP17L27 Proteins 0.000 description 1
- 229950005972 Urelumab Drugs 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 201000006051 Usher syndrome Diseases 0.000 description 1
- 201000008575 Usher syndrome type 1D Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 102100008060 WT1 Human genes 0.000 description 1
- 101700062995 WT1 Proteins 0.000 description 1
- 108009000607 Wnt Signaling Proteins 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 1
- ULFUTCYGWMQVIO-PCVRPHSVSA-N [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentano Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 ULFUTCYGWMQVIO-PCVRPHSVSA-N 0.000 description 1
- IOJUJUOXKXMJNF-UHFFFAOYSA-N [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001436 acantholytic Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000002009 allergen Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000007961 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent Effects 0.000 description 1
- 230000005164 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent Effects 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006877 autophagy Effects 0.000 description 1
- 230000003376 axonal Effects 0.000 description 1
- IWOUKMZUPDVPGQ-UHFFFAOYSA-N barium nitrate Inorganic materials [Ba+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O IWOUKMZUPDVPGQ-UHFFFAOYSA-N 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 201000009467 benign meningioma Diseases 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000001612 cachectic Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000017484 calcium-dependent cell-cell adhesion Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- QUPYHCHUQVNFJW-UHFFFAOYSA-M cesium;thiocyanate Chemical compound [Cs+].[S-]C#N QUPYHCHUQVNFJW-UHFFFAOYSA-M 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 201000002547 conjunctival squamous cell carcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 125000004989 dicarbonyl group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 108060003523 dnaK Proteins 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004363 doconexent Drugs 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 108010016436 durvalumab Proteins 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000467 effect on cytodieresis Effects 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002357 endometrial Effects 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 230000001973 epigenetic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000003364 extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
- 201000008069 familial hemophagocytic lymphohistiocytosis 2 Diseases 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003328 fibroblastic Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 210000004904 fingernail beds Anatomy 0.000 description 1
- 108091004535 flt3 ligand protein Proteins 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 201000009608 hair disease Diseases 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000017945 hippo signaling cascade Effects 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000001744 histochemical Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000012 isoleucine group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000002122 leukaemogenic Effects 0.000 description 1
- 101700063973 lgg-1 Proteins 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000005291 magnetic Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 201000000281 malignant syringoma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 201000007007 meningothelial meningioma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- ZCQGVFNHUATAJY-UHFFFAOYSA-N methyl 2-[methyl(prop-2-enoyl)amino]acetate Chemical compound COC(=O)CN(C)C(=O)C=C ZCQGVFNHUATAJY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 235000019785 monomagnesium phosphate Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 1
- 201000000720 morpheaform basal cell carcinoma Diseases 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 101700034118 myca Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000000174 oncolytic Effects 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000470 poly(p-phenylene terephthalate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000016434 protein splicing Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000007347 radical substitution reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000008001 rakum palm Nutrition 0.000 description 1
- 244000217124 rakum palm Species 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000012385 regulation of binding Effects 0.000 description 1
- 208000005039 renal Oncocytoma Diseases 0.000 description 1
- 230000003252 repetitive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000714 sipuleucel-T Drugs 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 201000001019 spiradenoma Diseases 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000005531 stress granule assembly Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 108010010186 talactoferrin alfa Proteins 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 102000015496 thiol-dependent ubiquitin-specific protease activity proteins Human genes 0.000 description 1
- 108040006143 thiol-dependent ubiquitin-specific protease activity proteins Proteins 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 230000025934 tissue morphogenesis Effects 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- JVJFIQYAHPMBBX-UHFFFAOYSA-N trans-4-hydroxy-2-nonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 108091007206 transmembrane glycoprotein Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010072993 tremelimumab Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000002100 tumorsuppressive Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108010053952 urelumab Proteins 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 201000008758 vulvar sarcoma Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- OJUGVDODNPJEEC-UHFFFAOYSA-N α-oxobenzeneacetaldehyde Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. on with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Description
Novel peptides and scaffolds for use in immunotherapy against head and neck
squamous cell oma and other cancers
The present application is a divisional application from New Zealand patent application
number 751962, the entire disclosure of which is incorporated herein by way of this
reference.
The present ion relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention s to the
immunotherapy of cancer. The present invention furthermore relates to tumorassociated
T-cell peptide epitopes, alone or in combination with other tumorassociated
peptides that can for example serve as active ceutical ingredients
of e compositions that stimulate anti-tumor immune responses, or to stimulate T
cells ex vivo and transfer into patients. Peptides bound to molecules of the major
histocompatibility complex (MHC), or peptides as such, can also be targets of
antibodies, soluble T-cell receptors, and other binding molecules.
The present invention relates to several novel peptide sequences and their variants
derived from HLA class I les of human tumor cells that can be used in vaccine
compositions for eliciting anti-tumor immune responses, or as targets for the
development of pharmaceutically / logically active compounds and cells.
OUND OF THE INVENTION
Head and neck squamous cell omas (HNSCC) are heterogeneous tumors with
differences in epidemiology, etiology and treatment (Economopoulou et al., 2016).
These tumors are categorized by the area in which they begin. They include cancers
of the oral cavity (lips, front two-thirds of the tongue, gums, lining inside the cheeks
and lips, floor of the mouth, hard palate), the x (nasopharynx, oropharynx
including soft palate, base of the tongue, tonsils, hypopharynx), larynx, paranasal
sinuses and nasal cavity and salivary glands (National Cancer Institute, 2015).
HNSCC is the sixth most common malignancy in the world and accounts for about 6%
of all cancer cases diagnosed worldwide (Economopoulou et al., 2016). HNSCC is
characterized by a wide geographical ion in the incidence and anatomic
distribution (Vigneswaran and Williams, 2014). High risk countries are located in South
and Southeast Asia (i.e. India, Sri Lanka, Bangladesh, Pakistan). In these regions,
squamous cell oma of the oral cavity (OSCC) is the most common cancer in men
and the third most common cancer in women (Vigneswaran and Williams, 2014). In
Europe, high incidence rates of OSCC are found in regions of France, Hungary,
Slovakia and Slovenia. In the United States, HNSCC is the eighths most common
cancer among men.
Major risk factors for HNSCC are l and tobacco use. Other HNSCC risk s
include consumption of mate, but also of preserved or salted foods, use of betel quid,
occupational exposure to wood dust, asbestos and synthetic fibers, radiation exposure,
infection with cancer-causing types of human papillomavirus (HPV) or Epstein-Barr
virus (EBV) and ancestry (particularly Chinese ry in nasopharyngeal SCC)
(National Cancer Institute, 2015).
While OSCC and laryngeal SCC have decreased in developed countries, the incidence
of oropharyngeal SCC has increased. This is attributed to a change in the biologic driver
of SCC (HPV-related SCC instead of smoking-related SCC). lated
oropharyngeal cancers have sed by 225% from 1988 to 2004 (National Cancer
Institute, 2015). HPV-positive HNSCC may represent a distinct disease entity. Those
tumors are associated with significantly improved survivals.
Rates of incidence depend on gender: male to female ratio ranges from 2:1 to 4:1 (2014
Review of cancer Medicines on the WHO list of essential medicines). The five-year
overall survival rate of patients with HNSCC is 40-50% (World Health Organization,
2014). While early cancers (T1, T2) have cure rates of 70%-95% (Nat Cancer Inst), the
majority of patients with HNSCC present with locally advanced disease (Bauml et al.,
2016).
_ 3 _
Treatment for early HNSCC involves single-modality therapy with either y or
radiation (World Health Organization, 2014). Advanced cancers are treated by a
combination of chemotherapy with surgery and/or radiation therapy.
Chemotherapy includes mostly cisplatin or drug combinations that contain cisplatin like
docetaxel, cisplatin, fluorouracil (5-FU) or cisplatin, epirubicin, cin or cisplatin, 5-
FU. lsotretinoin (13-cis-retinoic acid) is used in oral cavity SCC and laryngeal SCC,
daily for 1 year to reduce the incidence of second tumors (National Cancer Institute,
2015).
HNSCC is ered an immunosuppressive disease, characterized by the
dysregulation of immunocompetent cells and impaired cytokine secretion
(Economopoulou et al., 2016). lmmunotherapeutic strategies differ between HPV-
negative and HPV-positive tumors.
In HPV-positive tumors, the viral oncoproteins E6 and E7 represent good targets, as
they are continuously expressed by tumor cells and are essential to maintain the
transformation status of HPV-positive cancer cells. Several vaccination ies are
currently under investigation in HPV-positive HNSCC, including DNA vaccines, e
vaccines and vaccines involving tic cells (DCs). Additionally, an ongoing phase II
clinical trial investigates the efficacy of lymphodepletion ed by autologous infusion
of TILs in patients with HPV-positive tumors (Economopoulou et al., 2016).
In gative tumors, several lmmunotherapeutic strategies are currently used and
under igation. The chimeric lgG1 anti-EGFR monoclonal antibody cetuximab has
been ed by the FDA in combination with chemotherapy as standard first line
treatment for recurring/metastatic HNSCC. Other anti-EGFR monoclonal antibodies,
including panitumumab, zumab and mumab, are evaluated in HNSCC.
Several immune checkpoint inhibitors are investigated in clinical trials for their use in
HNSCC. They include the following antibodies: lpilimumab (anti-CTLA-4),
tremelimumab (anti-CTLA-4), lizumab (anti-PD-1), nivolumab (anti-PD-1),
durvalumab PD-1), anti-KIR, urelumab (anti-CD137), and anti-LAG-3.
Two clinical s with HNSCC patients evaluated the use of DCs loaded with p53
peptides or apoptotic tumor cells. The immunological responses were satisfactory and
side effects were acceptable.
Several studies have been conducted using adoptive T cell therapy (ACT). T cells were
induced against either irradiated autologous tumor cells or EBV. Results in disease
l and overall survival were promising (Economopoulou et al., 2016).
Considering the severe side-effects and expense ated with treating cancer, there
is a need to fy factors that can be used in the treatment of cancer in general and
head and neck squamous cell carcinoma in ular. There is also a need to identify
s representing biomarkers for cancer in general and head and neck squamous cell
carcinoma in particular, leading to better diagnosis of cancer, assessment of prognosis,
and prediction of treatment success.
lmmunotherapy of cancer represents an option of specific targeting of cancer cells while
minimizing side s. Cancer immunotherapy makes use of the existence of tumor
associated antigens.
The current classification of tumor associated antigens (TAAs) comprises the following
major groups:
a) Cancer-testis antigens: The first TAAs ever identified that can be recognized by T
cells belong to this class, which was originally called cancer-testis (CT) antigens
because of the expression of its members in histologically different human tumors and,
among normal tissues, only in spermatocytes/spermatogonia of testis and, occasionally,
in ta. Since the cells of testis do not express class I and II HLA molecules, these
antigens cannot be recognized by T cells in normal tissues and can therefore be
_ 5 _
considered as immunologically tumor-specific. Well-known examples for CT antigens
are the MAGE family s and NY-ESO-1.
b) Differentiation antigens: These TAAs are shared between tumors and the normal
tissue from which the tumor arose. Most of the known differentiation antigens are found
in melanomas and normal melanocytes. Many of these cyte lineage-related
proteins are ed in biosynthesis of melanin and are therefore not tumor specific but
nevertheless are widely used for cancer immunotherapy. Examples include, but are not
limited to, nase and Melan-A/MART-1 for melanoma or PSA for te cancer.
c) Over-expressed TAAs: Genes ng widely expressed TAAs have been detected
in histologically different types of tumors as well as in many normal tissues, generally
with lower expression . It is possible that many of the epitopes processed and
potentially ted by normal tissues are below the threshold level for T-cell
recognition, while their over-expression in tumor cells can trigger an anticancer
response by breaking usly established tolerance. Prominent examples for this
class of TAAs are Her-2/neu, survivin, telomerase, or WT1.
d) Tumor-specific antigens: These unique TAAs arise from mutations of normal genes
(such as B-catenin, CDK4, etc.). Some of these molecular changes are associated with
neoplastic transformation and/or progression. Tumor-specific antigens are lly
able to induce strong immune ses without bearing the risk for autoimmune
reactions against normal tissues. On the other hand, these TAAs are in most cases only
relevant to the exact tumor on which they were identified and are usually not shared
between many individual tumors. Tumor-specificity (or -association) of a peptide may
also arise if the peptide originates from a tumor- (-associated) exon in case of proteins
with specific (-associated) isoforms.
e) TAAs arising from abnormal post-translational modifications: Such TAAs may arise
from proteins which are neither specific nor overexpressed in tumors but nevertheless
become tumor associated by posttranslational processes primarily active in tumors.
Examples for this class arise from altered glycosylation patterns leading to novel
epitopes in tumors as for MUC1 or events like protein splicing during degradation which
may or may not be tumor specific.
_ 6 _
f) Oncoviral proteins: These TAAs are viral proteins that may play a critical role in the
oncogenic process and, because they are foreign (not of human origin), they can evoke
a T-cell response. Examples of such proteins are the human papilloma type 16 virus
proteins, E6 and E7, which are expressed in cervical carcinoma.
T-cell based immunotherapy targets peptide epitopes derived from tumor-associated or
tumor-specific proteins, which are presented by les of the major
histocompatibility x (MHC). The antigens that are recognized by the tumor
specific T lymphocytes, that is, the epitopes thereof, can be les d from all
protein classes, such as enzymes, receptors, transcription factors, etc. which are
expressed and, as compared to unaltered cells of the same origin, usually ulated
in cells of the respective tumor.
There are two classes of MHC-molecules, MHC class I and MHC class II. MHC class I
molecules are composed of an alpha heavy chain and betamicroglobulin, MHC class
II molecules of an alpha and a beta chain. Their three-dimensional conformation results
in a binding groove, which is used for non-covalent interaction with peptides.
MHC class I molecules can be found on most ted cells. They present peptides
that result from proteolytic cleavage of predominantly endogenous proteins, defective
ribosomal products (DRlPs) and larger peptides. However, es derived from
endosomal compartments or exogenous sources are also frequently found on MHC
class I molecules. This assical way of class I presentation is referred to as cross-
presentation in the literature (Brossart and Bevan, 1997; Rock et al., 1990). MHC class
II molecules can be found inantly on sional antigen presenting cells
(APCs), and primarily present peptides of exogenous or transmembrane proteins that
are taken up by APCs e.g. during endocytosis, and are subsequently processed.
Complexes of peptide and MHC class I are recognized by CD8—positive T cells bearing
the appropriate T-cell receptor (TCR), whereas complexes of e and MHC class II
molecules are recognized by CD4-positive-helper—T cells g the appropriate TCR.
It is well known that the TCR, the peptide and the MHC are thereby present in a
stoichiometric amount of 1:1 :1.
CD4-positive helper T cells play an important role in inducing and sustaining effective
responses by CD8—positive cytotoxic T cells. The identification of CD4-positive T-cell
epitopes derived from tumor associated antigens (TAA) is of immense ance for
the development of pharmaceutical products for triggering anti-tumor immune
responses (anatic et al., 2003). At the tumor site, T helper cells, support a cytotoxic T
cell- (CTL-) friendly cytokine milieu (Mortara et al., 2006) and attract effector cells, e.g.
CTLs, natural killer (NK) cells, macrophages, and granulocytes (Hwang et al., 2007).
In the absence of inflammation, expression of MHC class II molecules is mainly
restricted to cells of the immune , especially professional n-presenting
cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells. In
cancer patients, cells of the tumor have been found to express MHC class II molecules
(Dengjel et al., 2006). Elongated (longer) peptides of the invention can act as MHC
class II active epitopes.
T-helper cells, activated by MHC class II epitopes, play an important role in
orchestrating the or function of CTLs in umor immunity. T-helper cell epitopes
that trigger a T-helper cell response of the TH1 type t effector ons of CD8-
positive killer T cells, which include cytotoxic functions directed against tumor cells
displaying tumor-associated e/MHC xes on their cell surfaces. In this way
tumor-associated T-helper cell peptide epitopes, alone or in combination with other
tumor-associated peptides, can serve as active ceutical ingredients of vaccine
compositions that stimulate anti-tumor immune responses.
It was shown in mammalian animal models, e.g., mice, that even in the absence of
CD8—positive T lymphocytes, sitive T cells are sufficient for inhibiting
manifestation of tumors via inhibition of angiogenesis by secretion of interferon-gamma
_ 8 _
(lFNy) (Beatty and Paterson, 2001; Mumberg et al., 1999). There is evidence for CD4 T
cells as direct anti-tumor effectors (Braumuller et al., 2013; Tran et al., 2014).
Since the constitutive expression of HLA class II molecules is usually limited to immune
cells, the possibility of isolating class II peptides directly from primary tumors was
previously not considered possible. However, Dengjel et al. were sful in
identifying a number of MHC Class II epitopes directly from tumors (
EP 1 760 088 B1).
Since both types of response, CD8 and CD4 dependent, contribute jointly and
synergistically to the anti-tumor effect, the identification and characterization of tumor-
associated antigens recognized by either CD8+ T cells (ligand: MHC class I le +
peptide e) or by CD4-positive T-helper cells (ligand: MHC class II molecule +
peptide epitope) is ant in the development of tumor vaccines.
For an MHC class I peptide to r (elicit) a cellular immune response, it also must
bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule
and specific polymorphisms of the amino acid sequence of the peptide. MHC-Class-l-
binding peptides are usually 8-12 amino acid residues in length and usually contain two
conserved residues ("anchors") in their sequence that interact with the corresponding
binding groove of the MHC-molecule. In this way, each MHC allele has a “binding motif”
determining which es can bind specifically to the binding groove.
In the MHC class I dependent immune reaction, peptides not only have to be able to
bind to certain MHC class I molecules expressed by tumor cells, they subsequently also
have to be recognized by T cells bearing specific T cell receptors (TCR).
For ns to be recognized by T-lymphocytes as tumor-specific or -associated
antigens, and to be used in a y, particular prerequisites must be fulfilled. The
n should be expressed mainly by tumor cells and not, or in comparably small
amounts, by normal healthy tissues. In a preferred embodiment, the peptide should be
_ g _
over-presented by tumor cells as compared to normal healthy tissues. It is furthermore
desirable that the respective n is not only present in a type of tumor, but also in
high concentrations (i.e. copy numbers of the respective peptide per cell). Tumor-
specific and tumor-associated antigens are often derived from proteins directly ed
in transformation of a normal cell to a tumor cell due to their function, e.g. in cell cycle
control or suppression of apoptosis. Additionally, downstream targets of the proteins
directly causative for a transformation may be up-regulated und thus may be indirectly
tumor-associated. Such indirect tumor-associated antigens may also be targets of a
vaccination approach (Singh-Jasuja et al., 2004). It is essential that epitopes are
present in the amino acid sequence of the antigen, in order to ensure that such a
peptide ("immunogenic peptide"), being derived from a tumor associated antigen, leads
to an in vitro or in vivo T-cell-response.
Basically, any peptide able to bind an MHC molecule may function as a T-cell epitope. A
prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a
T cell having a corresponding TCR and the absence of immunological nce for this
ular epitope.
ore, TAAs are a starting point for the pment of a T cell based therapy
including but not limited to tumor vaccines. The methods for fying and
characterizing the TAAs are usually based on the use of T-cells that can be isolated
from patients or healthy subjects, or they are based on the generation of ential
transcription profiles or ential peptide expression patterns between tumors and
normal tissues. However, the identification of genes over-expressed in tumor tissues or
human tumor cell lines, or selectively sed in such tissues or cell lines, does not
provide precise information as to the use of the antigens being transcribed from these
genes in an immune therapy. This is because only an individual subpopulation of
epitopes of these antigens are le for such an application since a T cell with a
ponding TCR has to be present and the immunological nce for this
particular epitope needs to be absent or minimal. In a very preferred embodiment of the
invention it is therefore important to select only those over— or selectively presented
peptides t which a functional and/or a proliferating T cell can be found. Such a
functional T cell is defined as a T cell, which upon stimulation with a specific antigen can
be clonally expanded and is able to execute effector functions (“effector T cell”).
In case of targeting peptide-MHC by specific TCRs (e.g. soluble TCRs) and antibodies
or other binding molecules (scaffolds) according to the invention, the immunogenicity of
the underlying peptides is secondary. In these cases, the presentation is the
determining factor.
SUMMARY OF THE INVENTION
In a first aspect of the present invention, the present ion relates to a peptide
comprising an amino acid sequence ed from the group consisting of SEQ ID NO:
1 to SEQ ID NO: 91 or a variant sequence thereof which is at least 77%, ably at
least 88%, homologous (preferably at least 77% or at least 88% identical) to SEQ ID
NO: 1 to SEQ ID NO: 91, wherein said variant binds to MHC and/or induces T cells
cross-reacting with said peptide, or a pharmaceutical acceptable salt thereof, wherein
said peptide is not the underlying full-length polypeptide.
The present invention further relates to a e of the present ion comprising a
sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 91
or a variant thereof, which is at least 77%, preferably at least 88%, homologous
(preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 91,
wherein said peptide or variant thereof has an l length of between 8 and 100,
preferably between 8 and 30, and most preferred of between 8 and 14 amino acids.
The following tables show the peptides according to the present ion, their
respective SEQ ID NOs, and the prospective source (underlying) genes for these
es. All peptides in Table 1 and Table 2 bind to 02. The peptides in Table 2
have been disclosed before in large listings as results of high-throughput screenings
with high error rates or calculated using algorithms, but have not been associated with
cancer at all before. The peptides in Table 3 are additional peptides that may be useful
in combination with the other peptides of the invention. The peptides in Table 4A and B
are furthermore useful in the diagnosis and/or treatment of various other malignancies
that involve an over-expression or over-presentation of the respective underlying
polypeptide.
Table 1: Peptides according to the present invention.
J = phospho-serine
ID No. ce Gene |D(s) Official Gene (s)
1 GLAGGFGGPGFPV 286887, 3853, 3854 KRT6C, KRT6A, KRT6B
286887, 3848, 3852, KRT6C, KRT1, KRT5,
2 PVCPPGGIQEV 3853, 3854, 9119 KRT6A, KRT6B, KRT75
3 SLYGLGGSKRISI 286887, 3853, 3854 KRT6C, KRT6A, KRT6B
137, 1830,
4 NPPV 64072 DSG3, CDH23
286887, 3848, 3852, KRT6C, KRT1, KRT5,
VCPPGGIQEV 3853, 3854, 9119 KRT6A, KRT6B, KRT75
6 ALYDAELSQM 286887, 3853, 3854 KRT6C, KRT6A, KRT6B
3860, 3861, 3866, KRT13, KRT14, KRT15,
3868, 400578, 644945, KRT16, KRT16P2,
7 ALEEANADLEV 729252 KRT16P3, KRT16P1
8 AQLNIGNVLPV 6132 RPL8
9 STASAITPSV 3852 KRT5
TLWPATPPKA 647024 C6orf132
11 PVI 5621 PRNP
12 TLTDEINFL 286887, 3853, 3854 KRT6C, KRT6A, KRT6B
13 SLVSYLDKV unknown gene
14 RIMEGIPTV 242 ALOX12B
SMLNNIINL 5317 PKP1
16 ALKDSVQRA 10765 KDM5B
17 SIWPALTQV 100381270 ZBED6
18 YLYPDLSRL 6538 1
19 PLL 5655 KLK10
YLINEIDRIRA 667 DST
21 FLHEPFSSV 122665, 84659 RNASE8, RNASE7
22 KLPEPCPSTV 6707 SPRR3
23 SLPESGLLSV 2178 FANCE
24 LLIAINPQV 9635 CLCA2
SLCPPGGIQEV 196374 KRT78
26 TLVDENQSWYL 341208 HEPHL1
_ 12 _
ID No. ce Gene |D(s) Official Gene Symbo|(s)
27 WAV 2196 FAT2
28 AVDPVSGSLYV 57451 TENM2
29 RLLPDLDEV 121551 BTBD11
TLASLGYAW 91039 DPP9
31 HLATVKLLV 54101 RI PK4
32 IQDAEGAIHEV 165904 XIRP1
33 AIYEGVGWNV 571 15 PGLYRP4
34 ALDTFSVQV 171 177 RHOV
ALVGDVILTV 2196 FAT2
36 GLWSSIFSL 123745 PLA2G4E
37 ILLEDVFQL 285973 ATG9B
38 KLLPGVQYV 390928 PAPL
39 LLPEDDTRDNV 1001 CDH3
286887, 3852, 3853, KRT6C, KRT5, KRT6A,
40 LLTPLNLQI 3854 KRT6B
41 RLNGEGVGQVNISV 3853, 3854 KRT6A, KRT6B
42 ALYTSGHLL 5653 KLK6
43 AVLGGKLYV 9903 KLHL21
44 GLGDDSFPI 2125 EVPL
45 GLIEWLENTV 5591 PRKDC
46 GLISSIEAQL 3860 KRT13
47 QLLEGELETL 5493 PPL
48 YLLDYPNNL 26057 ANKRD17
49 YLWEAHTNI 729830 FAM160A1
50 ALSNVVHKV 5268 SERPINB5
51 FLIPSIIFA 150696 PROM2
52 LLFTGLVSGV 284434 NWD1
53 RLVEVGGDVQL 3963, 653499 LGALS7, LGALS7B
54 RLSGEGVGPV 3852 KRT5
55 VLNVGVAEV 285848 PNPLA1
56 FLQLETEQV 64426 SUDS3
ATP5G1, ,
57 AILGFALSEA 516, 517, 518 ATP5G3
58 SLSDIQPCL 3691 ITGB4
59 YLQNEVFGL 1832 DSP
60 SLGNFKDDLL 23650 TR|M29
61 FVAGYIAGV 5250 SLC25A3
62 ILSSACYTV 5317 PKP1
63 NFMKM 3852 KRT5
64 FVJL unknown gene
ID No. Sequence Gene |D(s) Official Gene Symbol(s)
65 ALWGFFPVLL 56851 EMC7
66 TLLSEIAEL 84629 TNRC18
67 WQL 80381 CD276
68 KILEMDDPRA 6512 SLC1A7
69 YVMESMTYL 28976 ACAD9
70 FLFPAFLTA 2150 F2RL1
71 SLFPYWLI 55117 5
72 SLDGNPLAV 25987 TSKU
73 YIDPYKLLPL 54433 GAR1
74 SLTSFLISL 101060198, 7851 MALL
75 ALASAPTSV 80004 ESRP2
76 ILFDEVLTFA 83666 PARP9
77 SLRAFLMPI 79901 CYBRD1
78 VLYGDVEEL 10970 CKAP4
79 GLHQDFPSVVL 51056 LAP3
80 GLYGIKDDVFL 3939 LDHA
Table 2: Additional peptides ing to the present invention with no prior known
cancer association.
ID No. Sequence Gene |D(s) Official Gene (s)
81 VLAENPDIFAV 6541 SLC7A1
82 VLDINDNPPV 120114, 1828, 2195 FAT3, DSG1, FAT1
83 QLLQYWNL 4173 MCM4
84 ALMAGCIQEA 1026 CDKN1A
85 QLIEKITQV 114827 FHAD1
86 SLQERQVFL 9333 TGM5
87 ALPEPSPAA 5339 PLEC
88 LMAPAPSTV 7071 KLF10
89 VLDEGLTSV 25909, 285116 AHCTF1, AHCTF1 P1
90 TLNDGVVVQV 10146 G3BP1
91 MLFENMGAYTV 4953 ODC1
Table 3: es useful for e.g. personalized cancer therapies.
ID No. Sequence Gene |D(s) Official Gene Symbol(s)
92 |LLDVKTRL 3728, 3861, 3868, 3872 JUP, KRT14, KRT16,
_ 14 _
ID No. Sequence Gene |D(s) Official Gene (s)
KRT17
93 ALSNVIHKV 5268 B5
94 SIFEGLLSGV 2709 GJB5
95 SLDENSDQQV 6273 S100A2
96 FQLDPSSGVLVTV 2196 FAT2
97 LILESIPW 5597 MAPK6
98 SLYKGLLSV 25788 RAD54B
99 TASAITPSV 3852 KRT5
100 VLVSDGVHSV 1952 CELSR2
101 GLLPSAESIKL 132989 C4orf36
102 TLAELQPPVQL 157922 CAMSAP1
103 VLAEGGEGV 10630 PDPN
104 SLSPVILGV 26525 |L36RN
105 STYGGGLSV 3861, 3868 KRT14, KRT16
106 VLVDQSWVL 5655 KLK10
107 YLEEDVYQL 23255 SOGA2
108 SLYNLGGSKRISI 3852 KRT5
109 TQV 10643 |GF2BP3
110 LLPPPPPPA 9509 ADAMTS2
111 SLAPGDWRQV 79729 SH3D21
112 ALLDGGSEAYWRV 84985 FAM83A
113 NLMASQPQL 5317 PKP1
1 14 VLVPYEPPQV 8626 TP63
1 15 VTAAYMDTVSL 7498 XDH
116 SLWPSPEQL 90480 GADD45G|P1
117 YQA 871 SERPINH1
286887, 3852, 3853, KRT6C, KRT5, KRT6A,
1 18 TLLQEQGTKTV 3854 KRT6B
119 GLLDPSVFHV 79050 NOC4L
120 YLVAKLVEV 10277 UBE4B
121 RGA 9790 BMS1
122 ILDEAGVKYFL 113828 FAM83F
123 LLSGDLIFL 2709 GJB5
124 YMLDIFHEV 3038 HAS3
125 ALNPEIVSV 5277 PIGA
126 ILVDWLVEV 85417, 890, 8900 CCNB3, CCNA2, CCNA1
127 SLFGKKYIL 2274 FHL2
128 TLHRETFYL 9134 CCNE2
129 SLSGEIILHSV 121441 NEDD1
130 TLDGAAVNQV 3918 LAMC2
W0 37085
_ 15 _
ID No. Sequence Gene |D(s) Official Gene Symbol(s)
131 LQLDKEFQL 24140 FTSJ1
132 FDYV 338322 NLRP10
133 LLLPLQILL 5650 KLK7
134 lLlGETlKl 5742, 5743 PTGS1, PTGS2
135 GLFSQHFNL 1789 DNMT3B
136 SLMEPPAVLLL 8900 CCNA1
689, 154761,
137 GLAPFLLNAV 285966 FAM1 15C
138 ALLTGIISKA 23165 NUP205
139 VTI 285966 FAM1 15C
140 YLFENISQL 57115 PGLYRP4
141 FLNPDEVHAI 81610 FAM83D
142 SLVSEQLEPA 11187 PKP3
143 YVYQNNIYL 2191 FAP
144 KISTITPQI 996 CDC27
145 LLYGKYVSV 84065 TMEM222
146 GLLEELVTV 642475 MROH6
147 ILMDPSPEYA 1786 DNMT1
148 LLFDAPDLRL 55561 CDC42BPG
149 VLLNINGIDL 222484 LNX2
150 ILAEEPIYIRV 55655 NLRP2
151 QLCDLNAEL 3833 KIFC1
152 SLWQDIPDV 128272 ARHGEF19
153 VLFLGKLLV 204962 SLC44A5
154 KMWEELPEW 622 BDH1
155 GLLDNPELRV 26263 FBXO22
156 ALINDILGELVKL 85463 C
The present invention furthermore generally relates to the peptides according to the
present invention for use in the treatment of proliferative diseases, such as, for
e, acute myelogenous leukemia, breast cancer, bile duct cancer, brain cancer,
chronic lymphocytic leukemia, colorectal carcinoma, esophageal cancer, gallbladder
cancer, gastric cancer, hepatocellular cancer, melanoma, non-Hodgkin lymphoma, non-
small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell
cancer, small cell lung cancer, urinary bladder cancer and e cancer.
Particularly preferred are the es — alone or in ation - according to the
present invention selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:
91. More preferred are the peptides — alone or in combination - selected from the group
consisting of SEQ ID NO: 1 to SEQ ID NO: 31 (see Table 1), and their uses in the
immunotherapy of head and neck us cell carcinoma, acute enous
leukemia, breast cancer, bile duct , brain cancer, chronic lymphocytic leukemia,
colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer,
hepatocellular cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer,
ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung
cancer, urinary bladder cancer, uterine cancer, and preferably head and neck
squamous cell carcinoma.
As shown in the following Table 4, many of the peptides according to the present
invention are also found on other tumor types and can, thus, also be used in the
immunotherapy of other indications. Also refer to Figure 1 and Example 1.
Table 4A: Peptides ing to the present invention and their ic uses in other
proliferative diseases, especially in other cancerous diseases. The table shows for
selected es on which additional tumor types they were found and either over-
presented on more than 5% of the measured tumor samples, or presented on more
than 5% of the ed tumor samples with a ratio of geometric means tumor vs
normal tissues being larger than 3. Over-presentation is defined as higher presentation
on the tumor sample as compared to the normal sample with highest presentation.
Normal tissues against which over-presentation was tested were: adipose tissue,
adrenal gland, bile duct, blood cells, blood , bone marrow, brain, esophagus, eye,
gallbladder, heart, kidney, large intestine, liver, lung, lymph node, nerve, pancreas,
parathyroid gland, peritoneum, pituitary, pleura, salivary gland, skeletal muscle, skin,
small intestine, spleen, stomach, thymus, thyroid gland, a, ureter, urinary bladder.
SEQ ID
No Sequence Other relevant organs / diseases
1 GLAGGFGGPGFPV Gallbladder Cancer, Bile Duct Cancer
2 PVCPPGGIQEV NSCLC, SCLC
_ 17 _
SEQ ID
No Sequence Other relevant organs / diseases
3 SLYGLGGSKRISI Esophageal Cancer, y bladder cancer
BRCA, Esophageal Cancer, Urinary bladder
4 NPPV cancer
7 ALEEANADLEV geal Cancer, Urinary bladder cancer
8 AQLNIGNVLPV Melanoma, Esophageal Cancer
9 STASAITPSV Melanoma
1O TLWPATPPKA Gallbladder Cancer, Bile Duct Cancer
11 VLFSSPPVI Melanoma
SMLNNIINL Urinary r cancer
AML, BRCA, Melanoma, Esophageal Cancer,
16 ALKDSVQRA Urinary bladder cancer, Uterine Cancer
SCLC, AML, BRCA, Melanoma, Uterine Cancer,
17 SIWPALTQV Gallbladder Cancer, Bile Duct Cancer
18 YLYPDLSRL Brain Cancer
geal Cancer, Urinary bladder cancer,
19 PLL Uterine Cancer
YLINEIDRIRA NSCLC, Urinary bladder cancer
21 FLHEPFSSV Urinary bladder cancer
23 SLPESGLLSV Esophageal Cancer
24 LLIAINPQV AML, Urinary bladder cancer
27 YLAEPQWAV Esophageal Cancer, Urinary bladder cancer
29 RLLPDLDEV AML
31 HLATVKLLV Urinary bladder cancer, Uterine Cancer
NHL, ma, Esophageal Cancer, Urinary
32 IQDAEGAIHEV bladder cancer
37 lLLEDVFQL Gallbladder , Bile Duct Cancer
BRCA, Esophageal Cancer, Urinary bladder
39 LLPEDDTRDNV cancer
41 RLNGEGVGQVNISV Esophageal Cancer
Esophageal Cancer, Gallbladder Cancer, Bile
42 ALYTSGHLL Duct Cancer
43 LYV CLL, NHL, AML, Melanoma, Uterine Cancer
45 GLIEWLENTV SCLC, OC, Urinary bladder cancer
Esophageal Cancer, Urinary r cancer,
46 GLISSIEAQL Uterine Cancer
47 QLLEGELETL Urinary bladder cancer, Uterine Cancer
NHL, BRCA, Melanoma, Esophageal Cancer,
Urinary bladder cancer, Uterine ,
48 YLLDYPNNL Gallbladder Cancer, Bile Duct Cancer
49 YLWEAHTNI Esophageal Cancer, Uterine Cancer
50 ALSNVVHKV GC, BRCA, geal Cancer, Urinary bladder
W0 37085
_ 18 _
SEQ ID
No ce Other relevant organs / diseases
cancer
51 FLIPSIIFA Urinary bladder cancer, Uterine Cancer
52 LLFTGLVSGV Esophageal Cancer
53 GDVQL Esophageal , Urinary bladder cancer
54 RLSGEGVGPV Esophageal Cancer
BRCA, Melanoma, Urinary bladder cancer,
56 FLQLETEQV Uterine Cancer
AML, BRCA, Melanoma, Uterine Cancer,
57 AILGFALSEA Gallbladder Cancer, Bile Duct Cancer
Brain Cancer, BRCA, Esophageal Cancer,
58 SLSDIQPCL Urinary bladder cancer, Uterine Cancer
59 YLQNEVFGL SCLC, NHL
NHL, Esophageal Cancer, Urinary bladder
60 SLGNFKDDLL cancer
NSCLC, SCLC, RCC, Brain Cancer, GC, CLL,
NHL, Esophageal Cancer, Gallbladder Cancer,
61 FVAGYIAGV Bile Duct Cancer
62 ILSSACYTV RCC, BRCA, Esophageal Cancer
63 ALMDEINFMKM NSCLC, SCLC, NHL
NSCLC, Urinary bladder , Gallbladder
64 KILEJLFVJL Cancer, Bile Duct Cancer
65 ALWGFFPVLL CLL, Melanoma
66 TLLSEIAEL CLL, NHL, AML, Melanoma, OC, Uterine Cancer
SCLC, Melanoma, OC, Uterine Cancer,
67 WQL Gallbladder , Bile Duct Cancer
Urinary r cancer, Gallbladder Cancer, Bile
69 YVMESMTYL Duct Cancer
70 FLFPAFLTA AML, Gallbladder Cancer, Bile Duct Cancer
71 SLFPYWLI Melanoma
Esophageal Cancer, e Cancer, Gallbladder
72 SLDGNPLAV Cancer, Bile Duct Cancer
73 YIDPYKLLPL CLL, NHL, AML, Melanoma
74 ISL Urinary bladder cancer
BRCA, Esophageal Cancer, Uterine Cancer,
75 ALASAPTSV Gallbladder Cancer, Bile Duct Cancer
CLL, NHL, AML, BRCA, Uterine Cancer,
76 lLFDEVLTFA Gallbladder Cancer, Bile Duct Cancer
77 SLRAFLMPI AML
CLL, Urinary bladder cancer, Gallbladder
78 VLYGDVEEL Cancer, Bile Duct Cancer
79 GLHQDFPSVVL NHL, BRCA, e Cancer
81 VLAENPDIFAV SCLC, MCC, Melanoma, Urinary bladder cancer
_ 1g _
SEQ ID
No Sequence Other relevant organs / diseases
82 VLDINDNPPV Melanoma
83 QLLQYWNL SCLC, NHL, AML, Uterine Cancer
SCLC, NHL, Melanoma, Urinary bladder cancer,
85 QLIEKITQV Gallbladder , Bile Duct Cancer
86 SLQERQVFL NHL, y bladder cancer
RCC, NHL, Melanoma, Gallbladder Cancer, Bile
87 ALPEPSPAA Duct Cancer
Brain Cancer, Esophageal Cancer, Urinary
88 LMAPAPSTV bladder cancer
SCLC, RCC, CLL, NHL, BRCA, Melanoma,
89 VLDEGLTSV Urinary bladder cancer, Uterine Cancer
RCC, CLL, NHL, geal Cancer, Urinary
90 TLNDGVVVQV bladder cancer, Uterine Cancer
91 MLFENMGAYTV SCLC, CLL, NHL, Uterine Cancer
NSCLC= non-small cell lung cancer, SCLC= small cell lung cancer, RCC= kidney
cancer, CRC= colon or rectum cancer, GC= h cancer, HCC= liver cancer, PC=
pancreatic cancer, PrC= prostate cancer, leukemia, BRCA=breast cancer, OC = ovarian
cancer, NHL = non-Hodgkin ma, AML = acute myelogenous leukemia, CLL =
chronic lymphatic leukemia
Table 4B: Peptides according to the present ion and their specific uses in other
proliferative diseases, especially in other cancerous diseases. The table shows for
ed peptides on which onal tumor types they were found and either over-
presented on more than 5% of the measured tumor samples, or presented on more
than 5% of the measured tumor samples with a ratio of ric means tumor vs
normal tissues being larger than 3. Over-presentation is defined as higher presentation
on the tumor sample as compared to the normal sample with highest presentation.
Normal tissues against which resentation was tested were: adipose tissue,
adrenal gland, artery, bone marrow, brain, central nerve, colon, esophagus, eye,
gallbladder, heart, kidney, liver, lung, lymph node, white blood cells, pancreas,
parathyroid gland, peripheral nerve, peritoneum, pituitary, , rectum, salivary
gland, skeletal muscle, skin, small intestine, spleen, stomach, thymus, thyroid gland,
trachea, ureter, urinary bladder, vein.
WO 37085
_ 20 _
SEQ ID
No Sequence Additional Entities
2 PVCPPGGIQEV Esophageal Cancer
6 ALYDAELSQM Esophageal Cancer
8 AQLNIGNVLPV y bladder cancer
9 STASAITPSV Esophageal Cancer
16 ALKDSVQRA HCC
43 AVLGGKLYV RCC, GC, HCC
45 GLIEWLENTV HCC
47 QLLEGELETL 0C
50 ALSNVVHKV NSCLC
51 FLIPSIIFA 0C
56 FLQLETEQV 0C
57 AILGFALSEA HCC
60 SLGNFKDDLL NSCLC
61 FVAGYIAGV HCC
65 PVLL HCC
66 TLLSEIAEL HCC
BRCA, y bladder
73 YIDPYKLLPL cancer
75 ALASAPTSV HCC
88 LMAPAPSTV Melanoma
89 VLDEGLTSV GC
NSCLC= non-small cell lung cancer, HCC= liver cancer, BRCA= breast cancer, RCC=
renal cell oma, GC= gastric cancer, rian .
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 1, 10, 17, 37, 42,
48, 57, 61, 67, 69, 70, 72, 75, 76, 78, and 87 for the — in one preferred embodiment
combined - treatment of gallbladder cancer and/or bile duct cancer.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 2, 20, 50, 60, 61,
63, and 64 for the — in one preferred embodiment combined - treatment of NSCLC.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention ing to any one of SEQ ID No. 2, 17, 45, 59, 61,
63, 67, 81, 83, 85, 89, and 91 for the — in one preferred embodiment combined -
treatment of SCLC.
Thus, r aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 2, 3, 4, 6, 7, 8, 9,
16, 19, 23, 27, 32, 39, 41, 42, 46, 48, 49, 50, 52, 53, 54, 58, 60, 61, 62, 72, 75, 88, and
90 for the — in one red embodiment combined - ent of esophageal cancer.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 3, 4, 7, 8, 15, 16,
19, 20, 21, 24, 27, 31, 32, 39, 45,46, 47, 48, 50, 51, 53, 56, 58, 60, 64, 69, 73, 74, 78,
81, 85, 86, 88, 89, and 90 for the — in one preferred ment combined - ent
of urinary bladder cancer.
Thus, another aspect of the present invention relates to the use of at least one peptide
ing to the present invention according to any one of SEQ ID No. 4, 16, 17, 39, 48,
50, 56, 57, 58, 62, 73, 75, 76, 79, and 89, for the — in one preferred embodiment
combined - treatment of BRCA.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 8, 9, 11, 16, 17,
32, 43, 48, 56, 57, 65, 66, 67, 71, 73, 81, 82, 85, 87, 88, and 89 for the — in one
preferred embodiment combined - treatment of melanoma.
Thus, another aspect of the present invention s to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 16, 17, 24, 29,
43, 57, 66, 70, 73, 76, 77, and 83 for the — in one preferred embodiment combined -
treatment of AML.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 16, 17, 19, 31,
43, 46, 47, 48, 49, 51, 56, 57, 58, 66, 67, 72, 75, 76, 79, 83, 89, 90, and 91 forthe — in
one preferred embodiment combined - treatment of uterine cancer.
Thus, another aspect of the present invention s to the use of at least one peptide
according to the t invention according to any one of SEQ ID No. 18, 58, 61, and
88 for the — in one preferred embodiment combined - treatment of brain cancer.
Thus, another aspect of the present invention s to the use of at least one e
according to the present invention according to any one of SEQ ID No. 32, 43, 48, 59,
60, 61, 63, 66, 73, 76, 79, 83, 85, 86, 87, 89, 90, and 91 for the — in one preferred
embodiment combined - treatment of NHL.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 43, 61, 65, 66,
73, 76, 78, 89, 90, and 91 for the — in one preferred embodiment combined - treatment
of CLL.
Thus, another aspect of the t invention relates to the use of at least one peptide
according to the t invention according to any one of SEQ ID No. 45, 47, 51, 56,
66, and 67 for the — in one preferred ment combined - treatment of 00.
Thus, another aspect of the present invention relates to the use of at least one e
according to the present invention according to any one of SEQ ID No. 43, 50, 89, and
61 for the — in one red embodiment combined - treatment of GC.
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 16, 43, 45, 57,
61, 65, 66, and 75 for the — in one preferred embodiment combined - treatment of HCC.
_ 23 _
Thus, another aspect of the present invention relates to the use of at least one peptide
according to the present invention according to any one of SEQ ID No. 43, 61, 62, 87,
89, and 90 for the — in one preferred embodiment combined - treatment of RCC.
Thus, another aspect of the present invention relates to the use of the peptides
according to the present invention for the - ably combined - ent of a
proliferative disease selected from the group of head and neck squamous cell
carcinoma, acute myelogenous leukemia, breast cancer, bile duct cancer, brain cancer,
chronic lymphocytic leukemia, colorectal carcinoma, esophageal cancer, gallbladder
cancer, gastric cancer, hepatocellular , melanoma, non-Hodgkin lymphoma, non-
small cell lung cancer, ovarian cancer, atic cancer, prostate cancer, renal cell
cancer, small cell lung cancer, urinary bladder cancer and uterine cancer.
The present invention furthermore relates to peptides according to the present ion
that have the ability to bind to a molecule of the human major histocompatibility complex
(MHC) Class-I or - in an elongated form, such as a length-variant - MHC class -II.
The present invention r relates to the peptides ing to the present invention
wherein said peptides (each) consist or consist essentially of an amino acid sequence
according to SEQ ID NO: 1 to SEQ ID NO: 91.
The present invention further relates to the peptides according to the t ion,
wherein said e is modified and/or includes non-peptide bonds.
The present invention further relates to the peptides ing to the present invention,
wherein said peptide is part of a fusion protein, in particular fused to the N-terminal
amino acids of the HLA-DR antigen-associated invariant chain (Ii), or fused to (or into
the sequence of) an antibody, such as, for example, an antibody that is specific for
dendritic cells.
The present invention r relates to a nucleic acid, encoding the peptides according
to the present invention. The present invention further relates to the nucleic acid
according to the present invention that is DNA, cDNA, PNA, RNA or ations
thereof.
The present ion further relates to an expression vector capable of expressing
and/or expressing a nucleic acid according to the present invention.
The present invention further relates to a peptide according to the present invention, a
nucleic acid according to the present ion or an expression vector according to the
present invention for use in the treatment of diseases and in medicine, in particular in
the ent of cancer.
The present invention further relates to antibodies that are ic against the peptides
according to the present invention or complexes of said peptides ing to the
present ion with MHC, and methods of making these.
The t ion further relates to T-cell receptors (TCRs), in particular soluble
TCR (sTCRs) and cloned TCRs engineered into autologous or allogeneic T cells, and
methods of making these, as well as NK cells or other cells bearing said TCR or cross-
reacting with said TCRs.
The antibodies and TCRs are additional embodiments of the immunotherapeutic use of
the peptides according to the invention at hand.
The present invention further relates to a host cell comprising a nucleic acid according
to the present invention or an expression vector as described before. The present
invention further relates to the host cell according to the present invention that is an
antigen presenting cell, and preferably is a dendritic cell.
The present invention further relates to a method for producing a peptide according to
the present invention, said method comprising culturing the host cell according to the
present invention, and isolating the peptide from said host cell or its culture medium.
The present invention further relates to said method according to the present invention,
wherein the antigen is loaded onto class I or II MHC molecules sed on the
surface of a suitable n-presenting cell or artificial antigen-presenting cell by
contacting a sufficient amount of the antigen with an antigen-presenting cell.
The present invention further relates to the method according to the present invention,
wherein the antigen-presenting cell comprises an expression vector capable of
expressing or expressing said peptide ning SEQ ID No. 1 to SEQ ID No.: 91,
preferably containing SEQ ID No. 1 to SEQ ID No. 31, or a variant amino acid
sequence.
The present invention further relates to activated T cells, produced by the method
according to the present invention, n said T cell ively recognizes a cell
which expresses a polypeptide comprising an amino acid sequence ing to the
present invention.
The present invention further relates to a method of killing target cells in a patient which
target cells aberrantly express a polypeptide comprising any amino acid sequence
according to the present invention, the method comprising administering to the t
an effective number ofT cells as produced according to the present invention.
The present invention further relates to the use of any peptide as described, the nucleic
acid according to the t invention, the expression vector according to the present
invention, the cell according to the t invention, the activated T lymphocyte, the T
cell receptor or the antibody or other e- and/or peptide-MHC-binding molecules
according to the present invention as a medicament or in the manufacture of a
medicament. ably, said medicament is active against cancer.
Preferably, said medicament is a cellular therapy, a vaccine or a protein based on a
soluble TCR or antibody.
The present invention further relates to a use according to the present invention,
wherein said cancer cells are head and neck squamous cell carcinoma, acute
myelogenous leukemia, breast cancer, bile duct , brain cancer, chronic
lymphocytic leukemia, colorectal carcinoma, geal cancer, adder cancer,
gastric cancer, hepatocellular cancer, ma, non-Hodgkin lymphoma, non-small
cell lung cancer, ovarian cancer, pancreatic cancer, prostate , renal cell ,
small cell lung cancer, urinary bladder cancer, uterine cancer, and preferably head and
neck squamous cell carcinoma cells.
The present invention further relates to biomarkers based on the peptides according to
the t invention, herein called “targets” that can be used in the sis of
cancer, preferably head and neck squamous cell carcinoma. The marker can be over-
presentation of the peptide(s) themselves, or over-expression of the corresponding
gene(s). The markers may also be used to predict the probability of success of a
treatment, ably an immunotherapy, and most red an immunotherapy
targeting the same target that is identified by the biomarker. For example, an antibody
or soluble TCR can be used to stain ns of the tumor to detect the presence of a
peptide of interest in complex with MHC.
Optionally the antibody carries a further effector function such as an immune stimulating
domain or toxin.
The present invention also s to the use of the inventive novel targets in the context
of cancer treatment.
ALOX’IZB is involved in terminal skin differentiation and epidermal barrier function
(Furstenberger et al., 2007; Epp et al., 2007). ALOX’IZB is an immunosuppressive
factor amplified in cancer (Rooney et al., 2015). Cisplatin induces and ATM
phosphorylates (p)—DeltaNp63alpha. Subsequently, it up-regulates miR5p which
down-regulates let7-5p resulting in the modulation of ALOX12B expression in
squamous cell carcinoma (Ratovitski, 2013). ALOX12B is associated with breast cancer
and lung cancer risk (Lee et al., 2009; Shen et al., 2009).
7 mRNA levels are widely down-regulated in colorectal carcinomas and make
this protein a potential marker for multi-target assay panels for ctal cancer
detection (loana et al., 2010). Through the phosphorylation of ANKRD17 by cyclin
E/CdK2 the protein is ed in cell cycle regulation. Over-expression promotes S
phase entry, whereas depletion of expression inhibits DNA replication, blocks cell cycle
progression and ulates the expression of the tumor suppressors p53 and p21
(Deng et al., 2009).
ATP5G1 is enriched in the oxidative phosphorylation pathway in c cancer (Song et
al., 2016). ATP5G1 sion is reduced in head and neck squamous cell carcinoma
(Koc et al., 2015). Knock-out of augmenter of liver regeneration (ALR) results in
accelerated development of steatohepatitis and hepatocellular carcinoma in mice.
Further, ATP5G1 expression is reduced in ALR knock-down mice (Gandhi et al., 2015).
ATP5G2 is more ated in high-grade bladder cancer tumors compared to low-
ediate-grade tumors (Kitchen et al., 2016). RIZ1 is a tumor suppressor whose
depletion results in altered ATP5G2 expression (Xie et al., 2016b). ATP5G2 is highly
expressed upon estrogen and progesterone treatment in endometrial lshikawa cancer
cell line (Tamm-Rosenstein et al., 2013). ATP5G2 promoter is methylated in primary
renal cell carcinoma (Morris et al., 2011).
ATP5G3 is enriched in the oxidative phosphorylation pathway in gastric cancer (Song et
al., 2016). ATP5G3 is up-regulated upon pha activation which is negatively
correlated with tumor ssion and which suppresses cell ion (Huang and
Chang, 2016). ATP5G3 may be a radiation susceptibility gene (Tsuji et al., 2005).
BTBD11 encodes BTB domain ning 11 and is located on chromosome 3
(RefSeq, 2002). BTBD11 is differentially sed in papillary thyroid cancer (Qu et al.,
2016). BTBD11 is a TGF-beta target gene (Sawada et al., 2016). BTBD11 is mutated in
gastric cancer (Leiserson et al., 2015; son et al., 2016).
Prognostic association of CD276 differs between smoking and non-smoking patients
with lung adenocarcinoma. High CD276 expression is linked to smoking ra et al.,
2017). CD276 is hyper-methylated in prostate cancer (Wang et al., 2016b). CD276 is
regulated by miR-124 which is down-regulated in osteosarcoma. ta1 up-
regulates 5 through SMAD 3 and 4 signaling resulting in miR-143 attenuation by
CEBPB inhibition which causes CD276 accumulation. CD276 is regulated by miR-187
which is down-regulated in colorectal cancer (Wang et al., 2016e; Trojandt et al., 2016;
Zhou et al., 2016; Wang et al., 2016a). CD276 mediates abnormal lipid metabolism in
lung cancer by affecting SREBP-1/FASN signaling. Soluble CD276 mediates pancreatic
cancer invasion and metastasis through TLR4/NF-kappaB signaling (Xie et al., 2016a;
Luo et al., 2016). CD276 is an immune checkpoint which may be a promising target in
cancer therapy. It may be targeted during tumor growth to suppress anti-tumor immunity
providing immune evasion for the emerging tumor (Leung and Suh, 2014; Swatler and
Kozlowska, 2016; Janakiram et al., 2016). CD276 is expressed by most isk
neuroblastomas, is over-expressed in tumor vasculature and plays an ant role in
tumor survival and veness (Bottino et al., 2014). Knock-down of CD276 increases
chemo sensitivity and decreases metastatic potential. Knock-down of CD276 results in
increased apoptotic marker expression and STAT3 phosphorylation. Astragaloside N
treatment reduces cell growth and increases chemo sensitivity to cisplatin by inhibiting
CD276 in non-small cell lung cancer cells (Nygren et al., 2011; He et al., 2016). CD276
is over-expressed in geal cancer, breast cancer, adder cancer, prostate
cancer, and ovarian cancer (Barach et al., 2011; Janakiram et al., 2012; Fauci et al.,
2012; Chen et al., 2016; Liu et al., 2016). CD276 over-expression is correlated with poor
sun/ival, prognosis, and tumor grade. CD276 promotes cancer on and
progression. However, CD276 may also have anti-tumor effects. High CD276
WO 37085
_ 29 _
expression is an indicator of lymph node metastasis and advanced TNM stage in non-
small cell lung cancer (Yi and Chen, 2009; Loos et al., 2010; Nygren et al., 2011; Fauci
et al., 2012; Wang et al., 2014a; Ye et al., 2016; Benzon et al., 2016; Wu et al., 2016).
CD276 down-regulates natural killer cells cytotoxicity supporting cancer immune
evasion (Bottino et al., 2014).
CDH23 encodes cadherin related 23 which is a member of the cadherin superfamily,
whose genes encode calcium dependent cell-cell adhesion glycoproteins. The encoded
protein is thought to be ed in stereocilia organization and hair bundle formation.
The gene is located in a region containing the human deafness loci DFNB12 and
USH1D. Usher syndrome 1D and nonsyndromic autosomal recessive deafness
DFNB12 are caused by allelic mutations of this cadherin-like gene. Up-regulation of this
gene may also be associated with breast cancer (RefSeq, 2002). TMPRSS3 is a poor
prognostic factor in breast cancer and can interact with CDH23 (Rui et al., 2015).
CDH23 is up-regulated upon leptin treatment in ERalpha expressing breast cancer cells
(Binai et al., 2013). CDH23 is up-regulated in breast cancer and may be involved in
early stage asis (Apostolopoulou and Ligon, 2012). Loss of CDH23 can be
ed in pancreatic cancer cell lines (Suzuki et al., 2008).
CDH3 is involved in oncogenic signaling and activates integrins, receptor tyrosine
kinases, small molecule GTPases, EMT transcription factors, and other in family
members. CDH3 signaling induces invasion and metastasis (Albergaria et al., 2011;
Paredes et al., 2012; Bryan, 2015; Vieira and Paredes, 2015). Oncogenic activation of
CDH3 is involved in gastric carcinogenesis (Resende et al., 2011). CDH3 over-
expression promotes breast , bladder cancer, ovarian cancer, prostate cancer,
endometrial cancer, skin , gastric cancer, pancreas cancer, and colon cancer
(Albergaria et al., 2011; Paredes et al., 2007; Bryan and Tselepis, 2010; Reyes et al.,
2013; Vieira and Paredes, 2015). CDH3 is a basal epithelial marker expressed in basal-
like breast cancer. BRCA1 carcinomas are terized by the expression of basal
markers like CDH3 and show a high-grade, highly proliferating, ER-negative, and
HER3-negative ype (Honrado et al., 2006; Palacios et al., 2008; Rastelli et al.,
2010; Dewar et al., 2011). CDH3 is a tumor suppressor in melanoma and oral
squamous cell carcinoma (Haass et al., 2005; Vieira and s, 2015). CDH3 may be
used as EMT marker. There is a shift from E-cadherin to N-cadherin and CDH3
expression during tumor formation and progression (Piura et al., 2005; Bonitsis et al.,
2006; Bryan and Tselepis, 2010; Ribeiro and Paredes, 2014). Competitive interaction
between CDH3 and beta-catenin causes impaired intercellular interactions and
metastases in gastric cancer (Moskvina and Mal'kov, 2010). CDH3 may be an early
marker of cancer formation in colon cancer (Alrawi et al., 2006). Dys-regulation of CDH3
is a marker for poor prognosis and increased malignancy (Knudsen and Wheelock,
2005).
Over-expression of CLCA2 down-regulates beta-catenin and beta-catenin-activated
genes (Ramena et al., 2016). CLCA2 strongly interacts with EVA1 which is also
inducible by p53 and p63, frequently down-regulated in breast cancer causing EMT, and
important for epithelial differentiation. Both proteins interact with E-cadherin (Ramena et
al., 2016). There is an AML1-CLCA2 and a RUNX1-CLCA2 gene fusion product in adult
acute myeloid leukemia (Giguere and Hebert, 2010; Jiang et al., 2013). CLCA2 is
inducible by p73, p53, and p63 upon DNA damage and acts as an inhibitor of
proliferation (Walia et al., 2009; Sasaki et al., 2012; Yu et al., 2013; Ramena et al.,
2016). CLCA2 expression is ed in circulating tumor cells from patients with lung
adenocarcinoma and sed detection is ated with shortened t survival
(Hayes et al., 2006; Man et al., 2014). CLCA2 is higher expressed in squamous cell
oma of the lung compared to adenocarcinoma and is associated with histological
tumor grade. CLCA2 sion may be used to detect non-small cell lung carcinoma
and small cell lung carcinoma (Hayes et al., 2006; Shinmura et al., 2014). down
of CLCA2 causes epithelial-to-mesenchymal transition, cancer cell migration, and
invasion. Under normal condition, CLCA2 is thought to suppress ion and invasion
through inhibition of the FAK signaling pathway. CLCA2 mediates lung metastasis in
association with beta(4) integrin -Ghany et al., 2001; Walia et al., 2012; Sasaki et
al., 2012; Ramena et al., 2016). CLCA2 is down-regulated in breast cancer because of
promotor hyper-methylation and is down-regulated in colorectal cancer. CLCA2 is
_ 31 _
differentially expressed in bladder carcinoma and during the metastatic transformation
of melanoma. There are copy number losses for CLCA2 in mantle cell lymphoma
(Gruber and Pauli, 1999; Bustin et al., 2001; Li et al., 2004; Balakrishnan et al., 2006;
Riker et al., 2008; Walia et al., 2012; Matin et al., 2014; Ramena et al., 2016).
DSG1 is over-expressed in keratocystic odontogenic tumors and shows high rates of
expression in oral intra-epithelial neoplasms (Aizawa et al., 2014; Heikinheimo et al.,
2015). DSG1 expression is lost in acantholytic squamous cell oma and down-
regulated in chondrosarcoma, oral squamous cell carcinoma, and lung cancer (Xin et
al., 2014; Saaber et al., 2015; Galoian et al., 2015; Jurcic et al., 2015). DSG1
expression is regulated by GRHL1 and GRHL1-negative mice treated with a standard
chemical skin carcinogenesis protocol develop fewer papilloma but more squamous cell
carcinomas (Mlacki et al., 2014). DSG1, which is a downstream target of Rhoda and
GEF Bcr, is a keratinocyte entiation marker (Dubash et al., 2013). KLK5 cleaves
DSG1 which may be ated with metastases formation in oral squamous cell
carcinoma. Reduced levels of DSG1 might be involved in pancreatic cancer invasion
(Ramani et al., 2008; Jiang et al., 2011). Negative DSG1 staining is associated with
improved anal cancer-specific survival and positive staining is associated with large
tumor size and lymph node ases. Loss of DSG1 is linked to bad prognosis in
head and neck squamous cell carcinoma (Wong et al., 2008; Myklebust et al., 2012).
Autoantibodies against DSG1 can be detected in paraneoplastic pemphigus (Seishima
et al., 2004).
DSG3 expression in esophageal squamous cell carcinoma was shown to be highly
correlated with histological grade and to have an impact on survival in esophageal
squamous cell carcinoma, with negative DSG3 sion indicating worse survival.
Thus, DSG3 may be involved in the progression of esophageal us cell
carcinoma and may serve as a prognostic marker (Fang et al., 2014). In primary lung
, higher expression of DSG3 and DSG2 was shown to be correlated to the
diagnosis of squamous cell lung carcinoma, while a lower expression of DSG3 was
shown to be significantly linked to higher tumor grade. Thus, DSG3 may serve as a
potential diagnostic marker for squamous cell lung oma and a ial
differentiation marker for lung cancer (Saaber et a|., 2015). DSG3 was described as a
negative prognostic biomarker in resected pancreatic ductal adenocarcinoma as high
DSG3 expression was shown to be ated with poor overall survival and poor
tumor-specific survival. Thus, DSG3 and its downstream signaling pathways may be
possible therapeutic s in xpressing pancreatic ductal adenocarcinoma
(Ormanns et a|., 2015).
Reduced expression of DSP is correlated with the tumor progression of several s
including breast, lung and cervical cancer (Schmitt-Graeff et al., 2007; Davies et al.,
1999; Yang et a|., 2012b). Expression of DSP significantly suppresses cell proliferation,
anchorage-independent growth, migration and invasion in lung cancer cells through
inhibiting the Wnt/beta-catenin signaling pathway (Yang et a|., 2012b).
DST may be related to breast cancer metastasis (Sun et a|., 2006). Autoantibodies
t DST can be found in lymphocytic leukemia and follicular lymphomas (Aisa et a|.,
2005; Taintor et a|., 2007). DST is ulated in 5-8F cells (high tumorigenic and
metastatic ability) in comparison to 6-1OB cells (tumorigenic, but lacking atic
ability) in nasopharyngeal carcinoma (Fang et a|., 2005). DST is highly expressed in
head and neck squamous cell carcinoma (Lin et a|., 2004). There are autoantibodies
against DST in paraneoplastic pemphigus which is associated with neoplasms (Yong
and Tey, 2013; Wang et a|., 2005; Preisz and Karpati, 2007; Zhu and Zhang, 2007).
DST expression in prostate cancer is strongly inverse correlated with progression
(Vanaja et a|., 2003). Anti-DST autoantibodies are a promising marker for the diagnosis
of melanoma (Shimbo et al., 2010). DST can be found in the urine of cachectic cancer
patients (Skipworth et al., 2010). DST is differentially expressed in adenocarcinomas
and squamous cell carcinomas of the lung (McDoniels-Silvers et al., 2002). DST is
ctly up-regulated with the onset of ve cell growth (Herold-Mende et a|.,
2001).
_ 33 _
EMC7 s ER membrane protein complex subunit 7 and is located on
chromosome 15q14 (RefSeq, 2002). EMC7 may be a novel druggable target and
stic biomarker in cancer (Delgado et al., 2014). EMC7 is down-regulated in a
pingyangmycin-resistant tongue squamous cell carcinoma cell line (Zheng et al., 2010).
ESRP2 encodes an epithelial cell-type-specific splicing regulator (RefSeq, 2002).
ESRP2 inhibits cancer cell motility in different cancer types including lung and breast
cancer cells. ESRP2 is egulated by TGF-beta in invasive fronts, leading to an
increased expression of epithelial-mesenchymal transition-associated ription
factors (Gemmill et al., 2011; Horiguchi et al., 2012; lshii et al., 2014).
A on in the PH-domain binding motif of F2RL1 is sufficient to decrease breast
tumor growth (Bar-Shavit et al., 2016). F2RL1 is over-expressed in gastric cancer and is
inversely correlated with overall survival of patients (Sedda et al., 2014). Tryptase is a
mediator of angiogenesis released by mast cells which activates F2RL1 resulting in
cancer cell proliferation, invasion, and metastasis (Marech et al., 2014; Ammendola et
al., 2014). F2RL1 is affected by differentially expressed and d genes in cancer
(D'Asti et al., 2014). F2RL1 is involved in cancer progression, invasion, and metastasis
(Wojtukiewicz et al., 2015; Canto et al., 2012; Lima and ro, 2013; Gieseler et al.,
2013). F2RL1 is expressed in arcinomas, melanomas, osteosarcomas,
glioblastomas, meningiomas, leukemias, and squamous cell carcinomas (Elste and
Petersen, 2010). F2RL1 regulates the expression of ALK5 which is a TGF-beta type I
receptor. F2RL1 activates MAP kinases (Oikonomopoulou et al., 2010; Witte et al.,
2016). Up-regulation of tissue factor and integrins mediate F2RL1 signaling promoting
metastasis (Kasthuri et al., 2009; Ruf et al., 2011; Kocaturk and Versteeg, 2012; Ruf,
2012; Kocaturk and eg, 2013). Trypsin and PAR2 form an autocrine loop
promoting proliferation, invasion, and metastasis. Trypsin stimulation may result in
MAPK-ERK pathway activation through MMP- and PAR2-dependent activation of
mal growth factor or (Soreide et al., 2006).
FAM160A1 s family with sequence similarity 160 member A1 and is located on
chromosome 4q31.3 (RefSeq, 2002). FAM160A1 expression is altered upon DY131
_ 34 _
binding to estrogen d receptor beta in prostate cancer (Lu et a|., 2015b). There is
a NFKB-FAM160A1 gene fusion product in te cancer (Teles, I et a|., 2015).
FAM160A1 is up-regulated in ovarian cancer compared to benign tumors (Li et a|.,
2012a). A deletion in FAM160A1 can be found in familial and early-onset breast cancer
schi et a|., 2012). FAM160A1 is down-regulated in colorectal cancer (Li et a|.,
2012b).
FANCE is associated with esophageal squamous cell carcinoma risk (Li et al., 2013).
Rare down-regulation of FANCE can be obsen/ed in head and neck squamous cell
carcinoma (Wreesmann et a|., 2007). Chk1 mediates the orylation of FANCE
upon DNA inking (Wang et al., 2007). Familial colorectal cancer shows a
heterozygous genotype for FANCE. Fanconi anemia DNA damage repair may be linked
to inherited pre-disposition to colorectal cancer. An indel mutation might be involved in
inherited esophageal squamous cell carcinoma. A missense variant in FANCE was
found in one family with breast cancer (Akbari et a|., 2011; Seal et a|., 2003; Esteban-
Jurado et a|., 2016). FANCE is ed in the regulation of cisplatin sensitivity
(Taniguchi et a|., 2003).
FAT1 was described as being significantly mutated in squamous-cell cancer of the head
and neck, frequently mutated in al adenocarcinoma, bladder , early T-cell
precursor acute lymphoblastic ia, fludarabine refractoriness chronic lymphocytic
leukemia, glioblastoma and ctal cancer and mutated in esophageal squamous cell
carcinoma (Gao et a|., 2014; Neumann et al., 2013; Morris et al., 2013; Messina et al.,
2014; ios et a|., 2014; Cazier et a|., 2014; Chung et a|., 2015). FAT1 was
described as being repressed in oral cancer and preferentially down-regulated in
invasive breast cancer (Katoh, 2012). FAT1 was described as being up-regulated in
leukemia which is associated with a poor prognosis in preB-acute blastic
leukemia (Katoh, 2012). FAT1 was shown to be up-regulated in pancreatic
adenocarcinoma and hepatocellular carcinoma (Valletta et al., 2014; Wojtalewicz et al.,
2014). FAT1 was described to suppress tumor growth via activation of Hippo signaling
and to promote tumor migration via induction of actin polymerization (Katoh, 2012).
FAT1 was shown to be a candidate cancer driver gene in cutaneous squamous cell
oma (Pickering et al., 2014). FAT1 was described as a tumor suppressor which is
associated with Wnt signaling and tumorigenesis (Morris et a|., 2013).
FAT3 was shown to be down-regulated in Taxol resistant n carcinoma cell lines
upon silencing of en receptor, resulting in increased sensitization to Taxol in
these cell lines. Thus, FAT3 may be a candidate gene associated with Taxol resistance
(Sun et al., 2015b). FAT3 was shown to be mutated in esophageal us cell
carcinoma, resulting in ulation of the Hippo signaling pathway (Gao et a|., 2014).
FAT3 was shown to be mutated recurrently in early T-cell precursor acute |ymphob|astic
leukemia nn et al., 2013). FAT3 was described as a gene with signatures
specific for meningothelial meningiomas, therefore being associated with tumorigenesis
in this subtype of benign meningiomas (Fevre-Montange et a|., 2009). FAT3 was
described as a tumor suppressor which is repressed upon lung cancer development
from dysp|astic cells (Rohrbeck and Borlak, 2009).
FHAD1 is down-regulated upon NFE2 knock-down which is involved in oxidative stress
response (Williams et al., 2016). CpG methylation of FHAD1 may be used as ker
in metastatic-lethal prostate cancer (Zhao et a|., 2017). FHAD1 is down-regulated in
esophageal squamous cell carcinoma and may contribute to chemoresistance t
cisplatin (Tsutsui et al., 2015). FHAD1 may be a tumor suppressor gene in breast
cancer (lorns et al., 2012).
G3BP1 encodes G3BP stress granule ly factor 1 which is one of the DNA-
unwinding enzymes which prefers partially unwound 3'-tailed ates and can also
unwind partial RNA/DNA and RNA/RNA duplexes in an ATP-dependent fashion
(RefSeq, 2002). G3BP1 may be used as kerfor drug response in HER2+ breast
cancer (Chien et a|., 2016). miR-193a-3p, which inhibits the progression and metastasis
of lung cancer in vitro and in vivo, down-regulates G3BP1 (Deng et a|., 2015). G3BP1 is
a direct target of resveratrol. Depletion of G3BP1 reduces the resveratrol-induced p53
expression and apoptosis. G3BP1 is a negative regulator of p53 by interacting with
_ 36 _
USP10, a p53-specific deubiquitinase (Oi et al., 2015). G3BP1 is recruited by MYCNOS
to the promotor region of MYCN to regulate its expression. G3BP1 negatively regulates
PMP22 to increase eration in breast cancer (Winslow et al., 2013; Vadie et al.,
2015). G3BP1 may be the target of a ctional peptide consisting of a cancer
recognition peptide and a pro-apoptotic peptide (Meschenmoser et al., 2013). Late-
stage oral squamous cell omas are sensitive to G3BP1 knock-down g
increased apoptosis (Xu et al., 2013). G3BP1 is up-regulated in breast cancer, oral
squamous cell carcinoma, colon cancer, pancreas cancer, hepatocellular carcinoma
and gastric cancer and is ated with poor patient prognosis, tumor size, vascular
invasion, T classification, lymph node asis, TNM stage, and reduced overall
al (Lo et al., 2012; Winslow et al., 2013; Min et al., 2015; Dou et al., 2016). Y-box
binding protein 1 binds to the 5’UTR of G3BP1 mRNA to regulate the availability of the
G3BP1 stress granule nucleator for stress granule assembly. Down-regulation of either
YB-1 or G3BP1 results in reduced stress granule formation and tumor invasion (Ward et
al., 2011; Annibaldi et al., 2011; Somasekharan et al., 2015). G3BP1 controls the
activity of the H+-ATPase and the translation of beta-F1-ATPase mRNA (Willers and
Cuezva, 2011). G3BP1 co-localizes with promyelocytic leukemia nuclear bodies before
and after ionizing radiation (Liu et al., 2010). Epigallocatechin e, the major
compound of green tea, suppresses lung tumorigenesis by binding to G3BP1. G3BP1
expression is affected by lovostatin (Klawitter et al., 2010; Shim et al., 2010). G3BP1 is
involved in cancer cell growth, apoptosis, motility, migration, invasion, and metastasis
by up-regulating Slug. Knock-down of G3BP1 decreases Slug expression and increases
the epithelial marker E-cadherin. ulation of G3BP1 in breast cancer activates
epithelial-to-mesenchymal tion via the Smad signaling pathway. G3BP1 is
involved in Ras and NF-kappaB signaling, ubiquitin proteasome pathway, and RNA
processing (French et al., 2002; Zhang et al., 2015; Dou et al., 2016). Forced G3BP1
expression promotes cell ion in hepatocellular carcinoma (Dou et al., 2016).
GAR1 is able to activate p53 (Zhang et al., 2012). GAR1 is ed in the telomerase
complex (Zhu et al., 2004; Rashid et al., 2006; Tomlinson et al., 2008; Pigullo et al.,
_ 37 _
2009; Low and Tergaonkar, 2013; Heidenreich et a|., 2014). GAR1 is important for cell
viability (Lubben et a|., 1995).
ITGB4 is associated with prostate cancer, gastric cancer, breast cancer, oral squamous
cell carcinoma and ovarian cancer and was shown to be up-regulated in pancreatic
ductal arcinoma (Chen et a|., 2014; Xin et al., 2014; Zubor et al., 2015; Masugi
et a|., 2015; Gao et a|., 2015; Kawakami et a|., 2015). ITGB4 (also called CD104) tends
to associate with the alpha 6 subunit and is likely to play a pivotal role in the biology of
several invasive carcinoma such as esophageal squamous cell carcinoma, bladder and
ovarian carcinoma (Kwon et a|., 2013; Pereira et a|., 2014; Chen et a|., 2014). A single
nucleotide polymorphism in ITGB4 seems to influence tumor aggressiveness and
survival and may have prognostic value for breast cancer patients (Brendle et a|., 2008).
KDM5B encodes the protein JARID1B, a lysine-specific histone demethylase that is
capable of sing certain tumor suppressor genes by de-methylating lysine 4 of
histone H3 (RefSeq, 2002). As epigenetic factor, KDM5B supports eration,
migration and invasion of human OSCC, head and neck us cell carcinoma
), breast cancer and lung cancer by suppressing p53 expression (Shen et a|.,
2015; Tang et a|., 2015a; Zhao and Liu, 2015; Lin et a|., 2015). Also, known as
JARID1B, KDM5B es metastasis an epithelial-mesenchymal transition in various
tumor types via PTEN/AKT signaling (Tang et a|., 2015a).
KLHL21 is up-regulated in hepatocellular carcinoma and may be used as bioclinical
marker (Shi et a|., 2016). KLHL21 is a negative regulator of a. KLHL21
expression is down-regulated in macrophages upon pro-inflammatory stimuli. Over-
expression of KLHL21 inhibits IKKbeta activation and lkappaBalpha degradation (Mei et
a|., 2016). KLHL21 is over-expressed by the aberrant gene fusion transcription factor
ASPSCR1-TFE3 which is found in two distinct entities, alveolar soft part sarcoma and
renal cell carcinoma (Kobos et a|., 2013). KLHL21 may be ed in cancer (Martinez
et al., 2010). KLHL21 is necessary for cytokinesis and regulates chromosomal
ger complex translocation from chromosomes to the spindle midzone in
anaphase. It interacts with the Cullin3-based E3 tin ligase and directly binds to
WO 37085
_ 38 _
Aurora B g its ubiquitination (Maerki et al., 2009). KLHL21 negatively regulates
TNF alpha-activated NF-kappa B signaling via targeting IKK beta (Mei et al., 2016).
KLK6 encodes kallikein related peptidase 6 which is a member of the kallikrein
subfamily of the peptidase 81 family of serine proteases. Growing ce suggests
that many kallikreins are implicated in carcinogenesis and some have potential as novel
cancer and other disease biomarkers. Expression of this protease is regulated by
steroid hormones and may be elevated in le human cancers and in serum from
psoriasis patients. The encoded protease may participate in the cleavage of amyloid
sor protein and alpha-synuclein, thus implicating this protease in Alzheimer's and
Parkinson's disease, respectively. This gene is located in a gene cluster on
chromosome 19 (RefSeq, 2002). KLK6 is inducible by p53 and its expression increased
autophagy and drug ance in gastric cancer (Kim et al., 2016). Down-regulation of
KLK6 is associated with sed GNA13 expression which is linked to invasiveness of
benign breast tumors (Teo et al., 2016). KLK6 is able to up- and down-regulate several
miRNAs, which may affect cell cycle, MYC, MAPK, and other signaling ys
(Sidiropoulos et al., 2016). KLK6 belongs to a set which is linked to panitumumab
resistance in metastatic colorectal cancer (Barry et al., 2016). KLK6 is associated with
the regulation of axonal growth following spinal injury, tumor cell metastasis, and alpha
synuclein aggregate pathologies like Parkinson’s disease (Xi et al., 2015). KLK6 is over-
expressed in highly ve PC3 prostate cancer and ovarian cancer and dys-regulated
in cervical pre-cancer (Tamir et al., 2014; Hwang and Lindholm, 2015). KLK6 may be
used as biomarker in a variety of entities including hepatocellular carcinoma, breast
cancer, colon cancer, gastrointestinal cancer, and astrocytoma (Vakrakou et al., 2014;
Yu et al., 2015b; Grin et al., 2015; Schrader et al., 2015; Drucker et al., 2015; Mange et
al., 2016). KLK6 is associated with overall al in advanced serous ovarian cancer
and its expression might be linked to other al parameters (Kolin et al., 2014; Dorn
et al., 2015; Yang et al., 2016a; Leung et al., 2016; Ahmed et al., 2016).
Knock-down of CD34, whose expression in head and neck squamous cell carcinoma is
associated with cell cycle progression, up-regulates KRT1 expression (Ettl et al., 2016).
KRT1 is down-regulated in HepG2 cells upon odin D ent (Lu et al., 2015a).
lmmunohistochemical staining of a clear cell focus from a Bowens e superficial
invasive carcinoma is negative for KRT1 (Misago et al., 2016). miR-944 induces KRT1
expression by up-regulation of p53 and impairing of ERK signaling (Kim et al., 2015).
KRT1 sion is up-regulated in early and late stage of squamous cell carcinoma
(Tang et al., 2015b). Nuclear degradation down-regulates KRT1 expression (Naeem et
al., 2015). KRT1 expression may be a marker for differentiation status. In combination
with NMP-52 and AFP expression, it may be used to detect hepatocellular carcinoma
(Attallah et al., 2015; Bruna et al., 2017). KRT1 is up-regulated upon docosahexaenoic
acid treatment, which is known to reduce breast cancer invasion (Blanckaert et al.,
2015). Proliferating basophilic cells from cytic carcinoma failed to express KRT1
(Wang et al., 2015a). Up-regulation of KRT1 is indirectly associated with Notch1
receptor ation (Vliet-Gregg et al., 2015). S100A7 down-regulates KRT1 (Li et al.,
2015). Expression of KRT1 is associated with p21 and hsp70 expression in oral
squamous cell carcinoma. KRT1 absence is correlated with the absence of Klf4, which
is a transcription factor that suppresses cell proliferation and promotes differentiation
(Paparella et al., 2015; Frohwitter et al., 2016).
KRT13 s keratin 13 which is a member of the keratin gene family. Vitamin D
alters KRT13 expression (Narayanan, 2006). Immunostaining for CK13 is positive in the
epidermoid component of mucoepidermoid carcinoma and is negative in canalicular
adenoma and oncolytic carcinoma arising in dibular gland (Muramatsu et al.,
2003; Matsuzaka et al., 2004; do Prado et al., 2007). Aberrant expression of alpha 6
beta 4 integrin up-regulates KRT13, an early event in the development of us
cancer of the skin nbaum et al., 1996). KRT13 may be used as biomarker for
cervical intraepithelial neoplasia. Loss of KRT13 is a marker for tumor grade and stage
in transitional urothelial cell carcinoma. KRT13 expression is a marker for skin cancer
progression (Slaga et al., 1995; Southgate et al., 1999; Duggan, 2002; Baak et al.,
2006). KRT13 expression is down-regulated in oral cancer stem cells and oral
us cell carcinoma (Morgan and Su, 1994; Sinha et al., 2013).
WO 37085
KRT14 was highly expressed in various squamous cell omas such as
esophageal, lung, larynx, uterine cervical as well as in adenomatoid odontogenic tumor.
However, it was absent in small cell carcinoma of the urinary bladder and weak in lung
arcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular
carcinoma, pancreatic ductal adenocarcinoma, breast rating dutal adenocarcinoma,
thyroid ary carcinoma and uterine endometrioid adenocarcinoma (Xue et al., 2010;
Terada, 2012; Vasca et al., 2014; Hammam et al., 2014; Shruthi et al., 2014). In bladder
cancer, KRT14 expression was strongly associated with poor survival (Volkmer et al.,
2012).
Long-time re of MCF-7 breast cancer cells to ethanol up-regulates KRT15 which
is a malignancy-related gene (Gelfand et al., 2017). Basal cell carcinomas with ve
growth show a negative expression of KRT15 (Ziari et al., 2015). KRT15 may be used
to minate spiradenomas and cylindromas (Sellheyer, 2015). KRT15 is sequentially
up-regulated in r carcinogenesis (Chuang et al., 2014). SIRT2, which is down-
regulated in skin cancer, ts KRT15 expression, which is an epithelial stem cell
marker (Wang et al., 2014b). KRT15 is a hair follicle stem cell marker (Bongiovanni et
al., 2014; Koba et al., 2015; Narisawa et al., 2015). KRT15 is an undifferentiated basal
cell marker more strongly expressed in malignant compared to benign ocular surface
squamous neoplasia (Nagata et al., 2014). Spheroid-selected epidermal squamous cell
carcinomas have an enriched KRT15 expression (Adhikary et al., 2013). KRT15 is up-
regulated in urothelial carcinoma (Tai et al., 2013). KRT15 staining of actinic keratoses
associated with head and neck tumors is positive in 7% of the cases and in 36% in
adenoid cystic carcinoma. ng is higher in desmoplastic trichoepithelioma
compared to morphea form basal cell carcinoma and microcystic adnexal carcinoma
(Sabeti et al., 2013; Evangelista and North, 2015; North et al., 2015; Solus et al., 2016).
KRT15 up-regulation affects overall survival in non-small cell lung cancer and may be
used as marker for differential diagnosis of NSCLC (Gomez-Morales et al., 2013;
Boyero et al., 2013). KRT15 is regulated by p53 and ER (Lion et al., 2013).
Over-expression of KRT16 was found in basal-like breast cancer cell lines as well as in
oma in situ. Others did not find icant difference in immunohistochemical
expression of KRT16 n non-recurrent ameloblastomas and recurrent
ameloblastomas (Joosse et a|., 2012; nemochi et al., 2012; Safadi et al., 2016).
In addition, in silico analyses showed correlation between KRT16 expression and
shorter relapse-free survival in metastatic breast cancer (Joosse et a|., 2012).
KRT5 was shown to be up-regulated in breast cancers of young women (Johnson et a|.,
2015). KRT5 was shown to be associated with inferior disease-free survival in breast
cancer in young women and with unfavorable clinical outcome in premenopausal
patients with hormone receptor-positive breast cancer (Johnson et a|., 2015; Sato et a|.,
2014). KRT5 was shown to be regulated by the tumor suppressor BRCA1 in the breast
cancer cell lines 7 and T47D (Gorski et a|., 2010). KRT5 was shown to be de-
regulated in malignant pleural mesothelioma (Melaiu et a|., 2015). KRT5 was described
as a diagnostic mesothelial marker for malignant mesothelioma (Arif and Husain, 2015).
KRT5 was shown to be correlated with the progression of trial cancer (Zhao et
al., 2013). KRT5 was shown to be mutated and egulated in ve tumor areas
in a patient with ous carcinoma (Schumann et a|., 2012). KRT5 was shown to be
part of a four-protein panel which was differentially expressed in colorectal cancer
biopsies compared to normal tissue samples (Yang et al., 2012a). KRT5 and three other
proteins of the four-protein panel were described as novel markers and potential targets
for treatment for colorectal cancer (Yang et a|., 2012a). KRT5 was described as being
associated with basal cell carcinoma (Depianto et a|., 2010). KRT5 was described as a
candidate to identify urothelial carcinoma stem cells (Hatina and Schulz, 2012).
KRT6A was described as part of a seven-gene signature that could be used as a
prognostic model to predict distant ence-free survival in ts with triple
negative breast cancer who received adjuvant chemotherapy following surgery (Park et
al., 2015b). KRT6A was shown to be up-regulated in horn cancer in Bos indicus and in
gastric cancer (El-Rifai et a|., 2002; Koringa et a|., 2013). KRT6A was shown to be
down-regulated in two cases of vulvar sarcomas with morphologic and
immunohistochemical characteristics of extraskeletal myxoid chondrosarcoma (Dotlic et
al., 2014). KRT6A expression was shown to be altered in oral us cell carcinoma
(Chanthammachat et al., 2013). KRT6A was shown to be associated with negative
regulation of proto-oncogene Src kinase activity and the migratory potential of skin
keratinocytes during wound repair. This may be important in related contexts such as
cancer (Rotty and Coulombe, 2012). KRT6A was shown to mark mammary bi-potential
progenitor cells that can give rise to a unique mammary tumor model resembling human
normal-like breast cancer (Bu et al., 2011). KRT6A was bed as an important part
of a 25-gene transcriptional network signature which can be used to distinguish
adenocarcinomas and squamous cell carcinomas of the lung (Chang et al., 2011).
KRTBB was shown to be a candidate for down-regulated genes in the esophageal
cancer cell line KYSE170 (Kan et al., 2006). KRTBB was shown to be up-regulated in
renal cell carcinoma, sporadic keratocystic genic tumors and in horn cancer in
Bos indicus (Koringa et al., 2013; Hu et al., 2015; Heikinheimo et al., 2007). KRTBB
f-function was shown to inhibit the expression of notch1 and induce renal cell
carcinoma cell death in vitro. Thus, KRTBB interaction with notch1 was described to
contribute to ssion of renal cell carcinoma (Hu et al., 2015). KRTBB was
described as a like breast cancer-associated cytokeratin whose expression was
diminished upon decreased expression of basal-like tumor-associated GABRP in the
cell lines 7 and HCC70 (Sizemore et al., 2014). Selective inhibition of ERK1/2
was also shown to result in sed sion of basal-like cytokeratins such as
KRTBB and decreased migration in basal-like breast cancer (Sizemore et al., 2014).
Thus, the GABRP-ERK1/2-cytokeratin axis is involved in maintaining the migratory
phenotype of basal-like breast cancer (Sizemore et al., 2014). KRTBB was shown to be
associated with negative regulation of proto-oncogene Src kinase activity and the
migratory potential of skin keratinocytes during wound repair. This may be ant in
related contexts such as cancer (Rotty and Coulombe, 2012). KRTBB was described as
an important part of a 25-gene transcriptional network signature which can be used to
distinguish arcinomas and squamous cell carcinomas of the lung (Chang et al.,
2011). KRTBB was shown to be differentially expressed during benzo (a) pyrene
induced tumorigenesis of human immortalized oral epithelial cells (Li et al., 2008).
KRT6C was bed as an important part of a 25-gene transcriptional network
signature which can be used to distinguish adenocarcinomas and squamous cell
carcinomas of the lung (Chang et al., 2011).
KRT75 s n 75 which is a member of the type II keratin family clustered on
the long arm of some 12. The encoded protein plays an essential role in hair and
nail formation. Variations in this gene have been associated with the hair disorders
folliculitis barbae (PFB) and loose anagen hair syndrome (LAHS) (RefSeq,
2002). KRT75 is down-regulated in an in vivo ed and re-derived prostatic cell line
compared to the parental cell line (Sivanathan et al., 2014). KRT75 is expressed in
onychomatricoma which may suggest a differentiation toward the nail bed and the nail
isthmus (Perrin et al., 2011). KRT75 is down-regulated in 21T breast cells (Xu et al.,
2010). KRT75 expression can be changed by proteasome inhibitors and
thasone (Kinyamu et al., 2008).
Inhibition of LAP3 was shown to result in ssed invasion in the ovarian cancer cell
line ES-2 through down-regulation of fascin and MMP-2/9. Thus, LAP3 may act as a
potential anti-metastasis therapeutic target (Wang et al., 2015b). High expression of
LAP3 was shown to be correlated with grade of malignancy and poor sis of
glioma patients (He et al., 2015). LAP3 was shown to promote glioma progression by
regulating cell growth, migration and invasion and thus might be a new prognostic factor
(He et al., 2015). Frameshift mutations in genes involved in amino acid metabolism
including LAP3 were detected in microsatellite instability-high gastric and colorectal
cancer (Oh et al., 2014). LAP3 was shown to be up-regulated in hepatocellular
carcinoma, esophageal squamous cell carcinoma and prostate cancer (Zhang et al.,
2014a; Tian et al., 2014; Lexander et al., 2005). LAP3 was shown to promote
hepatocellular carcinoma cells proliferation by regulating G1/S checkpoint in cell cycle
and advanced cells migration (Tian et al., 2014). Expression of LAP3 was further shown
to be correlated with prognosis and ant development of hepatocellular carcinoma
(Tian et al., 2014). Silencing of LAP3 in the esophageal squamous cell carcinoma cell
line ECA109 was shown to reduce cell eration and colony formation while LAP3
knock-down resulted in cell cycle arrest (Zhang et al., 2014a). Over-expression of LAP3
in the esophageal squamous cell carcinoma cell line TE1 was shown to favor cell
proliferation and invasiveness (Zhang et al., 2014a). Thus, LAP3 was shown to play a
role in the malignant development of esophageal squamous cell carcinoma (Zhang et
aL,2014a)
High levels of LGALS7 are associated with an aggressive phenotype in breast cancer
with increased cancer invasiveness, growth, and asis (Grosset et al., 2016).
LGALS7 is differentially expressed in the serum of colorectal cancer patients whereas
histochemical staining of CRC tumors is negative for LGALS7 (Lim et al., 2016).
LGALS7 is down-regulated in prostate cancer, cen/ical , and vulvar squamous
cell carcinoma and is correlated with advanced clinical stage, poor differentiation, and
regional lymph node metastasis. ression leads to increased apoptosis. Increased
promotor methylation is associated with advanced clinical stage, poor differentiation,
and regional lymph node metastasis in VSCC (Labrie et al., 2015; Jiang et al., 2015;
Higareda-Almaraz et al., 2016). Cytoplasmic expressed LGALS7 inhibits p53 and
ses chemoresistance in breast cancer (Grosset et al., 2014). LGALS7 is not
expressed in normal ovarian tissue and expressed in epithelial ovarian cancer.
Expression is more frequent in high grade and metastatic tumors and correlates with
l al. LGALS7 expression is induced by mutant p53 (Kim et al., 2013; Labrie
et al., 2014). LGALS7 may be used as biomarker for metastatic cutaneous melanoma. It
is also correlated with clinical parameters in head and neck squamous and basal cell
carcinoma (Timar et al., 2010; Cada et al., 2009). LGALS7 is related to breast cancer
incidence (Tang et al., 2008). LGALS7 expression can be induced by p53 and is able to
act optotic (Ueda et al., 2004).
LGALS7B potentiates the HER2 ve breast cancer aggressiveness (Grosset et al.,
2016). LGALS7B regulates molecules involved in apoptosis, tissue morphogenesis,
_ 45 _
metabolism, transport, chemokine activity, and immune response (Higareda-Almaraz et
al., 2016). LGALS7B is down-regulated in cervical cancer. High LGALS7B expression in
association with low Gal-1 expression is linked to better prognosis (Higareda-Almaraz et
al., 2016). LGALS7B is hyper-methylated in vulvar squamous cell oma (Jiang et
al., 2015). ression of LGALS7B in prostate cancer enhances chemosensitivity to
etoposide and cisplatin (Labrie et al., 2015). LGALS7B is down-regulated in vulvar
squamous cell carcinoma, prostate cancer, and colorectal cancer. Down-regulation of
LGALS7B is associated with advanced clinical stage, poor tumor differentiation, and
al lymph node metastasis (Labrie et al., 2015; Lim et al., 2016; Jiang et al., 2015).
Cytosolic B inhibits dox-induced PARP-1 cleavage resulting in ssed p53
activation and decreased p21 and CDKN1A expression in breast cancer et et al.,
2014). LGALS7B up-regulates apoptosis and inhibits lL-2 and lFN-gamma expression
(Yamaguchi et al., 2013). LGALS7B is over-expressed in ovarian cancer and is
ated with greater age, high mortality, increased tumor volume, and poor survival
(Kim et al., 2013; Labrie et al., 2014). lmmunohistochemical staining of LGALS7B may
be used to guish salivary gland tumor types (Remmelink et al., 2011). LGALS7B is
down-regulated in head and neck basal cell carcinoma. In head and neck squamous
cell carcinoma, B shows different expression patterns and different expression
levels are correlated with keratinization and differentiation (Cada et al., 2009).
MALL may be used to categorize lung cancer subtypes (Watanabe et al., 2010). MALL
may be a metastasis suppressor gene in prostate cancer (Yi et al., 2009). MALL mRNA
and protein expression is reduced in colon cancer patients and is associated with vessin
invasion, disease recurrence, and metastasis or death. Loss of MALL is associated with
sed overall survival and e-free survival. Over-expression of MALL
suppresses cell proliferation and inhibits migration in cell lines (Fan et al., 2011; Kim et
al., 2008a; Wang et al., 2016c). MALL can be found on prostasomes secreted by a
prostate cancer cell line where it interacts with in-1 (Llorente et al., 2004). MALL
is down-regulated in non-small cell lung cancer and cervical squamous cell cancer. It is
differentially expressed in glioma cells (Ai et al., 2003; Hatta et al., 2004; Kettunen et al.,
2004).
MCM4 expression is associated with ulated carbonic anhydrase IX, a
transmembrane glycoprotein which is correlated with decreased al and cancer
ssion in several es including esophageal cancer (Huber et al., 2015). Has-
miR3p may be involved in nasopharyngeal oma by regulating MCM4 (Chen
et al., 2015). MCM4 might play a role in the development of bladder cancer (Zekri et al.,
2015). A gain-of-function mutant of p53 increases the expression of MCM4 in breast
cancer (Polotskaia et al., 2015). There is a mutation of MCM4 in human skin cancer
which shows reduced DNA helicase activity (lshimi and lrie, 2015). MCM4 over-
expression alone is only weakly associated with shorter survival in breast cancer. Over-
sion of all six parts of the MCM complex is strongly associated with shorter
survival (Kwok et al., 2015). MCM4 is differentially expressed in lung adenocarcinoma
and laryngeal squamous cell carcinoma (Lian et al., 2013; Zhang et al., . MCM4
is significantly xpressed in cervical cancer (Das et al., 2013; Das et al., 2015).
MCM4 may be used as biomarker for ctal cancer (Fijneman et al., 2012).
Antizyme inhibitor inhibits ubiquitin-independent degradation of ODC1 resulting in
accelerated polyamine formation which triggers the development of c cancer,
breast cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma
(Qiu et al., 2016). Piroxicam inhibits ODC1-dependent polyamine production involved in
non-melanoma skin carcinogenesis one et al., 2015). ODC1 regulates
cine which is important for cell division regulation, differentiation, maturation, and
apoptosis (Ramani et al., 2014; Zdrojewicz and Lachowski, 2014). ODC1 is a Myc and
MYCN target gene and high ODC1 expression is associated with reduced event-free
sun/ival in neuroblastoma (Funakoshi-Tago, 2012; Saletta et al., 2014). Blocking ODC1
may be used for chemoprophylaxis in colorectal cancer (Zhou et al., 2012).
PARP9 (also known as ARTD9) encodes poly(ADP-ribose) polymerase family member
9 and is located on chromosome 3q21.1 (RefSeq, 2002). DTX3L forms complexes with
ARTD8 and PARP9 promoting proliferation, chemoresistance, and survival of metastatic
prostate cancer cells by inhibiting the tumor suppressor IRF1 (Bachmann et al., 2014).
PARP9 inhibits lFN-gamma-STAT1-lRF1-p53 signaling in diffuse large B cell lymphoma
and activates the expression of the proto-oncogenes IRF2 and BCL-6. This results in
eration, survival, and chemoresistance in DLBCL (Camicia et al., 2013). PARP9
expression is mma-inducible (Juszczynski et al., 2006). PARP9 may be a drug
target in e large B cell lymphoma. PARP9 is an oncogenic survival factor in high-
risk, esistant DLBCL (Bachmann et al., 2014; Aguiar et al., 2005; Camicia et al.,
2015).
PKP1 was shown to be down-regulated in te cancer and esophageal
adenocarcinoma (Kaz et al., 2012; Yang et al., 2015). Knock-down of PKP1 in the non-
neoplastic, prostatic BPH-1 cell line led to reduced apoptosis and differential expression
of genes such as the prostate cancer-associated SPOCK1 gene (Yang et al., 2015).
Collectively, altered expression of PKP1 and SPOCK1 appears to be frequent and
critical event in prostate cancer and PKP1 is suggested to have a tumor-suppressive
function (Yang et al., 2015). Reduced expression of PKP1 was shown to be ated
with significantly shorter time to onset of distant metastasis in oral cavity squamous cell
carcinoma (Harris et al., 2015). PKP1 loss through promoter methylation was described
to be associated with the progression of Barrett’s esophagus to esophageal
adenocarcinoma (Kaz et al., 2012). PKP1 was shown to be up-regulated in non-small
cell lung cancer and may be a good marker to distinguish squamous-cell omas
samples (Sanchez-Palencia et al., 2011). PKP1 was shown to be up-regulated in the
well-differentiated rcoma cell line GOT3 on et al., 2008). Decreased PKP1
expression was described to promote increased motility in head and neck squamous
cell carcinoma cells (Sobolik-Delmaire et al., 2007). PKP1 loss was shown to be
associated with cervical carcinogenesis (Schmitt-Graeff et al., 2007). PKP1 was shown
to be associated with local recurrences or metastases as well as poor survival in
patients with us cell carcinoma of the oropharynx (Papagerakis et al., 2003).
PLEC is over-expressed in colorectal adenocarcinoma, head and neck squamous cell
carcinoma and pancreatic cancer (Lee et al., 2004; Katada et al., 2012; Bausch et al.,
2011).
Periplakin is decreased in T24CDDPR bladder cancer cells (Taoka et al., 2015). PPL
staining is lower in bladder cancer compared to healthy tissue. Loss of PPL is linked to
pathological stage and survival (Matsumoto et al., 2014). PPL is correlated with
epithelial-like tumor cells (Kohn et al., 2014). EVPL, periplakin, and involucrin-negative
mice show a skin cancer-resistant phenotype (Cipolat et al., 2014; Natsuga et al., 2015;
Natsuga et al., 2016). PPL is highly expressed in -negative breast cancer (Choi et
al., 2013). akin is down-regulated in geal squamous cell carcinoma
because of hyper-methylation. PPL knock-down in ESCC is associated with reduced
cellular movement and attachment (Otsubo et al., 2015; Tonoike et al., 2011).
Paraneoplastic pemphigus shows tibodies against PPL (Yong and Tey, 2013; Li
et al., 2009; Probst et al., 2009; Zimmermann et al., 2010).
PRKDC is a frequently mutated gene in endometriosis-associated ovarian cancer and
breast cancer (Er et al., 2016; Wheler et al., 2015). PRKDC is up-regulated in
cancerous tissues ed with normal tissues in colorectal oma. Patients with
high PRKDC expression show poorer overall survival (Sun et al., 2016).
PRNP encodes a membrane glycosylphosphatidylinositol-anchored rotein that
tends to aggregate into rod-like structures and contains a highly unstable region of five
tandem ptide repeats. Mutations in the repeat region as well as elsewhere in this
gene have been ated with various prion diseases. An overlapping open reading
frame has been found for this gene that encodes a smaller, structurally unrelated
protein, AltPrp (RefSeq, 2002). Although its physiological role is not completely defined,
PRNP is involved in self-renewal, pluripotency gene expression, proliferation and
differentiation of neural stem cells. PNRP plays a role in in human tumors including
glioblastoma, breast cancer, prostate cancer and colorectal cancer (Yang et al., 2016b;
o et al., 2016). In colorectal cancer PRNP has been shown to contribute to
epithelial-mesenchymal transition (Du et al., 2013). Over-expression of PNRP ed
with MGr1-Ag/37LRP is predictive of poor prognosis in gastric cancer (Zhou et al.,
2014). PNRP expression is related to redox state of cells and may participate in anti-
oxidative defense. Silencing PNRP has been shown to sensitize cancer cells to
_ 4g _
anticancer drugs in breast cancer and colon cancer (Sauer et a|., 1999; Meslin et a|.,
2007; Park et a|., 2015a; Yun et a|., 2016).
PROM2 is specifically up-regulated in lung arcinoma (Bao et a|., 2016). PROM2
is expressed in elastofibromas and human prostate cancer. PROM2 is higher expressed
in low aggressive prostate cancer and lower expressed in high aggressive prostate
cancer (Yamazaki, 2007; Zhang et a|., 2002). PROM2 is down-regulated in colon
cancer (Deng et al., 2013). PROM2 expression may be used to differ n
chromophobe renal cell carcinoma and oncocytoma (Rohan et a|., 2006).
RIPK4 was shown to be egulated in squamous cell carcinoma of the skin
one et a|., 2015). RIPK4 is ated with migration and invasion in the tongue
squamous cell carcinoma cell line Tca-8113, survival of diffuse large B-cell lymphoma
and overall as well as disease-free survival, progression and poor prognosis in cervical
squamous cell carcinoma (Wang et a|., 2014c; Liu et al., 2015; Kim et al., 2008b).
RIPK4 is associated with familial pancreatic cancer (Lucito et a|., 2007). RIPK4 may be
a potential stic and independent prognostic biomarker for cervical squamous cell
carcinoma and a biomarker for tongue cancer prognosis and treatment (Wang et al.,
2014c; Liu et al., 2015).
RNASE7 expression is gradually decreased in cutaneous cancer (Scola et a|., 2012).
RNASE7 expression is affected by several leukemogenic protein ne kinases
(Pierce et a|., 2008).
RPL8 expression can be affected by MYC-induced nuclear antigen and nucleolar
protein 66 (Chowdhury et al., 2014). RPL8 may be involved in osteosarcoma (Sun et a|.,
2015a; Yang and Zhang, 2013). RPL8 is regulated by NO-66 which is activated by MYC
(Ge et a|., 2012). A mutation in RPL8 is linked to Diamond-Blackfan anemia (Gazda et
al., 2012). RPL8 expression may be linked to chemotherapy response (Salas et a|.,
2009). RPL8 is ulated in hepatocellular carcinoma (Liu et al., 2007). MHCII-
ent expression of RPL8 can be found in melanoma (Swoboda et a|., 2007).
SERPINBS is both a valuable molecular marker for the diagnosis and a predictorfor the
prognosis of many cancer types including breast, lung, head and neck, oral and
prostate cancer (Marioni et al., 2009; Lonardo et al., 2010; Sager et al., 1996; Sheng,
2004). SERPINBS acts as an nous regulator of HDAC1 activity and cts
with the p53 tumor suppressor pathway (Maass et al., 2000; Kaplun et al., 2012).
SLC25A3 is de-regulated in chronic myeloid leukemia (Oehler et al., 2009). Depletion of
SLC25A3 abolishes stress-induced mitochondrial targeting of BAX (Buttner et al.,
2011).
SLC6A11 expression is reduced in rats with paclitaxel-induced neuropathic pain, a
phenomenon which can be observed in carcinoma patients treated with paclitaxel
(Yadav et al., 2015). ALA and its methyl ester MAL are pro-drugs used in photodynamic
y of skin . Their uptake is mediated by SLC6A11 (Novak et al., 2011;
Schulten et al., 2012; Baglo et al., 2013). Chronic treatment of glioma cells with sodium
valproate reduces SLC6A11 mRNA expression (Gao et al., 2003).
SLC6A15 is hyper-methylated and thereby down-regulated in colorectal cancer and
may be a candidate biomarker for a stool-based assay (Kim et al., 2011; Mitchell et al.,
2014).
SLC7A1 is constitutively expressed in acute myeloid leukemia blasts. These blasts
show deficiencies in arginine-recycling y enzymes resulting in arginine
accumulation and cell proliferation and al (Mussai et al., 2015). SLC7A1 is over-
expressed in colorectal cancer ing in arginine lation and cell growth. Over-
expression of chromosome 13 genes is quite common in CRC (Camps et al., 2013; Lu
et al., 2013). SLC7A1 may be used as a marker for macrophage differentiation. lts
expression increases during the induction of THP1 monocyte entiation (Barilli et
al., 2011). The growth of the MCF-7 breast cancer cell line is dependent on L-arginine.
lt expresses SLC7A1 and SLC7A1 knock-down results in reduced ne uptake,
WO 37085
sed cell viability, and increased apoptosis (Abdelmagid et al., 2011). SLC7A1
expression strongly correlates with the sion of Heme Oxygenase-1 which is
expressed in many cancers, promoting tumor growth and survival (Tauber et al., 2010).
SLC7A1 is a direct target of the liver-specific miR-122 which is down-regulated in
hepatocellular carcinoma. miR-122 down-regulation results in SLC7A1 up-regulation
and increased ellular arginine levels. This pathway is also an important
mechanism for colorectal cancer-derived liver metastases (Kedde and Agami, 2008;
lino et al., 2013; Kishikawa et al., 2015). Activation of protein kinase C results in
SLC7A1 internalization. Stress leads to differential expression of SLC7A1 (Kakuda et
al., 1998; Rotmann et al., 2006).
Loss of SUDS3 leads to altered cell morphology and increased cell migration (Smith et
al., 2012). SUDS3 is involved in yte differentiation (Lee et al., 2012). SUDS3
may have anti-tumor effects (Ramakrishna et al., 2012). USP17 de-ubiquitinates
SUDS3 resulting in altered SUDS3-associated HDAC activities in cancer (Ramakrishna
et al., 2011). SUDS3 is involved in mitosis (Pondugula et al., 2009). SUDS3 is
expressed in breast cancer (Silveira et al., 2009). SUDS3 controls chromosome
segregation and can interact with p53 (David et al., 2006).
TENM2 might be involved in age at menarche. Early AAM is associated with type 2
es mellitus, breast and ovarian cancer, and vascular diseases and late
AAM is associated with low bone mineral density and psychological disorders
(Yermachenko and Dvornyk, 2016). There is a DOCK2-TENM2 gene fusion transcript in
lung cancer patients living in highly polluted regions (Yu et al., 2015a). TENM2 is
expressed in the majority of malignant mesothelioma cells er et al., 2012). TENM2
may be down-regulated in esophageal squamous cell carcinoma (Kan et al., 2006).
Focal deletion of TGM5 in stage II colon cancer may be a driver for this entity (Brosens
et al., 2010). A TGM5 on occurring in non-small cell lung cancer shows no
difference between smokers and smokers (Yongjun Zhang et al., 2013; Broderick
_ 52 _
et al., 2009; Rafnar et al., 2011; Choi et al., 2016). Loss of TGFBR3 in prostate cancer
also down-regulates TGM5 (Sharifi et al., 2007).
XIRP1 is mutated in the metastases of basal-like breast cancer ey et al., 2016).
XIRP1 promotor motif gene signature is enriched in triple ve breast cancer
compared to ER+ HER2- breast cancer (Willis et al., 2015). XIRP1 is up-regulated upon
vitamin C ent which also decreases cell growth in cancer (Marshall et al., 2012;
Nagappan et al., 2013). XIRP1 is mutated in head and neck squamous cell carcinoma
and may be a tumor suppressor gene (Lee et al., 2010). XIRP1 is an oxidative stress
associated gene (Baluchamy et al., 2010).
ZBED6 is a transcriptional repressor of IGF2 which is over-expressed in colorectal
cancer and promotes cell proliferation. Knock-down of ZBED6 affects the cell cycle and
leads to enhanced cell growth in RKO cell line and reduced cell growth in HCT116 cells.
ZBED6 is a transcriptional repressor of several genes involved in Wnt, Hippo, TGF-
beta, EGFR, and PI3K signaling which are all involved in colorectal carcinogenesis
(Markljung et al., 2009; Andersson, 2009; Andersson et al., 2010; Huang et al., 2014;
Jiang et al., 2014; Clark et al., 2015; Akhtar et al., 2015).
DETAILED DESCRIPTION OF THE ION
ation of an immune response is dependent upon the presence of antigens
recognized as foreign by the host immune system. The discovery of the existence of
tumor associated antigens has raised the ility of using a host's immune system to
intervene in tumor growth. Various mechanisms of harnessing both the humoral and
ar arms of the immune system are currently being explored for cancer
therapy.
Specific elements of the cellular immune response are capable of specifically
recognizing and destroying tumor cells. The isolation of T-cells from tumor-infiltrating
cell tions or from peripheral blood suggests that such cells play an important role
in natural immune defense against cancer. CD8—positive T-cells in particular, which
recognize class I molecules of the major histocompatibility x (MHC)—bearing
peptides of usually 8 to 10 amino acid residues derived from proteins or defect
ribosomal products (DRIPS) located in the cytosol, play an important role in this
response. The MHC-molecules of the human are also designated as human leukocyte-
ns (HLA).
The term “T-cell response” means the specific proliferation and activation of effector
ons induced by a peptide in vitro or in vivo. For MHC class I restricted cytotoxic T
cells, or functions may be lysis of peptide-pulsed, peptide-precursor pulsed or
naturally peptide-presenting target cells, secretion of cytokines, ably Interferon-
gamma, TNF-alpha, or lL-2 induced by peptide, secretion of effector molecules,
preferably granzymes or perforins induced by peptide, or degranulation.
The term “peptide” is used herein to designate a series of amino acid residues,
connected one to the other typically by e bonds between the alpha-amino and
carbonyl groups of the nt amino acids. The peptides are preferably 9 amino acids
in length, but can be as short as 8 amino acids in length, and as long as 10, 11, 12, 13
or 14 or longer, and in case of MHC class II peptides (elongated variants of the es
of the invention) they can be as long as 15, 16, 17, 18, 19 or 20 or more amino acids in
length.
Furthermore, the term “peptide” shall include salts of a series of amino acid residues,
connected one to the other typically by peptide bonds between the alpha-amino and
carbonyl groups of the adjacent amino acids. ably, the salts are pharmaceutical
acceptable salts of the peptides, such as, for example, the chloride or acetate
(trifluoroacetate) salts. It has to be noted that the salts of the peptides according to the
present invention differ substantially from the peptides in their state(s) in vivo, as the
peptides are not salts in vivo.
The term “peptide” shall also e “oligopeptide”. The term “oligopeptide” is used
herein to designate a series of amino acid residues, connected one to the other typically
_ 54 _
by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino
acids. The length of the oligopeptide is not critical to the invention, as long as the
correct epitope or epitopes are maintained therein. The oligopeptides are typically less
than about 30 amino acid residues in length, and greater than about 15 amino acids in
length.
The term “polypeptide” designates a series of amino acid residues, connected one to
the other typically by peptide bonds between the alpha-amino and carbonyl groups of
the adjacent amino acids. The length of the polypeptide is not al to the invention as
long as the correct epitopes are maintained. In contrast to the terms e or
eptide, the term polypeptide is meant to refer to molecules containing more than
about 30 amino acid residues.
A peptide, oligopeptide, protein or polynucleotide coding for such a molecule is
“immunogenic” (and thus is an ogen” within the present invention), if it is e
of inducing an immune se. In the case of the present invention, immunogenicity
is more specifically defined as the ability to induce a T-cell response. Thus, an
“immunogen” would be a molecule that is capable of ng an immune response, and
in the case of the present invention, a molecule capable of inducing a T-cell response.
In another , the immunogen can be the peptide, the complex of the peptide with
MHC, oligopeptide, and/or protein that is used to raise specific antibodies or TCRs
against it.
A class I T cell “epitope” requires a short peptide that is bound to a class I MHC
receptor, forming a ternary complex (MHC class I alpha chain, betamicroglobulin,
and peptide) that can be recognized by a T cell bearing a matching T-cell receptor
binding to the MHC/peptide complex with appropriate ty. Peptides binding to MHC
class I molecules are typically 8-14 amino acids in length, and most typically 9 amino
acids in length.
In humans, there are three different genetic loci that encode MHC class I molecules (the
lecules of the human are also designated human leukocyte ns (HLA)):
HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-B*07 are es of
different MHC class I alleles that can be expressed from these loci.
Table 5: Expression frequencies F of 02 and HLA-A*24 and the most frequent
HLA-DR pes. Frequencies are deduced from haplotype frequencies Gf within the
American population adapted from Mori et al. (Mori et al., 1997) employing the Hardy-
rg formula F = 1 — (1-Gf)2. Combinations of A*02 or A*24 with certain HLA-DR
alleles might be enriched or less frequent than expected from their single frequencies
due to linkage disequilibrium. For details refer to Chanock et al. (Chanock et al., 2004).
Allele Population Calculated phenotype from
allele ncy
A*02 Caucasian (North America) 49.1%
A*02 African American (North America) 34.1%
A*02 Asian American (North America) 43.2%
A*02 Latin American (North American) 48.3%
DR1 Caucasian (North America) 19.4%
DR2 Caucasian (North America) 28.2%
DR3 Caucasian (North America) 20.6%
DR4 Caucasian (North America) 30.7%
DR5 Caucasian (North America) 23.3%
DR6 Caucasian (North America) 26.7%
DR7 Caucasian (North America) 24.8%
DR8 Caucasian (North America) 5.7%
DR9 Caucasian (North America) 2.1%
DR1 African (North) American 13.20%
DR2 African (North) American 29.80%
DR3 African (North) an 24.80%
DR4 African (North) American 11.10%
DR5 African (North) American 31.10%
DR6 African (North) American 33.70%
DR7 African (North) American 19.20%
DR8 African (North) American 12.10%
DR9 n (North) American 5.80%
DR1 Asian (North) American 6.80%
DR2 Asian (North) American 33.80%
_ 56 _
Allele Population Calculated phenotype from
allele frequency
DR3 Asian (North) American 9.20%
DR4 Asian (North) American 28.60%
DR5 Asian (North) American 30.00%
DR6 Asian (North) American 25.10%
DR7 Asian (North) American 13.40%
DR8 Asian (North) American 12.70%
DR9 Asian (North) American 18.60%
DR1 Latin ) American 15.30%
DR2 Latin (North) American 21.20%
DR3 Latin (North )American 15.20%
DR4 Latin (North )American 36.80%
DR5 Latin (North) American 20.00%
DR6 Latin (North )American 31.10%
DR7 Latin (North )American 20.20%
DR8 Latin (North) American 18.60%
DR9 Latin (North) an 2.10%
A*24 pines 65%
A*24 Russia Nenets 61%
A*24:02 Japan 59%
A*24 Malaysia 58%
A*24:02 Philippines 54%
A*24 India 47%
A*24 South Korea 40%
A*24 Sri Lanka 37%
A*24 China 32%
2 India 29%
A*24 Australia West 22%
A*24 USA 22%
A*24 Russia Samara 20%
A*24 South America 20%
A*24 Europe 18%
The peptides of the invention, preferably when included into a vaccine of the invention
as described herein bind to A*02. A vaccine may also include pan-binding MHC class II
peptides. Therefore, the vaccine of the invention can be used to treat cancer in patients
that are A*02 positive, whereas no selection for MHC class II allotypes is necessary due
to the pan-binding nature of these peptides.
If A*02 peptides of the invention are combined with peptides binding to another allele,
for example A*24, a higher tage of any patient population can be treated
compared with addressing either MHC class I allele alone. While in most populations
less than 50% of patients could be addressed by either allele alone, a vaccine
comprising HLA-A*24 and HLA-A*02 epitopes can treat at least 60% of patients in any
relevant population. Specifically, the ing percentages of patients will be positive for
at least one of these alleles in various regions: USA 61%, n Europe 62%, China
75%, South Korea 77%, Japan 86% (calculated from www.allelefrequencies.net).
In a red embodiment, the term “nucleotide sequence” refers to a heteropolymer of
deoxyribonucleotides.
The nucleotide sequence coding for a particular peptide, oligopeptide, or polypeptide
may be lly occurring or they may be synthetically ucted. Generally, DNA
segments encoding the peptides, polypeptides, and proteins of this ion are
assembled from cDNA fragments and short oligonucleotide linkers, or from a series of
oligonucleotides, to provide a synthetic gene that is capable of being expressed in a
recombinant transcriptional unit comprising regulatory ts derived from a
microbial or viral operon.
As used herein the term “a nucleotide coding for (or encoding) a peptide” refers to a
nucleotide sequence coding for the peptide including artificial ade) start and
stop codons compatible for the biological system the ce is to be expressed by,
for example, a dendritic cell or another cell system useful for the production of TCRs.
As used herein, reference to a nucleic acid sequence includes both single ed and
double stranded nucleic acid. Thus, for example for DNA, the specific sequence, unless
the context indicates otherwise, refers to the single strand DNA of such sequence, the
duplex of such sequence with its complement (double stranded DNA) and the
complement of such sequence.
The term “coding region” refers to that portion of a gene which either naturally or
normally codes for the expression product of that gene in its natural genomic
environment, i.e., the region coding in vivo for the native expression product of the
gene.
The coding region can be derived from a non-mutated (“normal”), mutated or altered
gene, or can even be derived from a DNA sequence, or gene, wholly synthesized in the
laboratory using methods well known to those of skill in the art of DNA synthesis.
The term “expression product” means the polypeptide or protein that is the natural
translation t of the gene and any nucleic acid ce coding lents
resulting from genetic code degeneracy and thus coding for the same amino acid(s).
The term “fragment”, when referring to a coding sequence, means a portion of DNA
comprising less than the complete coding region, whose expression product retains
essentially the same biological function or activity as the expression product of the
complete coding region.
The term “DNA segment” refers to a DNA polymer, in the form of a separate fragment or
as a component of a larger DNA construct, which has been derived from DNA isolated
at least once in substantially pure form, i.e., free of contaminating endogenous materials
and in a quantity or concentration enabling fication, manipulation, and recovery of
the segment and its component tide sequences by standard biochemical
methods, for example, by using a g vector. Such segments are provided in the
form of an open reading frame uninterrupted by internal non-translated sequences, or
introns, which are typically present in eukaryotic genes. Sequences of anslated
DNA may be present downstream from the open g frame, where the same do not
ere with manipulation or sion of the coding regions.
The term “primer” means a short nucleic acid sequence that can be paired with one
strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts
synthesis of a deoxyribonucleotide chain.
The term “promoter” means a region of DNA involved in binding of RNA polymerase to
initiate transcription.
The term “isolated” means that the material is removed from its original environment
(e.g., the natural environment, if it is naturally occurring). For example, a naturally-
occurring polynucleotide or polypeptide present in a living animal is not isolated, but the
same polynucleotide or polypeptide, separated from some or all of the coexisting
materials in the natural system, is isolated. Such cleotides could be part of a
vector and/or such polynucleotides or polypeptides could be part of a composition, and
still be isolated in that such vector or composition is not part of its natural environment.
The polynucleotides, and recombinant or immunogenic polypeptides, sed in
accordance with the present invention may also be in “purified” form. The term “purified”
does not require absolute purity; rather, it is intended as a relative definition, and can
include preparations that are highly purified or preparations that are only partially
purified, as those terms are tood by those of skill in the relevant art. For example,
individual clones isolated from a cDNA library have been tionally purified to
ophoretic homogeneity. cation of starting material or natural material to at
least one order of magnitude, preferably two or three orders, and more preferably four
or five orders of magnitude is expressly plated. Furthermore, a claimed
polypeptide which has a purity of preferably 99.999%, or at least 99.99% or 99.9%; and
even bly 99% by weight or greater is expressly encompassed.
The nucleic acids and ptide expression products disclosed according to the
present invention, as well as sion vectors containing such nucleic acids and/or
such polypeptides, may be in “enriched form”. As used herein, the term “enriched”
means that the concentration of the material is at least about 2, 5, 10, 100, or 1000
WO 37085
times its natural concentration (for example), advantageously 0.01%, by weight,
preferably at least about 0.1% by . Enriched preparations of about 0.5%, 1%, 5%,
%, and 20% by weight are also contemplated. The sequences, constructs, vectors,
clones, and other materials comprising the t invention can advantageously be in
enriched or ed form. The term “active fragment” means a fragment, usually of a
peptide, polypeptide or nucleic acid sequence, that generates an immune response
(i.e., has immunogenic activity) when administered, alone or ally with a suitable
adjuvant or in a vector, to an animal, such as a mammal, for example, a rabbit or a
mouse, and also including a human, such immune response taking the form of
stimulating a T-cell response within the ent animal, such as a human. Alternatively,
the "active fragment" may also be used to induce a T-cell response in vitro.
As used herein, the terms “portion”, “segment“ and “fragment“, when used in relation to
polypeptides, refer to a continuous sequence of residues, such as amino acid residues,
which sequence forms a subset of a larger sequence. For example, if a polypeptide
were subjected to treatment with any of the common endopeptidases, such as trypsin or
chymotrypsin, the oligopeptides resulting from such treatment would ent portions,
segments or fragments of the starting polypeptide. When used in relation to
polynucleotides, these terms refer to the products produced by treatment of said
polynucleotides with any of the endonucleases.
In accordance with the present ion, the term “percent identity” or “percent
identical”, when referring to a sequence, means that a sequence is compared to a
claimed or described sequence after alignment of the sequence to be compared (the
“Compared Sequence”) with the described or d sequence (the “Reference
ce”). The percent identity is then determined ing to the ing formula:
percent identity = 100 [1 -(C/R)]
wherein C is the number of differences between the Reference Sequence and the
Compared Sequence over the length of alignment n the Reference Sequence
and the Compared Sequence, wherein
(i) each base or amino acid in the Reference Sequence that does not have a
corresponding aligned base or amino acid in the Compared Sequence and
(ii) each gap in the Reference Sequence and
(iii) each d base or amino acid in the Reference Sequence that is different from an
aligned base or amino acid in the Compared ce, constitutes a difference and
(iiii) the alignment has to start at position 1 of the aligned sequences;
and R is the number of bases or amino acids in the Reference Sequence over the
length of the ent with the Compared Sequence with any gap created in the
Reference Sequence also being counted as a base or amino acid.
If an alignment exists between the Compared Sequence and the Reference ce
for which the percent identity as calculated above is about equal to or greater than a
specified minimum t Identity then the Compared Sequence has the ied
minimum percent identity to the Reference Sequence even though alignments may exist
in which the herein above calculated percent identity is less than the specified t
identity.
As mentioned above, the present invention thus provides a peptide comprising a
sequence that is ed from the group of consisting of SEQ ID NO: 1 to SEQ ID NO:
91 or a variant thereof which is 88% homologous to SEQ ID NO: 1 to SEQ ID NO: 91, or
a variant thereof that will induce T cells cross-reacting with said peptide. The peptides of
the invention have the ability to bind to a molecule of the human major histocompatibility
complex (MHC) Class-I or elongated versions of said peptides to class II.
In the present invention, the term “homologous” refers to the degree of identity (see
percent identity above) n sequences of two amino acid sequences, i.e. peptide
or ptide sequences. The aforementioned “homology” is determined by comparing
two sequences aligned under optimal conditions over the sequences to be compared.
Such a sequence homology can be calculated by creating an alignment using, for
example, the ClustalW algorithm. Commonly available sequence analysis software,
_ 62 _
more specifically, Vector NTI, GENETYX or other tools are provided by public
A person skilled in the art will be able to assess, r T cells induced by a variant of
a specific peptide will be able to cross-react with the peptide itself (Appay et al., 2006;
Colombetti et al., 2006; Fong et al., 2001; Zaremba et al., 1997).
By a "variant" of the given amino acid sequence the inventors mean that the side chains
of, for example, one or two of the amino acid residues are altered (for example by
replacing them with the side chain of another naturally occurring amino acid residue or
some other side chain) such that the peptide is still able to bind to an HLA molecule in
substantially the same way as a peptide consisting of the given amino acid sequence in
ting of SEQ ID NO: 1 to SEQ ID NO: 91. For example, a peptide may be modified
so that it at least maintains, if not improves, the ability to interact with and bind to the
binding groove of a le MHC molecule, such as HLA-A*02 or -DR, and in that way
it at least maintains, if not improves, the ability to bind to the TCR of activated T cells.
These T cells can subsequently cross-react with cells and kill cells that express a
polypeptide that contains the natural amino acid sequence of the cognate peptide as
defined in the s of the invention. As can be derived from the scientific literature
and databases (Rammensee et al., 1999; Godkin et al., 1997), certain positions of HLA
g peptides are typically anchor residues forming a core sequence fitting to the
binding motif of the HLA receptor, which is defined by polar, electrophysical,
hydrophobic and spatial properties of the ptide chains constituting the binding
groove. Thus, one skilled in the art would be able to modify the amino acid sequences
set forth in SEQ ID NO: 1 to SEQ ID NO 91, by maintaining the known anchor es,
and would be able to determine whether such variants maintain the ability to bind MHC
class I or II les. The variants of the present invention retain the ability to bind to
the TCR of ted T cells, which can subsequently cross-react with and kill cells that
s a polypeptide containing the natural amino acid sequence of the cognate
peptide as defined in the aspects of the invention.
The original (unmodified) peptides as disclosed herein can be modified by the
substitution of one or more residues at different, possibly selective, sites within the
peptide chain, if not otherwise stated. Preferably those substitutions are located at the
end of the amino acid chain. Such substitutions may be of a conservative nature, for
example, where one amino acid is replaced by an amino acid of similar structure and
characteristics, such as where a hydrophobic amino acid is replaced by another
hydrophobic amino acid. Even more conservative would be ement of amino acids
of the same or similar size and chemical nature, such as where leucine is replaced by
isoleucine. In studies of sequence variations in families of naturally occurring
homologous proteins, certain amino acid substitutions are more often tolerated than
others, and these are often show correlation with similarities in size, charge, polarity,
and hydrophobicity between the original amino acid and its replacement, and such is
the basis for defining rvative substitutions.”
Conservative substitutions are herein defined as ges within one of the following
five groups: Group 1-small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr,
Pro, Gly); Group r, negatively charged residues and their amides (Asp, Asn, Glu,
Gln); Group 3-polar, positively charged residues (His, Arg, Lys); Group 4-large,
aliphatic, nonpolar residues (Met, Leu, lle, Val, Cys); and Group 5-large, aromatic
residues (Phe, Tyr, Trp).
Less vative substitutions might involve the replacement of one amino acid by
another that has similar characteristics but is somewhat different in size, such as
replacement of an alanine by an isoleucine residue. Highly nservative
replacements might involve substituting an acidic amino acid for one that is polar, or
even for one that is basic in ter. Such al” substitutions , however, be
dismissed as ially ineffective since chemical effects are not totally table and
radical substitutions might well give rise to serendipitous effects not ise
predictable from simple chemical principles.
Of course, such substitutions may involve structures other than the common L-amino
acids. Thus, D-amino acids might be substituted for the L-amino acids commonly found
in the antigenic es of the invention and yet still be encompassed by the disclosure
herein. In addition, non-standard amino acids (i.e., other than the common naturally
occurring proteinogenic amino acids) may also be used for substitution purposes to
produce immunogens and immunogenic ptides according to the present
invenfion.
|f substitutions at more than one position are found to result in a peptide with
substantially equivalent or greater nic activity as defined below, then
combinations of those tutions will be tested to determine if the combined
substitutions result in additive or istic effects on the antigenicity of the peptide. At
most, no more than 4 positions within the e would be simultaneously substituted.
A peptide ting essentially of the amino acid sequence as indicated herein can
have one or two chor amino acids (see below regarding the anchor motif)
exchanged without that the y to bind to a molecule of the human major
histocompatibility complex (MHC) Class-l or —II is substantially changed or is negatively
affected, when compared to the non-modified peptide. In another embodiment, in a
peptide consisting essentially of the amino acid sequence as indicated herein, one or
two amino acids can be exchanged with their conservative exchange partners (see
herein below) without that the ability to bind to a molecule of the human major
histocompatibility complex (MHC) Class-l or —II is substantially changed, or is negatively
affected, when compared to the non-modified peptide.
The amino acid residues that do not substantially contribute to interactions with the T-
cell receptor can be modified by replacement with other amino acid whose incorporation
does not substantially affect T-cell reactivity and does not eliminate g to the
relevant MHC. Thus, apart from the proviso given, the e of the invention may be
any peptide (by which term the ors include oligopeptide or polypeptide), which
includes the amino acid sequences or a portion or variant thereof as given.
Table 6: Variants and motif of the peptides according to SEQ ID NO: 4, 6, and 10
on 1 2 3 4 5 6 7 8 9 10
SEQ ID NO. 4 | L D | N D N P P V
Variants |
M |
M L
M A
A |
A L
A A
V |
V L
V A
T |
T L
T A
Q |
Q L
Q A
Position 1 2 3 4 5 6 7 8 9 10
SEQ ID NO. 6 A L Y D A E L S Q M
Variants V
M V
M |
M L
M A
A V
A |
A L
A A
NQQQQ—l—l—|—|<<<< >|——<>|——<>|——<
Position 1 be A 01 c» \1 00 co _\ 0
SEQ ID NO.
T I. E "U > —I "U "U x
Variants I-<I-<>
QQQQ—l—l—l—l<<<<>>>>§§§§ I-<
Longer (elongated) peptides may also be le. It is possible that MHC class I
epitopes, although usually between 8 and 11 amino acids long, are generated by
peptide processing from longer peptides or proteins that include the actual epitope. It is
preferred that the es that flank the actual epitope are residues that do not
substantially affect proteolytic cleavage necessary to expose the actual epitope during
processing.
The es of the invention can be elongated by up to four amino acids, that is 1, 2, 3
or 4 amino acids can be added to either end in any combination between 4:0 and 0:4.
Combinations of the elongations according to the invention can be found in Table 7.
Table 7: ations of the elongations (extensions) of peptides of the invention
inus N-terminus
o—xmoohzo—xmooh O
Oor1 or2
Oor10r20r3
Oor10r20r3or4
-terminus C-terminus
Oorlor2
Oor10r20r3
Oor10r20r3or4
The amino acids for the elongation/extension can be the peptides of the original
sequence of the protein or any other amino acid(s). The elongation can be used to
enhance the stability or solubility of the peptides.
Thus, the epitopes of the present ion may be identical to naturally occurring
tumor-associated or tumor-specific es or may include epitopes that differ by no
more than four residues from the reference peptide, as long as they have substantially
identical antigenic activity.
In an alternative embodiment, the peptide is ted on either or both sides by more
than 4 amino acids, preferably to a total length of up to 30 amino acids. This may lead
_ 68 _
to MHC class II binding es. g to MHC class II can be tested by methods
known in the art.
ingly, the present invention provides peptides and variants of MHC class I
epitopes, n the peptide or variant has an overall length of from 8 and 100, from 9
and 100, from 10 and 100, from 11 and 100, from 12 and 100, preferably from 8 and 30,
and from 9 and 30, from 10 and 30, from 11 and 30, from 12 and 30, most preferred
from 8 and 14, from 9 and 14, from 10 and 14, from 11 and 14, from 12 and 14. The
present invention further provides peptides and variants of MHC class I epitopes,
wherein the peptide or variant has an overall length of namely 8, 9, 10, 11, 12, 13, or 14
amino acids, in case of the elongated class II binding peptides the length can also be
, 16, 17, 18, 19, 20, 21 or 22 amino acids.
Of course, the peptide or variant according to the present invention will have the ability
to bind to a molecule of the human major histocompatibility complex (MHC) class I or II.
g of a peptide or a variant to a MHC x may be tested by methods known in
the art.
Preferably, when the T cells specific for a peptide according to the present invention are
tested against the tuted peptides, the peptide concentration at which the
substituted peptides achieve half the maximal increase in lysis relative to background is
no more than about 1 mM, preferably no more than about 1 pM, more ably no
more than about 1 nM, and still more preferably no more than about 100 pM, and most
preferably no more than about 10 pM. It is also preferred that the substituted peptide be
recognized by T cells from more than one individual, at least two, and more preferably
three individuals.
In a particularly preferred embodiment of the invention the peptide consists or consists
essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 91.
“Consisting essentially of” shall mean that a peptide ing to the present invention,
in addition to the sequence according to any of SEQ ID NO: 1 to SEQ ID NO 91 or a
t thereof contains additional N- and/or C-terminally located stretches of amino
acids that are not necessarily forming part of the peptide that functions as an epitope for
MHC molecules epitope.
Nevertheless, these stretches can be important to provide an efficient uction of the
peptide according to the present invention into the cells. In one embodiment of the
present invention, the peptide is part of a fusion protein which comprises, for example,
the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33,
in the ing “li”) as derived from the NCBI, GenBank Accession number X00497. In
other fusions, the peptides of the present invention can be fused to an antibody as
described herein, or a functional part thereof, in particular into a sequence of an
antibody, so as to be specifically targeted by said antibody, or, for example, to or into an
dy that is specific for dendritic cells as described herein.
In addition, the peptide or variant may be modified r to improve stability and/or
binding to MHC molecules in order to elicit a stronger immune response. Methods for
such an optimization of a peptide ce are well known in the art and include, for
example, the introduction of reverse peptide bonds or non-peptide bonds.
In a reverse peptide bond amino acid residues are not joined by peptide (-CO-NH-)
linkages but the peptide bond is reversed. Such retro-inverso peptidomimetics may be
made using methods known in the art, for e such as those bed in Meziere
et al (1997) (Meziere et al., 1997), incorporated herein by reference. This approach
involves making pseudopeptides containing changes involving the backbone, and not
the ation of side . Meziere et al. (Meziere et al., 1997) show that for MHC
g and T helper cell responses, these pseudopeptides are useful. Retro-inverse
peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more
resistant to proteolysis.
_ 70 _
A non-peptide bond is, for example, -CH2-NH, -CH28-, -CH20H2-, -CH=CH-, -COCH2-, -
CH(OH)CH2—, and -CH280-. US 4,897,445 provides a method for the solid phase
synthesis of non-peptide bonds (-CHz-NH) in polypeptide chains which involves
polypeptides synthesized by rd procedures and the non-peptide bond
synthesized by reacting an amino aldehyde and an amino acid in the presence of
NaCNBHg.
Peptides comprising the ces described above may be synthesized with
additional chemical groups present at their amino and/or carboxy termini, to enhance
the stability, bioavailability, and/or affinity of the peptides. For example, hydrophobic
groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups may be added to
the peptides' amino termini. se, an acetyl group or a 9-fluorenylmethoxy-carbonyl
group may be placed at the peptides' amino i. Additionally, the hydrophobic
group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy
termini.
r, the peptides of the invention may be synthesized to alter their steric
configuration. For example, the D-isomer of one or more of the amino acid residues of
the peptide may be used, rather than the usual L-isomer. Still further, at least one of the
amino acid residues of the peptides of the invention may be substituted by one of the
nown non-naturally occurring amino acid residues. Alterations such as these may
sen/e to increase the stability, bioavailability and/or binding action of the peptides of the
Similarly, a peptide or variant of the invention may be modified chemically by reacting
specific amino acids either before or after synthesis of the peptide. Examples for such
modifications are well known in the art and are summarized e.g. in R. ad,
Chemical Reagents for Protein Modification, 3rd ed. CRC Press, 2004 (Lundblad,
2004), which is incorporated herein by reference. Chemical modification of amino acids
includes but is not d to, modification by ion, amidination, pyridoxylation of
, reductive alkylation, trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene
nic acid (TNBS), amide modification of carboxyl groups and sulphydryl
modification by performic acid oxidation of cysteine to cysteic acid, formation of
mercurial derivatives, formation of mixed disulphides with other thiol compounds,
reaction with ma|eimide, carboxymethylation with etic acid or iodoacetamide and
carbamoylation with cyanate at alkaline pH, although without tion thereto. In this
regard, the skilled person is referred to Chapter 15 of Current Protocols ln Protein
Science, Eds. Coligan et aI. (John Wiley and Sons NY 1995-2000) (Coligan et a|., 1995)
for more ive methodology relating to chemical modification of ns.
Briefly, modification of e.g. arginy| residues in proteins is often based on the reaction of
vicina| dicarbonyl nds such as phenylglyoxal, 2,3-butanedione, and 1,2-
cyclohexanedione to form an . Another example is the reaction of methylglyoxal
with arginine residues. Cysteine can be modified without concomitant modification of
other nucleophilic sites such as lysine and histidine. As a result, a large number of
reagents are available for the modification of cysteine. The websites of ies such
as Sigma-Aldrich //www.sigma-aldrich.com) provide information on specific
reagents.
Selective reduction of disu|fide bonds in proteins is also common. Disulfide bonds can
be formed and oxidized during the heat treatment of rmaceuticals. Woodward’s
Reagent K may be used to modify specific g|utamic acid residues. N-(3-
(dimethylamino)propy|)-N’-ethy|carbodiimide can be used to form intra-moIecuIar
cross|inks between a lysine residue and a g|utamic acid residue. For example,
diethylpyrocarbonate is a reagent for the modification of histidyl residues in proteins.
Histidine can also be modified using 4-hydroxynonenal. The on of lysine
residues and other o groups is, for example, useful in binding of peptides to
surfaces or the cross-linking of proteins/peptides. Lysine is the site of attachment of
poly(ethylene)g|ycol and the major site of modification in the glycosylation of proteins.
Methionine residues in proteins can be modified with e.g. iodoacetamide,
bromoethylamine, and chloramine T.
Tetranitromethane and N-acetylimidazole can be used for the modification of tyrosyl
residues. Cross-linking via the formation of dityrosine can be accomplished with
hydrogen peroxide/copper ions.
Recent studies on the modification of tryptophan have used N-bromosuccinimide, 2-
hydroxynitrobenzyl bromide or 3-bromomethyl(2—nitrophenylmercapto)—3H-
indole (BPNS-skatole).
Successful modification of therapeutic proteins and peptides with PEG is often
associated with an ion of circulatory half-life while cross-linking of proteins with
glutaraldehyde, polyethylene glycol diacrylate and formaldehyde is used for the
ation of hydrogels. al modification of allergens for immunotherapy is often
achieved by carbamylation with potassium cyanate.
r embodiment of the present invention s to a turally occurring
peptide wherein said peptide consists or consists essentially of an amino acid sequence
according to SEQ ID No: 1 to SEQ ID No: 156 and has been synthetically ed
(e.g. synthesized) as a ceutically acceptable salt. Methods to tically
produce peptides are well known in the art. The salts of the peptides according to the
present invention differ substantially from the peptides in their state(s) in vivo, as the
peptides as generated in vivo are no salts. The tural salt form of the peptide
mediates the solubility of the peptide, in ular in the context of pharmaceutical
compositions comprising the peptides, e.g. the peptide vaccines as disclosed herein. A
sufficient and at least substantial solubility of the peptide(s) is required in order to
efficiently provide the peptides to the subject to be treated. Preferably, the salts are
pharmaceutically acceptable salts of the peptides. These salts according to the
invention include alkaline and earth alkaline salts such as salts of the Hofmeister series
comprising as anions P04”, 304”, CchOO', cr, Br', Nog', CIO4', l', SCN' and as
cations NH4+, Rb”, k+, Na+, Cs+, Li+, Zn”, Mg”, Ca”, Mn”, Cu” and Ba”. Particularly
salts are selected from PO4, (NH4)2HPO4, (NH4)H2PO4, (NH4)2SO4, NH4CchOO,
NH4CI, NH4Br, NH4N03, NH4CIO4, NH4I, NH4SCN, Rb3PO4, szHPO4, RbH2P04,
_ 73 _
, Rb40H3000, Rb40l, Rb4Br, Rb4N03, Rb40lO4, Rb4l, Rb4SCN, K3PO4,
K2HPO4, KH2PO4, K2804, K0H3000, K0l, KBr, KNO3, K0lO4, Kl, KSCN, ,
Na2HP04, 4, Na2804, Na0H3000, Na0l, NaBr, NaNOs, NaCIO4, Nal, NaSCN,
Zn0|2 0s3PO4, 0s2HPO4, 0sH2PO4, 0s2804, 0s0H3000, 0s0l, CsBr, 0sN03, 0s0lO4,
0sl, CsSCN, Li3PO4, Li2HPO4, LiH2PO4, Li2804, Li0H3000, Li0l, LiBr, LiNOs, Li0lO4,
Lil, LiSCN, 0u2804, Mg3(PO4)2, MngPO4, Mg(H2PO4)2, , Mg(0H3000)2,
Mg0l2, MgBrg, Mg(N03)2, Mg(0lO4)2, Mglg, Mg(SCN)2, MnCI2, 0a3(PO4),, 0a2HPO4,
0a(H2PO4)2, CaSO4, 0a(0H3000)2, 0a0|2, CaBrg, 0a(N03)2, 0a(0lO4)2, 0aI2,
0a(SCN)2, Ba3(PO4)2, Ba2HP04, Ba(H2PO4)2, BaSO4, Ba(0H3000)2, Ba0l2, BaBrg,
Ba(N03)2, Ba(0lO4)2, Balg, and Ba(SCN)2. Particularly preferred are NH acetate, Mg0|2,
KH2PO4, Na2804, K0l, Na0l, and 0a0|2, such as, for example, the chloride or acetate
(trifluoroacetate) salts.
A peptide or variant, wherein the peptide is modified or es non-peptide bonds is a
preferred embodiment of the invention. Generally, peptides and variants (at least those
containing peptide linkages between amino acid residues) may be synthesized by the
olyamide mode of solid-phase peptide synthesis as disclosed by Lukas et al.
(Lukas et al., 1981) and by references as cited therein. Temporary N-amino group
protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive
cleavage of this highly base-labile protecting group is done using 20% piperidine in N,
N-dimethylformamide. Side-chain functionalities may be ted as their butyl ethers
(in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid
and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl
derivative (in the case of cysteine) and oxy-2,3,6-trimethylbenzenesulphonyl
derivative (in the case of arginine). Where glutamine or asparagine are 0-terminal
residues, use is made of the imethoxybenzhydryl group for protection of the side
chain amido functionalities. The solid-phase t is based on a polydimethyl-
acrylamide polymer tuted from the three monomers dimethylacrylamide
(backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine
methyl ester ionalizing agent). The peptide-to-resin cleavable linked agent used is
the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid
derivatives are added as their preformed symmetrical anhydride derivatives with the
exception of asparagine and glutamine, which are added using a reversed N, N-
dicyclohexyl-carbodiimide/1hydroxybenzotriazole mediated coupling procedure. All
coupling and deprotection reactions are monitored using rin, trinitrobenzene
nic acid or isotin test procedures. Upon completion of synthesis, es are
cleaved from the resin support with concomitant removal of side-chain protecting groups
by treatment with 95% trifluoracetic acid containing a 50 % scavenger mix. Scavengers
commonly used include ethanedithiol, phenol, e and water, the exact choice
depending on the constituent amino acids of the peptide being synthesized. Also a
combination of solid phase and solution phase methodologies for the sis of
peptides is possible (see, for example, (Bruckdorfer et al., 2004), and the references as
cited therein).
oracetic acid is removed by evaporation in vacuo, with subsequent trituration with
diethyl ether ing the crude peptide. Any scavengers present are removed by a
simple extraction procedure which on lyophilization of the aqueous phase affords the
crude peptide free of scavengers. Reagents for peptide sis are generally
available from e.g. Calbiochem-Novabiochem (Nottingham, UK).
Purification may be performed by any one, or a combination of, techniques such as re-
crystallization, size ion chromatography, ion-exchange chromatography,
hydrophobic interaction chromatography and (usually) reverse-phase high performance
liquid chromatography using e.g. acetonitrile/water gradient separation.
Analysis of peptides may be carried out using thin layer tography,
electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE),
reverse-phase high performance liquid chromatography, acid analysis after acid
hydrolysis and by fast atom bombardment (FAB) mass spectrometric is, as well
as MALDI and ESl-Q-TOF mass spectrometric analysis.
In order to select over-presented peptides, a presentation profile is calculated showing
the median sample presentation as well as replicate variation. The profile juxtaposes
samples of the tumor entity of interest to a ne of normal tissue samples. Each of
these profiles can then be consolidated into an over-presentation score by calculating
the p-value of a Linear Mixed-Effects Model (Pinheiro et al., 2015) ing for le
testing by False Discovery Rate (Benjamini and Hochberg, 1995) (cf. Example 1, Figure
For the identification and relative quantitation of HLA ligands by mass spectrometry,
HLA molecules from shock-frozen tissue samples were purified and HLA-associated
peptides were isolated. The isolated peptides were separated and ces were
identified by online nano-electrospray-ionization (nanoESl) liquid chromatography-mass
spectrometry ) experiments. The resulting peptide sequences were verified by
comparison of the fragmentation pattern of l tumor-associated peptides
(TUMAPs) recorded from head and neck squamous cell oma samples (N = 17
A*02—positive samples) with the fragmentation patterns of corresponding synthetic
reference peptides of identical sequences. Since the peptides were ly identified as
ligands of HLA molecules of y tumors, these results provide direct evidence for
the natural processing and presentation of the identified peptides on primary cancer
tissue obtained from 14 head and neck squamous cell carcinoma patients.
The discovery pipeline DENT® v2.1 (see, for example, US 2013-0096016,
which is hereby incorporated by reference in its entirety) allows the identification and
selection of relevant over-presented peptide vaccine candidates based on direct relative
quantitation of stricted e levels on cancer tissues in comparison to several
different ncerous tissues and organs. This was achieved by the development of
label-free differential quantitation using the acquired LC-MS data sed by a
proprietary data analysis pipeline, combining algorithms for sequence identification,
spectral clustering, ion counting, retention time alignment, charge state deconvolution
and normalization.
Presentation levels including error estimates for each e and sample were
established. Peptides exclusively presented on tumor tissue and es over-
presented in tumor versus ncerous tissues and organs have been identified.
ptide complexes from head and neck us cell carcinoma tissue samples
were purified and sociated peptides were isolated and analyzed by LC-MS (see
examples). All TUMAPs contained in the present application were identified with this
approach on primary head and neck squamous cell carcinoma samples confirming their
presentation on primary head and neck squamous cell carcinoma.
TUMAPs identified on multiple head and neck squamous cell carcinoma and normal
tissues were quantified using ion-counting of label-free LC-MS data. The method
assumes that LC-MS signal areas of a peptide correlate with its abundance in the
sample. All quantitative signals of a peptide in various LC-MS experiments were
normalized based on central tendency, averaged per sample and merged into a bar
plot, called presentation profile. The presentation profile consolidates different analysis
methods like protein database search, spectral clustering, charge state deconvolution
(decharging) and retention time alignment and normalization.
Besides over-presentation of the peptide, mRNA expression of the underlying gene was
tested. mRNA data were ed via RNASeq analyses of normal tissues and cancer
tissues (cf. Example 2, Figure 2). An additional source of normal tissue data was a
se of publicly ble RNA expression data from around 3000 normal tissue
samples (Lonsdale, 2013). Peptides which are d from proteins whose coding
mRNA is highly expressed in cancer tissue, but very low or absent in vital normal
tissues, were preferably included in the present invention.
The present invention provides peptides that are useful in treating cancers/tumors,
preferably head and neck squamous cell carcinoma that over- or exclusively present the
peptides of the invention. These peptides were shown by mass spectrometry to be
naturally presented by HLA molecules on primary human head and neck squamous cell
carcinoma samples.
Many of the source gene/proteins (also designated “full-length proteins” or “underlying
proteins”) from which the peptides are derived were shown to be highly over-expressed
in cancer compared with normal tissues — “normal tissues” in relation to this invention
shall mean either healthy [insert normal tissue of major tion] cells or other normal
tissue cells, demonstrating a high degree of tumor association of the source genes (see
e 2). Moreover, the es themselves are strongly over-presented on tumor
tissue — “tumor tissue” in relation to this invention shall mean a sample from a patient
suffering from head and neck squamous cell carcinoma, but not on normal tissues (see
Example 1).
HLA-bound peptides can be recognized by the immune system, specifically T
cytes. T cells can destroy the cells presenting the recognized ptide
complex, e.g. head and neck squamous cell carcinoma cells presenting the derived
peptides.
The peptides of the present ion have been shown to be capable of stimulating T
cell responses and/or are over-presented and thus can be used for the production of
antibodies and/or TCRs, such as soluble TCRs, according to the present invention (see
Example 3, Example 4). Furthermore, the peptides when complexed with the respective
MHC can be used for the production of antibodies and/or TCRs, in particular sTCRs,
according to the present invention, as well. Respective methods are well known to the
person of skill, and can be found in the respective ture as well. Thus, the peptides
of the present invention are useful for ting an immune response in a patient by
which tumor cells can be destroyed. An immune response in a patient can be induced
by direct stration of the described peptides or suitable precursor substances (e.g.
elongated peptides, ns, or c acids encoding these peptides) to the patient,
ideally in combination with an agent enhancing the immunogenicity (i.e. an adjuvant).
The immune response originating from such a therapeutic vaccination can be expected
_ 78 _
to be highly specific against tumor cells because the target peptides of the present
invention are not presented on normal tissues in able copy numbers, preventing
the risk of undesired autoimmune reactions against normal cells in the patient.
The present description further relates to T-cell receptors (TCRs) comprising an alpha
chain and a beta chain (“alpha/beta TCRs”). Also provided are inventive peptides
capable of binding to TCRs and dies when presented by an MHC molecule. The
present description also relates to nucleic acids, vectors and host cells for expressing
TCRs and peptides of the present description; and methods of using the same.
The term “T-cell receptor” viated TCR) refers to a heterodimeric molecule
comprising an alpha polypeptide chain (alpha chain) and a beta polypeptide chain (beta
chain), wherein the heterodimeric receptor is capable of binding to a e antigen
ted by an HLA molecule. The term also includes so-called gamma/delta TCRs.
In one embodiment, the description provides a method of producing a TCR as
described herein, the method comprising culturing a host cell capable of expressing the
TCR under conditions le to e expression of the TCR.
The description in r aspect relates to methods according to the description,
wherein the antigen is loaded onto class I or II MHC molecules expressed on the
surface of a suitable antigen-presenting cell or cial antigen-presenting cell by
ting a sufficient amount of the antigen with an antigen-presenting cell or the
antigen is loaded onto class I or II MHC tetramers by tetramerizing the antigen/class | or
II MHC complex monomers.
The alpha and beta chains of alpha/beta TCR's, and the gamma and delta chains of
gamma/delta TCRs, are generally regarded as each having two "domains", namely
variable and constant domains. The variable domain ts of a concatenation of
variable region (V), and joining region (J). The variable domain may also include a
leader region (L). Beta and delta chains may also e a diversity region (D). The
_ 7g _
alpha and beta constant domains may also include C-terminal transmembrane (TM)
domains that anchor the alpha and beta chains to the cell membrane.
With respect to gamma/delta TCRs, the term "TCR gamma variable domain" as used
herein refers to the enation of the TCR gamma V (TRGV) region without leader
region (L), and the TCR gamma J (TRGJ) region, and the term TCR gamma constant
domain refers to the extracellular TRGC region, or to a C-terminal truncated TRGC
ce. Likewise, the term "TCR delta variable domain" refers to the concatenation
of the TCR delta V (TRDV) region without leader region (L) and the TCR delta D/J
(TRDD/TRDJ) region, and the term “TCR delta constant domain” refers to the
extracellular TRDC region, or to a C-terminal truncated TRDC ce.
TCRs of the present description ably bind to an inventive peptide-HLA molecule
complex with a binding affinity (KD) of about 100 uM or less, about 50 uM or less, about
uM or less, or about 10 uM or less. More preferred are high affinity TCRs having
binding affinities of about 1 uM or less, about 100 nM or less, about 50 nM or less,
about 25 nM or less. Non-limiting examples of preferred binding affinity ranges for TCRs
of the present invention include about 1 nM to about 10 nM; about 10 nM to about 20
nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM; about 40 nM to about 50
nM; about 50 nM to about 60 nM; about 60 nM to about 70 nM; about 70 nM to about 80
nM; about 80 nM to about 90 nM; and about 90 nM to about 100 nM.
As used herein in connect with TCRs of the present description, fic binding” and
grammatical variants f are used to mean a TCR having a g ty (KD) for
a peptide-HLA molecule complex of 100 uM or less.
Alpha/beta heterodimeric TCRs of the present description may have an introduced
disulfide bond between their constant domains. Preferred TCRs of this type include
those which have a TRAC constant domain sequence and a TRBC1 or TRBCZ constant
domain sequence except that Thr 48 of TRAC and Ser 57 of TRBCl or TRBCZ are
replaced by cysteine residues, the said cysteines forming a disulfide bond between the
_ 80 _
TRAC constant domain sequence and the TRBC1 or TRBCZ nt domain
sequence of the TCR.
With or without the introduced inter-chain bond mentioned above, alpha/beta hetero-
dimeric TCRs of the present description may have a TRAC constant domain sequence
and a TRBCl or TRBCZ constant domain sequence, and the TRAC constant domain
sequence and the TR801 or TRBCZ constant domain sequence of the TCR may be
linked by the native ide bond between Cys4 of exon 2 of TRAC and Cys2 of exon
2 of TRBCl or TRBCZ.
TCRs of the t description may comprise a detectable label selected from the
group consisting of a radionuclide, a fluorophore and biotin. TCRs of the present
description may be conjugated to a therapeutically active agent, such as a radionuclide,
a chemotherapeutic agent, or a toxin.
In an embodiment, a TCR of the present ption having at least one mutation in the
alpha chain and/or having at least one mutation in the beta chain has modified
glycosylation compared to the unmutated TCR.
In an embodiment, a TCR comprising at least one mutation in the TCR alpha chain
and/or TCR beta chain has a binding affinity for, and/or a binding half-life for, a peptide-
HLA molecule complex, which is at least double that of a TCR comprising the
unmutated TCR alpha chain and/or unmutated TCR beta chain. Affinity-enhancement of
tumor-specific TCRs, and its exploitation, relies on the existence of a window for optimal
TCR ties. The existence of such a window is based on observations that TCRs
ic for HLA-A2-restricted pathogens have KD values that are generally about 10-
fold lower when compared to TCRs specific for HLA-A2—restricted tumor-associated
self-antigens. It is now known, gh tumor antigens have the potential to be
genic, because tumors arise from the individual’s own cells only mutated
proteins or proteins with altered translational processing will be seen as foreign by the
immune system. Antigens that are upregulated or overexpressed (so called self-
antigens) will not necessarily induce a functional immune response against the tumor:
T-cells expressing TCRs that are highly reactive to these antigens will have been
negatively selected within the thymus in a process known as l tolerance, meaning
that only T-cells with low-affinity TCRs for self-antigens remain. ore, affinity of
TCRs or variants of the present description to peptides of the ion can be
enhanced by methods well known in the art.
The present description further relates to a method of identifying and isolating a TCR
according to the present description, said method comprising incubating PBMCs from
HLA-A*02-negative healthy donors with A2/peptide rs, incubating the PBMCs
with er-phycoerythrin (PE) and ing the high y T-cells by fluorescence
ted cell sorting —Calibur analysis.
The present description further relates to a method of identifying and isolating a TCR
according to the present description, said method comprising obtaining a transgenic
mouse with the entire human TCRdB gene loci (1.1 and 0.7 Mb), whose T-cells express
a diverse human TCR repertoire that compensates for mouse TCR deficiency,
immunizing the mouse with peptide, incubating PBMCs obtained from the transgenic
mice with er—phycoerythrin (PE), and isolating the high avidity T-cells by
fluorescence activated cell g (FACS)—Calibur analysis.
In one aspect, to obtain T-cells expressing TCRs of the present description, nucleic
acids encoding TCR-alpha and/or TCR-beta chains of the present description are
cloned into expression vectors, such as gamma retrovirus or lentivirus. The recombinant
viruses are generated and then tested for functionality, such as antigen specificity and
functional avidity. An aliquot of the final t is then used to transduce the target T-
cell population (generally purified from patient PBMCs), which is expanded before
infusion into the t.
In another aspect, to obtain T-cells expressing TCRs of the present description, TCR
RNAs are synthesized by techniques known in the art, e.g., in vitro transcription
_ 82 _
systems. The in vitro-synthesized TCR RNAs are then introduced into primary CD8+ T-
cells obtained from healthy donors by electroporation to re-express tumor specific TCR-
alpha and/or TCR-beta chains.
To increase the expression, nucleic acids encoding TCRs of the present description
may be operably linked to strong promoters, such as retroviral long terminal repeats
(LTRs), cytomegalovirus (CMV), murine stem cell virus (MSCV) U3, phosphoglycerate
kinase (PGK), B-actin, ubiquitin, and a simian virus 40 (SV40)/CD43 composite
promoter, elongation factor (EF)—1a and the spleen focus-forming virus (SFFV)
promoter. In a preferred embodiment, the promoter is heterologous to the nucleic acid
being expressed.
In addition to strong promoters, TCR expression cassettes of the t description
may contain additional elements that can enhance transgene expression, including a
central rine tract (cPPT), which promotes the r translocation of lentiviral
constructs nzi et al., 2000), and the uck hepatitis virus posttranscriptional
regulatory element (wPRE), which increases the level of transgene expression by
increasing RNA stability (Zufferey et al., 1999).
The alpha and beta chains of a TCR of the present invention may be encoded by
nucleic acids located in separate vectors, or may be encoded by polynucleotides
located in the same vector.
Achieving high-level TCR surface expression es that both the TCR-alpha and
TCR-beta chains of the introduced TCR be transcribed at high levels. To do so, the
TCR-alpha and TCR-beta chains of the t description may be cloned into bicistronic
constructs in a single vector, which has been shown to be capable of over-
coming this obstacle. The use of a viral ibosomal entry site (IRES) between the
TCR-alpha and TCR-beta chains s in the nated expression of both chains,
because the TCR-alpha and TCR-beta chains are generated from a single transcript
WO 37085
_ 83 _
that is broken into two proteins during translation, ensuring that an equal molar ratio of
TCR-alpha and TCR-beta chains are produced. (Schmitt et al. 2009).
Nucleic acids encoding TCRs of the present description may be codon zed to
increase expression from a host cell. Redundancy in the genetic code allows some
amino acids to be encoded by more than one codon, but certain codons are less “op-
timal” than others because of the relative availability of matching tRNAs as well as other
s (Gustafsson et al., 2004). Modifying the TCR-alpha and TCR-beta gene
sequences such that each amino acid is encoded by the optimal codon for mammalian
gene expression, as well as eliminating mRNA instability motifs or cryptic splice sites,
has been shown to significantly e TCR-alpha and TCR-beta gene expression
(Scholten et al., 2006).
Furthermore, mispairing between the introduced and endogenous TCR chains may
result in the ition of specificities that pose a significant risk for autoimmunity. For
example, the formation of mixed TCR dimers may reduce the number of CD3 molecules
available to form properly paired TCR xes, and therefore can significantly
decrease the functional y of the cells expressing the introduced TCR l et al.,
2007).
To reduce mispairing, the C-terminus domain of the introduced TCR chains of the
present description may be modified in order to promote interchain affinity, while de-
ng the ability of the introduced chains to pair with the endogenous TCR. These
strategies may include replacing the human TCR-alpha and TCR-beta C-terminus
domains with their murine rparts (murinized C-terminus domain); generating a
second interchain disulfide bond in the C-terminus domain by introducing a second
cysteine residue into both the TCR-alpha and TCR-beta chains of the introduced TCR
(cysteine modification); swapping interacting residues in the TCR-alpha and TCR-beta
chain C-terminus domains (“knob-in-hole”); and fusing the variable domains of the
TCR-alpha and TCR-beta chains directly to CD3C (CD3C fusion). (Schmitt et al. 2009).
WO 37085
_ 84 _
In an embodiment, a host cell is engineered to express a TCR of the t
description. In preferred embodiments, the host cell is a human T-cell or T-cell
progenitor. In some ments, the T-cell or T-cell progenitor is obtained from a
cancer patient. In other ments, the T-cell or T-cell progenitor is obtained from a
healthy donor. Host cells of the present description can be allogeneic or autologous with
respect to a patient to be treated. In one embodiment, the host is a gamma/delta T-cell
transformed to express an alpha/beta TCR.
A “pharmaceutical composition” is a composition suitable for administration to a human
being in a medical setting. Preferably, a pharmaceutical composition is sterile and
produced according to GMP ines.
The pharmaceutical compositions comprise the peptides either in the free form or in the
form of a pharmaceutically able salt (see also above). In an aspect, a peptide
described herein is in the form of a pharmaceutically acceptable salt. In another aspect,
a peptide in the form of a pharmeutical salt is in crystalline form.
In an aspect, a pharmaceutically acceptable salt described herein refers to salts which
possess toxicity es within a range that is acceptable for pharmaceutical
applications.
As used herein, "a pharmaceutically acceptable salt" refers to a derivative of the
disclosed peptides wherein the peptide is modified by making acid or base salts of the
agent. For example, acid salts are prepared from the free base (typically wherein the
neutral form of the drug has a l —NH2 group) involving reaction with a suitable
acid. Suitable acids for ing acid salts include both organic acids, e.g., acetic acid,
propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, c acid, succinic
acid, maleic acid, fumaric acid, tartaric acid, citric acid, c acid, cinnamic acid,
mandelic acid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonic acid,
salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid,
hydrobromic acid, sulfuric acid, nitric acid phosphoric acid and the like. Conversely,
_ 85 _
preparation of basic salts of acid moieties which may be present on a peptide are
prepared using a ceutically acceptable base such as sodium hydroxide,
potassium hydroxide, ammonium ide, calcium hydroxide, trimethylamine or the
like.
In an aspect, pharmacuetically acceptable salts may increase the solubility and/or
stability of peptides of described herein. In another aspect, pharmacutical salts
described herein may be ed by conventional means from the corresponding
carrier peptide or complex by reacting, for example, the appropriate acid or base with
peptides or complexes as described . In r aspect, the pharmacuetically
acceptable salts are in crystalline form or semi-crystalline form. In yet another aspect,
pharmaceutically able salts may include, for example, those described in
Handbook of Pharmaceutical Salts: Properties, Selection, and Use By P. H. Stahl and
C. G. Wermuth (Wiley-VCH 2002) and L. D. Bighley, S. M. Berge, D. C. Monkhouse, in
“Encyclopedia of Pharmaceutical Technology”. Eds. J. Swarbrick and J. C. Boylan, Vol.
13, Marcel Dekker, Inc, New York, Basel, Hong Kong 1995, pp. 453-499, each of these
references is herein incorprated by reference in their entirety.
The pharmaceutically acceptable salt form of the peptides of the present ion
increases stability over native (naked) peptides, i.e., not in the form of a
pharmaceutically acceptable salt or otherwise modified. As used herein, sed
stability includes measurable decrease or reduction of the ing: deamidation,
oxidation, ysis, disulfide hange, racemization and hydrolysis. The stability
can be evaluated on a peptide as a finished product or during the production procedure
or during storage. Preferably the peptide in the form of a pharmaceutically acceptable
salt has sufficient stability in vitro to allow storage at a commercially relevant
temperature, such as between about 0° C. and about 60° C., for a commercially
relevant period of time, such as at least one week, preferably at least one month, more
preferably at least three months, and most preferably at least six months. Stability can
be measured using any physiochemical characterization ques known to those
skilled in the art, such as, for example high re liquid chromatography (HPLC).
Further, stability of the peptide salts can be determined by less enzymatic degradation
(such as by aminopeptidases, exopeptidases, and synthetases) in plasma, and/or
having an ed in vivo half life, compared to native peptide. It has been determined
that the intracellular half-life of native 9-mer peptides generated for MHC | antigen
presentation is only a few seconds, unless they are bound by other molecules such as
chaperons or MHC I molecules. Reits et al., Immunity. 2004; 20: 495-506.
In on, the pharmaceutically acceptable salts of the peptides of the t
invention exhibit improved solubility and stability in s solutions. Berge et al.,
Pharmaceutical Salts, J. Pharm. Sci. 1977; 66(1): 1-19. Preferably the peptide in the
form of a pharmaceutically acceptable salt in an aqueous solution is stable for at least 4
days, at least 5 days, at least 6 days, and more preferably at least 7 days.
In an especially preferred embodiment, the pharmaceutical compositions comprise the
peptides as salts of acetic acid (acetates), trifluoro acetates or hloric acid
(chlorides).
Preferably, the ment of the present invention is an immunotherapeutic such as a
vaccine. It may be administered directly into the patient, into the affected organ or
systemically i.d., i.m., s.c., i.p. and i.v., or d ex vivo to cells derived from the
patient or a human cell line which are uently administered to the patient, or used
in vitro to select a ulation of immune cells derived from the patient, which are
then re-administered to the patient. If the nucleic acid is administered to cells in vitro, it
may be useful for the cells to be transfected so as to co-express immune-stimulating
cytokines, such as interleukin-2. The peptide may be substantially pure, or combined
with an immune-stimulating adjuvant (see below) or used in combination with immune-
stimulatory cytokines, or be stered with a suitable delivery system, for example
liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole
limpet yanin (KLH) or mannan (see WO 95/18145 and (Longenecker et al.,
1993)). The peptide may also be tagged, may be a fusion protein, or may be a hybrid
_ 87 _
molecule. The peptides whose sequence is given in the present invention are expected
to ate CD4 or CD8 T cells. However, stimulation of CD8 T cells is more efficient in
the presence of help provided by CD4 T-helper cells. Thus, for MHC Class | epitopes
that stimulate CD8 T cells the fusion partner or sections of a hybrid molecule suitably
provide epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating
epitopes are well known in the art and include those identified in the present invention.
In one aspect, the vaccine comprises at least one peptide having the amino acid
sequence set forth SEQ ID No. 1 to SEQ ID No. 91, and at least one additional peptide,
preferably two to 50, more preferably two to 25, even more preferably two to 20 and
most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve,
thirteen, fourteen, fifteen, sixteen, seventeen or eighteen peptides. The peptide(s) may
be derived from one or more specific TAAs and may bind to MHC class I molecules.
A further aspect of the invention provides a nucleic acid (for example a polynucleotide)
encoding a peptide or peptide variant of the ion. The polynucleotide may be, for
e, DNA, cDNA, PNA, RNA or combinations thereof, either single- and/or double-
stranded, or native or stabilized forms of polynucleotides, such as, for example,
polynucleotides with a orothioate backbone and it may or may not contain
introns so long as it codes for the peptide. Of course, only peptides that contain
naturally occurring amino acid residues joined by naturally ing e bonds are
encodable by a polynucleotide. A still further aspect of the invention provides an
expression vector capable of sing a polypeptide according to the invention.
A variety of methods have been developed to link polynucleotides, especially DNA, to
vectors for e via complementary cohesive termini. For instance, complementary
homopolymer tracts can be added to the DNA t to be inserted to the vector
DNA. The vector and DNA segment are then joined by hydrogen bonding between the
mentary lymeric tails to form recombinant DNA molecules.
Synthetic linkers ning one or more restriction sites provide an ative method
of joining the DNA segment to vectors. Synthetic linkers containing a variety of
restriction endonuclease sites are commercially available from a number of sources
ing International Biotechnologies Inc. New Haven, CN, USA.
A desirable method of modifying the DNA encoding the polypeptide of the invention
employs the rase chain on as disclosed by Saiki RK, et al. (Saiki et al.,
1988). This method may be used for introducing the DNA into a suitable vector, for
example by engineering in suitable restriction sites, or it may be used to modify the DNA
in other useful ways as is known in the art. If viral vectors are used, pox- or adenovirus
vectors are preferred.
The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable
host to produce a polypeptide sing the peptide or t of the invention. Thus,
the DNA encoding the peptide or variant of the invention may be used in accordance
with known techniques, appropriately modified in view of the teachings contained
herein, to construct an expression vector, which is then used to transform an
appropriate host cell for the expression and tion of the polypeptide of the
ion. Such techniques include those disclosed, for example, in US 4,440,859,
4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006,
4,766,075, and 4,810,648.
The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide
constituting the compound of the invention may be joined to a wide variety of other DNA
sequences for introduction into an appropriate host. The companion DNA will depend
upon the nature of the host, the manner of the introduction of the DNA into the host, and
r episomal maintenance or integration is desired.
Generally, the DNA is inserted into an sion vector, such as a plasmid, in proper
orientation and correct reading frame for expression. If necessary, the DNA may be
linked to the appropriate transcriptional and translational regulatory control nucleotide
WO 37085
sequences recognized by the desired host, although such controls are lly
available in the expression vector. The vector is then introduced into the host through
standard techniques. Generally, not all of the hosts will be ormed by the vector.
Therefore, it will be necessary to select for transformed host cells. One selection
technique involves incorporating into the expression vector a DNA sequence, with any
necessary control elements, that codes for a selectable trait in the transformed cell,
such as antibiotic resistance.
atively, the gene for such selectable trait can be on another vector, which is used
to co-transform the desired host cell.
Host cells that have been transformed by the recombinant DNA of the invention are
then cultured for a ient time and under riate conditions known to those
skilled in the art in view of the teachings disclosed herein to permit the expression of the
polypeptide, which can then be recovered.
Many expression systems are known, including bacteria (for example E. coli and
Bacillus subtilis), yeasts (for example Saccharomyces cerevisiae), filamentous fungi (for
example Aspergillus spec), plant cells, animal cells and insect cells. Preferably, the
system can be mammalian cells such as CHO cells available from the ATCC Cell
Biology Collection.
A typical mammalian cell vector plasmid for constitutive expression comprises the CMV
or SV4O promoter with a suitable poly A tail and a resistance marker, such as neomycin.
One example is pSVL ble from Pharmacia, Piscataway, NJ, USA. An e of
an inducible mammalian expression vector is pMSG, also available from Pharmacia.
Useful yeast d vectors are pRS403-406 and pRS413-416 and are generally
available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids
pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Ylps) and
incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. ds
pRS413-416 are Yeast Centromere plasmids (chs). CMV promoter-based vectors (for
_ 90 _
example from Sigma-Aldrich) provide transient or stable sion, cytoplasmic
expression or secretion, and inal or C-terminal tagging in various combinations of
FLAG, , c-myc or MAT. These fusion ns allow for detection, purification
and analysis of recombinant protein. Dual-tagged fusions provide flexibility in detection.
The strong human galovirus (CMV) promoter regulatory region drives
constitutive protein expression levels as high as 1 mg/L in COS cells. For less potent
cell lines, protein levels are typically ~0.1 mg/L. The presence of the SV4O replication
origin will result in high levels of DNA replication in SV4O replication permissive COS
cells. CMV vectors, for example, can contain the pMB1 (derivative of pBR322) origin for
replication in bacterial cells, the b-lactamase gene for ampicillin resistance selection in
ia, hGH polyA, and the f1 origin. Vectors containing the o-trypsin leader
(PPT) sequence can direct the secretion of FLAG fusion proteins into the e
medium for purification using ANTI-FLAG antibodies, resins, and plates. Other vectors
and expression systems are well known in the art for use with a y of host cells.
In another embodiment two or more peptides or peptide variants of the invention are
encoded and thus expressed in a successive order (similar to “beads on a string”
constructs). In doing so, the peptides or peptide variants may be linked or fused
together by stretches of linker amino acids, such as for example , or may be
linked without any additional peptide(s) between them. These constructs can also be
used for cancer therapy, and may induce immune responses both involving MHC l and
MHC II.
The present ion also relates to a host cell transformed with a polynucleotide
vector construct of the present invention. The host cell can be either prokaryotic or
eukaryotic. Bacterial cells may be preferred prokaryotic host cells in some
circumstances and lly are a strain of E. coli such as, for example, the E. coli
strains DH5 available from Bethesda Research Laboratories Inc, Bethesda, MD, USA,
and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD,
USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and
WO 37085
mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey
or human fibroblastic and colon cell lines. Yeast host cells include YPH499, YPH500
and YPH501, which are lly available from gene Cloning Systems, La Jolla,
CA 92037, USA. red mammalian host cells e Chinese hamster ovary (CHO)
cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3
available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available
from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells.
Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression
vectors. An oven/iew regarding the choice of suitable host cells for expression can be
found in, for example, the textbook of Paulina Balbas and Argelia Lorence “Methods in
Molecular Biology Recombinant Gene Expression, Reviews and Protocols,” Part One,
Second Edition, ISBN 978588299, and other literature known to the person of
skill.
Transformation of appropriate cell hosts with a DNA construct of the present invention is
accomplished by nown methods that typically depend on the type of vector used.
With regard to transformation of prokaryotic host cells, see, for example, Cohen et al.
(Cohen et al., 1972) and (Green and Sambrook, 2012) . Transformation of yeast cells is
described in Sherman et al. an et al., 1986) . The method of Beggs (Beggs,
1978) is also useful. With regard to vertebrate cells, reagents useful in transfecting such
cells, for e calcium phosphate and DEAE-dextran or liposome formulations, are
available from Stratagene Cloning Systems, or Life Technologies Inc, Gaithersburg,
MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells
and is well known in the art for transforming yeast cell, bacterial cells, insect cells and
vertebrate cells.
Successfully transformed cells, i.e. cells that contain a DNA construct of the present
invention, can be identified by well-known techniques such as PCR. Alternatively, the
ce of the n in the supernatant can be detected using antibodies.
It will be appreciated that certain host cells of the invention are useful in the preparation
of the peptides of the invention, for e bacterial, yeast and insect cells. However,
other host cells may be useful in certain therapeutic methods. For example, antigenpresenting
cells, such as dendritic cells, may usefully be used to express the peptides of
the invention such that they may be loaded into appropriate MHC molecules. Thus, the
current invention provides a host cell comprising a nucleic acid or an expression vector
according to the invention.
In a preferred embodiment, the host cell is an antigen presenting cell, in ular a
dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein
containing prostatic acid phosphatase (PAP) were approved by the U.S. Food and Drug
Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic
metastatic HRPC (Sipuleucel-T) (Rini et al., 2006; Small et al., 2006).
A r aspect of the invention provides a method of producing a peptide or its variant,
the method comprising culturing a host cell and isolating the peptide from the host cell
or its culture medium.
In r ment the peptide, the nucleic acid or the expression vector of the
invention are used in medicine. For example, the peptide or its variant may be prepared
for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection,
intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. red methods of
peptide ion include s.c., i.d., i.p., i.m., and i.v. Preferred methods of DNA ion
include i.d., i.m., s.c., i.p. and i.v. Doses of e.g. n 50 pg and 1.5 mg, preferably
125 pg to 500 pg, of peptide or DNA may be given and will depend on the respective
e or DNA. Dosages of this range were successfully used in previous trials (Walter
et al., 2012).
The polynucleotide used for active vaccination may be substantially pure, or contained
in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, PNA, RNA
or a combination thereof. s for designing and introducing such a nucleic acid are
well known in the art. An overview is ed by e.g. Teufel et al. l et al., 2005).
cleotide vaccines are easy to e, but the mode of action of these vectors in
inducing an immune response is not fully understood. le vectors and delivery
systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia
virus, retroviruses, herpes virus, adeno-associated virus or hybrids containing elements
of more than one virus. Non-viral delivery systems include cationic lipids and cationic
polymers and are well known in the art of DNA delivery. Physical delivery, such as via a
“gene-gun” may also be used. The peptide or peptides encoded by the c acid may
be a fusion protein, for example with an epitope that stimulates T cells for the respective
opposite CDR as noted above.
The medicament of the invention may also include one or more nts. Adjuvants
are substances that non-specifically enhance or potentiate the immune response (e.g.,
immune responses mediated by CD8—positive T cells and helper-T (TH) cells to an
antigen, and would thus be considered useful in the medicament of the present
invention. le adjuvants include, but are not limited to, 1018 lSS, aluminum salts,
AMPLIVAX®, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLlM, flagellin or TLR5
ligands derived from flagellin, FLT3 ligand, GM-CSF, lC30, lC31, lmiquimod
(ALDARA®), resiquimod, lmuFact IMP321, lnterleukins as lL-2, lL-13, lL-21, Interferon-
alpha or -beta, or pegylated derivatives thereof, IS Patch, lSS, ISCOMATRIX, lSCOMs,
Juvlmmune®, LipoVac, MALP2, MF59, monophosphoryl lipid A, ide IMS 1312,
ide ISA 206, Montanide lSA 50V, Montanide ISA-51, water-in-oil and oil-in-water
emulsions, OK-432, , OMMP-EC, ONTAK, OspA, PepTel® vector system,
poly(lactid co-glycolid) [PLG]—based and dextran microparticles, talactoferrin SRL172,
Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan,
Pam3Cys, Aquila's QSZ1 stimulon, which is derived from n, mycobacterial
extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such
as Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are
preferred. Several immunological adjuvants (e.g., MF59) ic for dendritic cells and
their preparation have been described previously (Allison and Krummel, 1995). Also,
cytokines may be used. Several cytokines have been directly linked to influencing
dendritic cell migration to lymphoid tissues (e.g., TNF-), accelerating the maturation of
dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF,
lL-1 and lL-4) (U.S. Pat. No. 5,849,589, specifically orated herein by reference in
its entirety) and acting as immunoadjuvants (e.g., lL-12, lL-15, lL-23, lL-7, lFN-alpha.
lFN-beta) (Gabrilovich et al., 1996).
CpG immunostimulatory oligonucleotides have also been reported to e the
effects of adjuvants in a vaccine g. Without being bound by theory, CpG
oligonucleotides act by activating the innate (non-adaptive) immune system via Toll-like
receptors (TLR), mainly TLR9. CpG triggered TLR9 tion enhances antigen-
specific humoral and cellular responses to a wide variety of antigens, including peptide
or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular
vaccines and polysaccharide conjugates in both prophylactic and therapeutic vaccines.
More importantly it enhances dendritic cell maturation and differentiation, ing in
enhanced activation of TH1 cells and strong cytotoxic T-lymphocyte (CTL) generation,
even in the e of CD4 T cell help. The TH1 bias induced by TLR9 stimulation is
maintained even in the presence of vaccine adjuvants such as alum or incomplete
Freund’s adjuvant (IFA) that normally promote a TH2 bias. CpG oligonucleotides show
even r adjuvant activity when formulated or co-administered with other adjuvants
or in formulations such as articles, nanoparticles, lipid emulsions or similar
formulations, which are especially necessary for inducing a strong se when the
antigen is vely weak. They also rate the immune se and enable the
antigen doses to be reduced by approximately two orders of magnitude, with
comparable antibody responses to the full-dose vaccine without CpG in some
experiments (Krieg, 2006). US 6,406,705 Bl describes the combined use of CpG
oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-
specific immune response. A CpG TLR9 antagonist is dSLlM (double Stem Loop
lmmunomodulator) by Mologen (Berlin, Germany) which is a preferred component of
the pharmaceutical composition of the present invention. Other TLR g molecules
such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.
Other es for useful adjuvants include, but are not limited to chemically modified
Cst (e.g. CpR, ldera), dsRNA analogues such as Poly(l:C) and derivates thereof (e.g.
AmpliGen®, Hiltonol®, poly-(ICLC), poly(|C-R), poly(l:C12U), non-CpG bacterial DNA or
RNA as well as immunoactive small molecules and antibodies such as
cyclophosphamide, nib, Bevacizumab®, Celebrex, NCX-4016, sildenafil, tadalafil,
vardenafil, Sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib,
VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodies targeting key structures
of the immune system (e.g. anti-CD40, GFbeta, NFalpha receptor) and
8058175, which may act therapeutically and/or as an adjuvant. The amounts and
concentrations of adjuvants and additives useful in the context of the present invention
can readily be determined by the skilled artisan without undue mentation.
Preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF,
cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and
derivates, poly-(|:C) and derivates, RNA, afil, and particulate formulations with
PLG or mes.
In a preferred embodiment, the pharmaceutical composition according to the invention
the adjuvant is selected from the group consisting of -stimulating factors, such as
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim),
cyclophosphamide, imiquimod, resiquimod, and eron-alpha.
In a preferred embodiment, the pharmaceutical composition according to the invention
the nt is selected from the group ting of colony-stimulating factors, such as
Granulocyte hage Colony Stimulating Factor (GM-CSF, sargramostim),
cyclophosphamide, imiquimod and resiquimod. In a preferred ment of the
pharmaceutical composition according to the invention, the adjuvant is
cyclophosphamide, imiquimod or resiquimod. Even more preferred adjuvants are
Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, poly-
ICLC (Hiltonol®) and anti-CD40 mAB, or combinations thereof.
This ition is used for parenteral administration, such as subcutaneous,
intradermal, intramuscular or oral administration. For this, the peptides and optionally
other les are dissolved or suspended in a ceutically acceptable,
preferably aqueous r. In addition, the composition can contain excipients, such as
buffers, binding agents, ng , diluents, s, lubricants, etc. The peptides
can also be administered together with immune stimulating substances, such as
cytokines. An extensive listing of excipients that can be used in such a composition, can
be, for example, taken from A. Kibbe, Handbook of Pharmaceutical Excipients (Kibbe,
2000). The composition can be used for a tion, laxis and/or therapy of
adenomatous or cancerous es. ary formulations can be found in, for
example, 253.
In an , peptides or other molecules described herein may be combined with an
aquous carrier. In an aspect, the aquous carrier is selected from ion exchangers,
alumina, aluminum stearate, magnesium stearate, lecithin, serum proteins, such as
human serum albumin, buffer substances such as phosphates, glycine, sorbic acid,
potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, salts or
electrolytes, such as protamine sulfate, disodium hydrogen phosphate, dicalcium
phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, nyl pyrrolidone, polyvinylpyrrolidone-vinyl acetate, cellulose-
based substances (e.g., microcrystalline cellulose, hydroxypropyl methylcellulose,
hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose
Phthalate), starch, lactose monohydrate, mannitol, trehalose sodium lauryl sulfate, and
crosscarmellose sodium, polyethylene glycol, sodium carboxymethylcellulose,
polyacrylates, polymethacrylate, waxes, polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.
In an aspect, the aquous carrier contains multiple components, such as water together
with a non-water carrier component, such as those ents described herein. In
another aspect, the aquous carrier is capable of imparting improved properties when
combined with a peptide or other molecule described herein, for example, improved
lity, efficiacy, and/or improved immunotherapy. In addition, the composition can
contain excipients, such as s, binding agents, blasting agents, diluents, flavors,
lubricants, etc. A “pharmaceutically acceptable diluent,” for example, may include
solvents, bulking agents, stabilizing agents, dispersion media, coatings, antibacterial
and antifungal agents, isotonic and absorption delaying agents, and the like which are
physiologically compatible. Examples of pharmaceutically acceptable diluents include
one or more of saline, phosphate ed , dextrose, glycerol, ethanol, and the
like as well as combinations f. In many cases it will be preferable to include one
or more isotonic agents, for example, sugars such as trehalose and sucrose,
polyalcohols such as ol, sorbitol, or sodium chloride in the composition.
Pharmaceutically acceptable substances such as wetting or minor s of auxiliary
substances such as wetting or emulsifying , preservatives or buffers, are also
within the scope of the present invention.ln addition, the composition can contain
excipients, such as buffers, binding agents, blasting agents, diluents, flavors, and
lubricants.
It is important to realize that the immune response triggered by the vaccine according to
the invention attacks the cancer in different cell-stages and different stages of
development. Furthermore, different cancer associated ing pathways are
attacked. This is an advantage over vaccines that address only one or few targets,
which may cause the tumor to easily adapt to the attack (tumor escape). rmore,
not all individual tumors express the same pattern of antigens. Therefore, a ation
of several tumor-associated peptides ensures that every single tumor bears at least
some of the targets. The composition is designed in such a way that each tumor is
expected to express several of the antigens and cover several independent pathways
ary for tumor growth and maintenance. Thus, the vaccine can easily be used
“off-the—shelf’ for a larger patient population. This means that a pre-selection of patients
to be treated with the vaccine can be restricted to HLA typing, does not require any
onal ker ments for antigen expression, but it is still ensured that
several targets are simultaneously attacked by the induced immune response, which is
important for efficacy (Banchereau et al., 2001; Walter et al., 2012).
As used herein, the term "scaffold" refers to a molecule that specifically binds to an (e.g.
antigenic) determinant. In one embodiment, a scaffold is able to direct the entity to
which it is attached (e.g. a (second) antigen binding ) to a target site, for example
to a specific type of tumor cell or tumor stroma bearing the antigenic determinant (e.g.
the complex of a peptide with MHC, according to the application at hand). In another
embodiment, a scaffold is able to activate ing through its target antigen, for
e a T cell receptor complex antigen. Scaffolds include but are not limited to
antibodies and fragments thereof, antigen binding domains of an antibody, sing
an antibody heavy chain variable region and an antibody light chain variable region,
binding proteins comprising at least one ankyrin repeat motif and single domain n
binding (SDAB) molecules, aptamers, (soluble) TCRs and (modified) cells such as
allogenic or autologous T cells. To assess r a molecule is a ld binding to a
target, binding assays can be performed.
“Specific” binding means that the scaffold binds the peptide-MHC-complex of interest
better than other naturally occurring peptide-MHC-complexes, to an extent that a
scaffold armed with an active molecule that is able to kill a cell bearing the specific
target is not able to kill another cell without the specific target but presenting another
peptide-MHC x(es). Binding to other peptide-MHC complexes is irrelevant if the
peptide of the cross-reactive e-MHC is not naturally occurring, i.e. not derived
from the human ptidome. Tests to assess target cell killing are well known in the
art. They should be med using target cells (primary cells or cell lines) with
unaltered peptide-MHC presentation, or cells loaded with peptides such that naturally
occurring peptide-MHC levels are reached.
Each scaffold can comprise a labelling which provides that the bound scaffold can be
detected by determining the presence or absence of a signal provided by the label. For
e, the scaffold can be labelled with a fluorescent dye or any other applicable
cellular marker molecule. Such marker molecules are well known in the art. For
example, a fluorescence-labelling, for example provided by a fluorescence dye, can
provide a visualization of the bound aptamer by fluorescence or laser scanning
microscopy or flow cytometry.
Each scaffold can be conjugated with a second active molecule such as for example IL-
21, anti-CD3, and anti-CD28.
For r information on polypeptide scaffolds see for example the background section
The present invention r relates to aptamers. Aptamers (see for example WO
2014/191359 and the literature as cited therein) are short -stranded nucleic acid
molecules, which can fold into defined three-dimensional structures and recognize
specific target structures. They have appeared to be suitable alternatives for developing
targeted therapies. rs have been shown to selectively bind to a y of
complex targets with high ty and specificity.
Aptamers recognizing cell surface located les have been identified within the
past decade and provide means for ping diagnostic and therapeutic approaches.
Since aptamers have been shown to possess almost no toxicity and immunogenicity
they are promising candidates for biomedical ations. lndeed, aptamers, for
e prostate-specific ne-antigen recognizing aptamers, have been
successfully employed for targeted therapies and shown to be functional in xenograft in
vivo models. Furthermore, aptamers recognizing specific tumor cell lines have been
idenfified.
DNA aptamers can be selected to reveal broad-spectrum recognition properties for
various cancer cells, and particularly those derived from solid tumors, while non-
tumorigenic and primary healthy cells are not recognized. If the identified aptamers
recognize not only a specific tumor sub-type but rather interact with a series of tumors,
this renders the aptamers applicable as so-called broad-spectrum diagnostics and
therapeutics.
Further, investigation of cell-binding behavior with flow cytometry showed that the
aptamers revealed very good apparent affinities that are within the nanomolar range.
Aptamers are useful for stic and eutic purposes. r, it could be shown
that some of the aptamers are taken up by tumor cells and thus can function as
molecular es for the targeted delivery of anti-cancer agents such as siRNA into
tumor cells.
Aptamers can be selected against complex targets such as cells and tissues and
complexes of the peptides comprising, preferably consisting of, a sequence ing
to any of SEQ ID NO 1 to SEQ ID NO 91, according to the invention at hand with the
MHC molecule, using the cell-SELEX (Systematic Evolution of Ligands by Exponential
enrichment) technique.
The peptides of the present invention can be used to generate and develop specific
antibodies against MHC/peptide complexes. These can be used for therapy, targeting
toxins or ctive nces to the diseased tissue. Another use of these antibodies
can be targeting radionuclides to the diseased tissue for imaging purposes such as
PET. This use can help to detect small metastases or to determine the size and precise
zation of diseased tissues.
Therefore, it is a further aspect of the invention to provide a method for producing a
recombinant antibody specifically binding to a human major histocompatibility complex
(MHC) class I or II being complexed with a HLA-restricted antigen, the method
sing: immunizing a genetically engineered non-human mammal comprising cells
expressing said human major histocompatibility complex (MHC) class I or II with a
soluble form of a MHC class I or II molecule being xed with said HLA-restricted
antigen; isolating mRNA molecules from antibody producing cells of said non-human
mammal; producing a phage display library displaying protein molecules encoded by
said mRNA les; and isolating at least one phage from said phage display library,
said at least one phage displaying said antibody specifically binding to said human
major histocompatibility complex (MHC) class I or II being xed with said HLA-
restricted antigen.
It is a further aspect of the invention to provide an antibody that specifically binds to a
human major histocompatibility complex (MHC) class I or II being complexed with a
HLA-restricted antigen, wherein the antibody preferably is a polyclonal antibody,
monoclonal antibody, bi-specific antibody and/or a chimeric antibody.
Respective methods for producing such antibodies and single chain class I major
histocompatibility xes, as well as other tools for the production of these
dies are disclosed in
03/070752, and in publications (Cohen et al., 2003a; Cohen et al., 2003b; Denkberg et
al., 2003), which for the purposes of the present invention are all explicitly incorporated
by reference in their entireties.
Preferably, the antibody is binding with a binding affinity of below 20 nanomolar,
preferably of below 10 nanomolar, to the complex, which is also regarded as “specific”
in the context of the present ion.
The present invention relates to a peptide comprising a sequence that is selected from
the group consisting of SEQ ID NO: 1 to SEQ ID NO: 91, or a variant thereof which is at
least 88% homologous (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 91 or a
variant thereof that induces T cells cross-reacting with said peptide, wherein said
peptide is not the underlying full-length ptide.
The present invention further s to a e sing a sequence that is
selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 91 or a variant
thereof which is at least 88% gous (preferably identical) to SEQ ID NO: 1 to SEQ
ID NO: 91, wherein said e or variant has an overall length of between 8 and 100,
preferably between 8 and 30, and most preferred between 8 and 14 amino acids.
The present invention further relates to the peptides according to the ion that have
the ability to bind to a molecule of the human major histocompatibility complex (MHC)
Class-I or -II.
The present invention further s to the peptides according to the invention wherein
the peptide consists or consists essentially of an amino acid sequence according to
SEQ ID NO: 1 to SEQ ID NO: 91.
The present invention further relates to the peptides according to the invention, wherein
the peptide is (chemically) modified and/or includes non-peptide bonds.
The present invention further relates to the peptides according to the invention, wherein
the peptide is part of a fusion n, in particular comprising N-terminal amino acids of
the HLA-DR antigen-associated invariant chain (Ii), or wherein the peptide is fused to
(or into) an antibody, such as, for example, an antibody that is specific for tic
cells.
The present invention further relates to a nucleic acid, encoding the peptides according
to the invention, ed that the peptide is not the te (full) human protein.
The t invention further relates to the nucleic acid according to the invention that is
DNA, cDNA, PNA, RNA or combinations thereof.
The present invention further s to an expression vector capable of expressing a
nucleic acid according to the present invention.
The present invention further relates to a peptide according to the present invention, a
nucleic acid ing to the present invention or an expression vector according to the
present invention for use in medicine, in particular in the treatment of head and neck
squamous cell carcinoma.
The present invention further relates to a host cell comprising a nucleic acid according
to the ion or an expression vector according to the invention.
The present invention further relates to the host cell according to the present invention
that is an antigen presenting cell, and preferably a dendritic cell.
The present invention further relates to a method of producing a peptide according to
the present invention, said method comprising ing the host cell according to the
present invention, and isolating the peptide from said host cell or its culture medium.
The present invention further relates to the method according to the present ion,
where-in the antigen is loaded onto class I or II MHC les expressed on the
e of a suitable antigen-presenting cell by contacting a sufficient amount of the
antigen with an antigen-presenting cell.
The present invention r relates to the method according to the invention, wherein
the antigen-presenting cell comprises an expression vector capable of expressing said
peptide containing SEQ ID NO: 1 to SEQ ID NO: 91 or said t amino acid
The t invention further relates to activated T cells, produced by the method
according to the present invention, wherein said T cells selectively recognizes a cell
which aberrantly expresses a polypeptide comprising an amino acid sequence
according to the t ion.
The present invention further relates to a method of killing target cells in a patient which
target cells aberrantly express a polypeptide comprising any amino acid sequence
according to the present invention, the method sing administering to the patient
an effective number ofT cells as according to the present invention.
The present invention further relates to the use of any peptide described, a nucleic acid
according to the present ion, an expression vector according to the present
invention, a cell according to the present invention, or an activated cytotoxic T
lymphocyte ing to the present invention as a medicament or in the manufacture
of a medicament. The present invention further relates to a use according to the present
invention, n the medicament is active t cancer.
The present invention r s to a use according to the invention, wherein the
medicament is a vaccine. The t invention further relates to a use according to the
invention, wherein the ment is active against cancer.
The present invention further relates to a use according to the ion, wherein said
cancer cells are head and neck squamous cell oma cells or other solid or
hematological tumor cells such as acute myelogenous leukemia, breast cancer, bile
duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal carcinoma,
esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer,
melanoma, non-Hodgkin ma, non-small cell lung cancer, ovarian cancer,
pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer, urinary
bladder cancer and uterine cancer.
The present ion further relates to particular marker proteins and biomarkers based
on the peptides according to the present invention, herein called “targets” that can be
used in the diagnosis and/or prognosis of head and neck us cell carcinoma. The
present invention also relates to the use of these novel targets for cancer treatment.
The term “antibody” or ”antibodies“ is used herein in a broad sense and includes both
polyclonal and monoclonal antibodies. In addition to intact or “full” immunoglobulin
molecules, also included in the term ”antibodies“ are fragments (e.g. CDRs, Fv, Fab and
Fc fragments) or polymers of those immunoglobulin les and humanized versions
of immunoglobulin molecules, as long as they exhibit any of the desired properties (e.g.,
ic binding of a head and neck us cell carcinoma marker (poly)peptide,
delivery of a toxin to a head and neck squamous cell carcinoma cell expressing a
cancer marker gene at an increased level, and/or inhibiting the activity of a head and
neck squamous cell carcinoma marker polypeptide) according to the invention.
Whenever possible, the antibodies of the invention may be purchased from commercial
sources. The dies of the invention may also be generated using well-known
s. The skilled artisan will understand that either full length head and neck
squamous cell carcinoma marker polypeptides or fragments thereof may be used to
generate the antibodies of the ion. A polypeptide to be used for generating an
antibody of the invention may be lly or fully purified from a natural source, or may
be produced using recombinant DNA techniques.
For example, a cDNA encoding a e according to the t invention, such as a
peptide according to SEQ ID NO: 1 to SEQ ID NO: 91 polypeptide, or a variant or
fragment thereof, can be sed in prokaryotic cells (e.g., bacteria) or eukaryotic
cells (e.g., yeast, insect, or mammalian cells), after which the recombinant protein can
be purified and used to generate a monoclonal or polyclonal antibody preparation that
specifically bind the head and neck squamous cell oma marker polypeptide used
to generate the antibody according to the invention.
One of skill in the art will realize that the generation of two or more different sets of
monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an antibody
with the specificity and affinity required for its intended use (e.g., ELISA,
immunohistochemistry, in vivo imaging, immunotoxin therapy). The dies are
tested for their desired activity by known methods, in accordance with the purpose for
which the antibodies are to be used (e.g., ELISA, immunohistochemistry,
immunotherapy, etc.; for further guidance on the generation and testing of antibodies,
see, e.g., ield, 2014 (Greenfield, 2014)). For example, the antibodies may be
tested in ELISA assays or, Western blots, immunohistochemical ng of in-
fixed cancers or frozen tissue ns. After their initial in vitro characterization,
antibodies intended for therapeutic or in vivo diagnostic use are tested ing to
known clinical testing s.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a
substantially homogeneous population of antibodies, i.e.; the individual antibodies
comprising the population are identical except for possible naturally occurring mutations
that may be present in minor amounts. The monoclonal antibodies herein ically
include "chimeric" antibodies in which a portion of the heavy and/or light chain is
identical with or homologous to corresponding sequences in antibodies derived from a
particular species or belonging to a particular antibody class or subclass, while the
remainder of the chain(s) is identical with or homologous to corresponding sequences in
antibodies derived from another species or belonging to another antibody class or
subclass, as well as fragments of such antibodies, so long as they exhibit the desired
antagonistic activity (US 4,816,567, which is hereby incorporated in its entirety).
Monoclonal antibodies of the invention may be ed using hybridoma methods. In a
hybridoma method, a mouse or other appropriate host animal is lly immunized
with an immunizing agent to elicit lymphocytes that produce or are capable of ing
antibodies that will specifically bind to the immunizing agent. Alternatively, the
lymphocytes may be immunized in vitro.
The monoclonal antibodies may also be made by recombinant DNA methods, such as
those described in US 4,816,567. DNA encoding the monoclonal dies of the
invention can be readily isolated and sequenced using conventional ures (e.g.,
by using oligonucleotide probes that are capable of g specifically to genes
encoding the heavy and light chains of murine antibodies).
In vitro methods are also suitable for ing monovalent antibodies. Digestion of
antibodies to produce fragments thereof, particularly Fab fragments, can be
accomplished using routine techniques known in the art. For instance, digestion can be
performed using papain. Examples of papain digestion are described in WO 48
and US 566. Papain digestion of antibodies typically es two identical
antigen binding fragments, called Fab fragments, each with a single antigen binding
site, and a residual Fc fragment. Pepsin treatment yields a 2 nt and a ch'
fragment.
The antibody fragments, whether attached to other sequences or not, can also include
insertions, deletions, tutions, or other selected modifications of particular regions
or ic amino acids residues, provided the activity of the fragment is not significantly
altered or impaired compared to the non-modified antibody or antibody fragment. These
modifications can provide for some additional property, such as to remove/add amino
acids capable of disulfide bonding, to se its bio-longevity, to alter its secretory
characteristics, etc. In any case, the antibody fragment must possess a bioactive
ty, such as binding activity, regulation of binding at the binding domain, etc.
Functional or active regions of the antibody may be identified by mutagenesis of a
specific region of the protein, followed by expression and testing of the sed
polypeptide. Such methods are readily nt to a skilled practitioner in the art and
can include site-specific mutagenesis of the nucleic acid encoding the antibody
fragment.
The antibodies of the invention may further se humanized dies or human
antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' or
other antigen-binding subsequences of antibodies) which contain l sequence
derived from non-human immunoglobulin. Humanized antibodies include human
immunoglobulins (recipient antibody) in which residues from a complementary
determining region (CDR) of the recipient are replaced by es from a CDR of a
non-human species (donor antibody) such as mouse, rat or rabbit having the desired
specificity, affinity and capacity. In some instances, Fv framework (FR) residues of the
human immunoglobulin are replaced by corresponding non-human residues.
zed antibodies may also comprise residues which are found neither in the
recipient antibody nor in the imported CDR or framework sequences. In general, the
humanized antibody will comprise substantially all of at least one, and typically two,
le domains, in which all or substantially all of the CDR regions correspond to
those of a non-human immunoglobulin and all or substantially all of the FR regions are
those of a human immunoglobulin consensus sequence. The humanized dy
optimally also will comprise at least a portion of an immunoglobulin constant region (Fc),
typically that of a human immunoglobulin.
Methods for humanizing non-human antibodies are well known in the art. Generally, a
zed antibody has one or more amino acid residues uced into it from a
source which is non-human. These non-human amino acid residues are often referred
to as t" es, which are lly taken from an "import" le domain.
Humanization can be essentially performed by substituting rodent CDRs or CDR
sequences for the ponding sequences of a human antibody. Accordingly, such
"humanized" dies are chimeric antibodies (US 4,816,567), wherein substantially
less than an intact human variable domain has been substituted by the corresponding
sequence from a non-human species. In ce, humanized antibodies are typically
human antibodies in which some CDR residues and possibly some FR residues are
substituted by residues from analogous sites in rodent antibodies.
Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full
repertoire of human antibodies in the absence of endogenous immunoglobulin
production can be employed. For example, it has been described that the homozygous
deletion of the antibody heavy chain joining region gene in chimeric and germ-line
mutant mice results in complete inhibition of endogenous antibody production. Transfer
of the human germ-line immunoglobulin gene array in such germ-line mutant mice will
result in the tion of human antibodies upon antigen challenge. Human antibodies
can also be produced in phage display libraries.
WO 37085
Antibodies of the ion are preferably administered to a t in a
pharmaceutically acceptable carrier. Typically, an appropriate amount of a
pharmaceutically-acceptable salt is used in the ation to render the ation
isotonic. Examples of the pharmaceutically-acceptable carrier include saline, Ringer's
solution and dextrose solution. The pH of the solution is preferably from about 5 to
about 8, and more preferably from about 7 to about 7.5. Further carriers include
sustained release preparations such as rmeable matrices of solid hobic
polymers containing the antibody, which matrices are in the form of shaped articles,
e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the
art that certain carriers may be more preferable depending upon, for instance, the route
of administration and tration of antibody being administered.
The antibodies can be administered to the subject, patient, or cell by injection (e.g.,
intravenous, intraperitoneal, subcutaneous, intramuscular), or by other methods such as
infusion that ensure its delivery to the bloodstream in an effective form. The antibodies
may also be administered by intratumoral or peritumoral routes, to exert local as well as
systemic therapeutic effects. Local or intravenous injection is preferred.
Effective s and schedules for administering the antibodies may be determined
empirically, and making such determinations is within the skill in the art. Those skilled in
the art will understand that the dosage of antibodies that must be administered will vary
ing on, for example, the subject that will receive the antibody, the route of
administration, the particular type of antibody used and other drugs being administered.
A typical daily dosage of the antibody used alone might range from about 1 (pg/kg to up
to 100 mg/kg of body weight or more per day, depending on the factors mentioned
above. ing administration of an antibody, preferably for ng head and neck
squamous cell carcinoma, the cy of the therapeutic antibody can be assessed in
various ways well known to the skilled practitioner. For instance, the size, number,
and/or distribution of cancer in a subject receiving treatment may be monitored using
standard tumor imaging techniques. A therapeutically-administered antibody that arrests
tumor growth, results in tumor shrinkage, and/or prevents the development of new
tumors, compared to the disease course that would occur in the e of antibody
administration, is an efficacious antibody for treatment of cancer.
It is a further aspect of the invention to provide a method for producing a soluble T-cell
receptor (sTCR) recognizing a specific peptide-MHC complex. Such soluble T-cell
ors can be generated from specific T-cell clones, and their affinity can be
increased by mutagenesis targeting the mentarity-determining regions. For the
purpose of T-cell receptor selection, phage display can be used (US 2010/0113300,
(Liddy et al., 2012)). For the purpose of stabilization of T-cell ors during phage
y and in case of practical use as drug, alpha and beta chain can be linked e.g. by
non-native disulfide bonds, other covalent bonds (single-chain T-cell receptor), or by
dimerization domains (Boulter et al., 2003; Card et al., 2004; Willcox et al., 1999). The
T-cell or can be linked to , drugs, cytokines (see, for e, US
2013/0115191), and domains recruiting effector cells such as an anti-CD3 domain, etc.,
in order to execute particular functions on target cells. Moreover, it could be sed
in T cells used for ve transfer. Further information can be found in WC
2004/033685A1 and
2012/056407A1. Further methods for the production are disclosed in WC
2013/057586A1.
In addition, the peptides and/or the TCRs or antibodies or other binding molecules of
the present invention can be used to verify a pathologist’s diagnosis of a cancer based
on a biopsied sample.
The dies or TCRs may also be used for in vivo diagnostic assays. Generally, the
antibody is labeled with a radionucleotide (such as 111in, 99To, 14c, 131i, 3H, 32p or 353)
so that the tumor can be localized using immunoscintiography. In one embodiment,
antibodies or fragments thereof bind to the extracellular domains of two or more targets
of a protein selected from the group consisting of the above-mentioned proteins, and
the affinity value (Kd) is less than 1 x 10pM.
dies for diagnostic use may be labeled with probes suitable for detection by
various imaging methods. Methods for detection of probes include, but are not limited
to, fluorescence, light, confocal and electron microscopy; magnetic nce g
and spectroscopy; fluoroscopy, computed tomography and positron emission
tomography. le probes include, but are not limited to, fluorescein, rhodamine,
eosin and other fluorophores, radioisotopes, gold, gadolinium and other lanthanides,
paramagnetic iron, fluorine-18 and other positron-emitting radionuclides. onally,
probes may be bi- or multi-functional and be detectable by more than one of the
methods listed. These antibodies may be directly or indirectly labeled with said probes.
Attachment of probes to the antibodies includes covalent attachment of the probe,
incorporation of the probe into the antibody, and the covalent attachment of a chelating
compound for binding of probe, amongst others well recognized in the art. For
immunohistochemistry, the disease tissue sample may be fresh or frozen or may be
embedded in paraffin and fixed with a preservative such as formalin. The fixed or
embedded section contains the sample are contacted with a labeled primary antibody
and secondary antibody, wherein the antibody is used to detect the expression of the
proteins in situ.
Another aspect of the present invention includes an in vitro method for ing
activated T cells, the method comprising contacting in vitro T cells with antigen loaded
human MHC molecules expressed on the surface of a suitable antigen-presenting cell
for a period of time sufficient to activate the T cell in an antigen ic manner,
wherein the antigen is a peptide according to the invention. Preferably a sufficient
amount of the n is used with an antigen-presenting cell.
Preferably the mammalian cell lacks or has a reduced level or function of the TAP
peptide transporter. Suitable cells that lack the TAP peptide transporter include T2,
RMA-S and Drosophila cells. TAP is the orter associated with antigen processing.
The human e loading deficient cell line T2 is available from the an Type
Culture tion, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under
Catalogue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the
ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in
ren et al. (Ljunggren and Karre, 1985).
ably, before transfection the host cell expresses substantially no MHC class I
molecules. It is also red that the stimulator cell expresses a molecule important for
providing a co-stimulatory signal for T-ce||s such as any of 87.1, 87.2, ICAM-1 and LFA
3. The nucleic acid sequences of us MHC class I molecules and of the co-
stimulator molecules are publicly available from the GenBank and EMBL databases.
In case of a MHC class I epitope being used as an antigen, the T cells are sitive
T cells.
If an antigen-presenting cell is ected to express such an epitope, preferably the
cell comprises an expression vector capable of expressing a peptide containing SEQ ID
NO: 1 to SEQ ID NO: 91, or a variant amino acid sequence thereof.
A number of other methods may be used for generating T cells in vitro. For example,
autologous tumor-infiltrating lymphocytes can be used in the generation of CTL.
Plebanski et al. (Plebanski et al., 1995) made use of autologous peripheral blood
lymphocytes (PLBs) in the ation of T cells. Furthermore, the production of
autologous T cells by pulsing dendritic cells with peptide or polypeptide, or via infection
with recombinant virus is possible. Also, B cells can be used in the production of
autologous T cells. In on, macrophages pulsed with peptide or polypeptide, or
infected with recombinant virus, may be used in the preparation of autologous T cells.
8. Walter et al. (Walter et al., 2003) describe the in vitro priming of T cells by using
cial antigen presenting cells ), which is also a suitable way for generating T
cells against the peptide of choice. In the present invention, aAPCs were generated by
the coupling of preformed MHC: peptide complexes to the surface of polystyrene
particles (microbeads) by biotin: streptavidin biochemistry. This system s the
exact control of the MHC density on aAPCs, which allows to selectively e|icit high- or
low-avidity antigen-specific T cell responses with high efficiency from blood samples.
Apart from MHC: peptide complexes, aAPCs should carry other proteins with co-
stimulatory activity like anti-CD28 antibodies coupled to their e. Furthermore, such
aAPC-based systems often require the addition of appropriate soluble factors, e. g.
cytokines, like interleukin-12.
Allogeneic cells may also be used in the preparation of T cells and a method is
described in detail in WO 97/26328, incorporated herein by reference. For example, in
addition to Drosophila cells and T2 cells, other cells may be used to present antigens
such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, and vaccinia-
infected target cells. In on, plant viruses may be used (see, for example, Porta et
al. (Porta et al., 1994) which describes the development of cowpea mosaic virus as a
ielding system for the presentation of foreign peptides.
The activated T cells that are directed against the peptides of the invention are useful in
y. Thus, a further aspect of the invention provides activated T cells able by
the foregoing methods of the invention.
Activated T cells, which are produced by the above , will selectively recognize a
cell that aberrantly expresses a polypeptide that comprises an amino acid sequence of
SEQ ID NO: 1 to SEQ ID NO 91.
Preferably, the T cell recognizes the cell by interacting through its TCR with the
HLA/peptide-complex (for example, binding). The T cells are useful in a method of
g target cells in a patient whose target cells aberrantly express a polypeptide
comprising an amino acid sequence of the ion wherein the patient is administered
an effective number of the ted T cells. The T cells that are administered to the
patient may be derived from the patient and activated as bed above (i.e. they are
autologous T cells). Alternatively, the T cells are not from the patient but are from
another individual. Of course, it is preferred if the individual is a healthy individual. By
“healthy individual” the inventors mean that the individual is generally in good health,
preferably has a competent immune system and, more ably, is not suffering from
any disease that can be readily tested for, and detected.
In vivo, the target cells for the CD8—positive T cells according to the present invention
can be cells of the tumor (which sometimes express MHC class II) and/or stromal cells
surrounding the tumor (tumor cells) (which sometimes also express MHC class II;
(Dengjel et al., 2006)).
The T cells of the present invention may be used as active ingredients of a therapeutic
composition. Thus, the invention also provides a method of killing target cells in a
patient whose target cells aberrantly express a polypeptide comprising an amino acid
sequence of the invention, the method comprising administering to the t an
effective number of T cells as d above.
By ”aberrantly sed“ the inventors also mean that the polypeptide is over-
expressed compared to levels of sion in normal tissues or that the gene is silent
in the tissue from which the tumor is derived but in the tumor, it is expressed. By ”over-
expressed“ the inventors mean that the polypeptide is t at a level at least ld
of that present in normal tissue; preferably at least 2—fold, and more preferably at least
-fold or 10-fold the level present in normal tissue.
T cells may be obtained by methods known in the art, e.g. those described above.
Protocols for this so-called adoptive transfer of T cells are well known in the art.
Reviews can be found in: Gattioni et al. and Morgan et al. (Gattinoni et al., 2006;
Morgan et al., 2006).
Another aspect of the present invention includes the use of the peptides xed with
MHC to generate a T-cell receptor whose nucleic acid is cloned and is introduced into a
host cell, preferably a T cell. This engineered T cell can then be transferred to a patient
for y of cancer.
Any le of the invention, i.e. the e, nucleic acid, antibody, expression vector,
cell, activated T cell, T-cell receptor or the nucleic acid encoding it, is useful for the
treatment of disorders, characterized by cells escaping an immune response. Therefore,
any molecule of the present invention may be used as medicament or in the
manufacture of a medicament. The molecule may be used by itself or combined with
other molecule(s) of the invention or (a) known molecule(s).
The present ion is further directed at a kit comprising:
(a) a container containing a pharmaceutical composition as described above, in solution
or in lyophilized form;
(b) optionally a second ner containing a diluent or reconstituting solution for the
lyophilized formulation; and
(c) optionally, ctions for (i) use of the solution or (ii) reconstitution and/or use of the
lyophilized formulation.
The kit may further comprise one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a
needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or test
tube; and it may be a multi-use container. The pharmaceutical composition is preferably
lyophmzed.
Kits of the present invention ably comprise a lyophilized formulation of the present
invention in a suitable container and instructions for its reconstitution and/or use.
Suitable containers include, for example, bottles, vials (e.g. dual chamber vials),
syringes (such as dual chamber syringes) and test tubes. The container may be formed
from a variety of materials such as glass or plastic. Preferably the kit and/or container
contain/s instructions on or associated with the ner that tes ions for
reconstitution and/or use. For example, the label may indicate that the lized
ation is to be reconstituted to peptide concentrations as described above. The
label may further indicate that the ation is useful or intended for subcutaneous
administration.
The container holding the formulation may be a multi-use vial, which allows for repeat
administrations (e.g., from 2-6 administrations) of the tituted formulation. The kit
may further comprise a second container comprising a suitable diluent (e.g., sodium
onate solution).
Upon mixing of the diluent and the lyophilized formulation, the final peptide
concentration in the reconstituted formulation is preferably at least 0.15 mg/mL/peptide
(=75 pg) and preferably not more than 3 mg/mL/peptide (=1500 pg). The kit may further
include other materials desirable from a commercial and user standpoint, including
other buffers, diluents, filters, needles, syringes, and package inserts with instructions
for use.
Kits of the present invention may have a single container that contains the formulation
of the pharmaceutical itions according to the present invention with or t
other components (e.g., other compounds or pharmaceutical compositions of these
other compounds) or may have distinct container for each ent.
Preferably, kits of the invention include a ation of the invention packaged for use
in combination with the co-administration of a second compound (such as adjuvants
(e.g. GM-CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist,
an anti-angiogenesis agent or tor, an apoptosis-inducing agent or a chelator) or a
pharmaceutical composition thereof. The components of the kit may be mplexed
or each component may be in a separate distinct container prior to administration to a
patient. The components of the kit may be provided in one or more liquid solutions,
preferably, an aqueous solution, more preferably, a sterile aqueous solution. The
components of the kit may also be provided as solids, which may be converted into
liquids by addition of le solvents, which are preferably provided in another ct
container.
The ner of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any
other means of enclosing a solid or liquid. y, when there is more than one
component, the kit will contain a second vial or other container, which allows for
separate dosing. The kit may also contain another container for a pharmaceutically
acceptable . Preferably, a eutic kit will contain an apparatus (e.g., one or
more s, syringes, eye droppers, pipette, etc.), which enables administration of the
agents of the invention that are components of the present kit.
The present formulation is one that is suitable for administration of the peptides by any
acceptable route such as oral (enteral), nasal, ophthal, subcutaneous, intradermal,
intramuscular, intravenous or transdermal. Preferably, the administration is so, and
most preferably i.d. administration may be by on pump.
Since the peptides of the invention were ed from head and neck squamous cell
carcinoma, the medicament of the ion is preferably used to treat head and neck
squamous cell carcinoma.
The present invention further relates to a method for producing a personalized
pharmaceutical for an individual patient comprising manufacturing a pharmaceutical
composition comprising at least one peptide selected from a warehouse of prescreened
TUMAPs, wherein the at least one peptide used in the pharmaceutical
composition is selected for suitability in the individual patient. In one embodiment, the
pharmaceutical composition is a vaccine. The method could also be d to produce
T cell clones for down-stream applications, such as TCR isolations, or e
antibodies, and other treatment options.
A “personalized pharmaceutical” shall mean specifically tailored therapies for one
individual t that will only be used for therapy in such individual patient, including
actively personalized cancer vaccines and adoptive cellular therapies using autologous
paflentfissue.
As used herein, the term “warehouse” shall refer to a group or set of peptides that have
been pre-screened for immunogenicity and/or over-presentation in a particular tumor
type. The term “warehouse” is not intended to imply that the ular peptides included
in the vaccine have been pre-manufactured and stored in a physical facility, although
that possibility is contemplated. It is expressly contemplated that the peptides may be
ctured de novo for each individualized vaccine produced, or may be pre-
manufactured and stored. The warehouse (e.g. in the form of a database) is composed
of tumor-associated peptides which were highly overexpressed in the tumor tissue of
head and neck squamous cell carcinoma patients with s HLA-A HLA-B and HLA-
C alleles. It may contain MHC class I and MHC class II peptides or elongated MHC
class I peptides. In addition to the tumor associated peptides collected from several
head and neck squamous cell carcinoma tissues, the use may contain HLA-
A*02 and HLA-A*24 marker peptides. These peptides allow comparison of the
magnitude of T-cell ty induced by TUMAPS in a tative manner and hence
allow important conclusion to be drawn on the capacity of the vaccine to elicit anti-tumor
responses. Secondly, they function as important positive control peptides d from a
“non-self” antigen in the case that any vaccine-induced T-cell responses to TUMAPs
derived from “self” antigens in a patient are not observed. And thirdly, it may allow
conclusions to be drawn, regarding the status of immunocompetence of the patient.
TUMAPs for the warehouse are fied by using an integrated functional genomics
approach combining gene expression analysis, mass ometry, and T-cell
immunology (XPresident ®). The approach assures that only TUMAPs truly present on
a high percentage of tumors but not or only minimally sed on normal tissue, are
chosen for further analysis. For initial peptide selection, head and neck squamous cell
carcinoma samples from patients and blood from healthy donors were analyzed in a
se approach:
1. HLA ligands from the malignant material were identified by mass spectrometry
2. Genome-wide messenger cleic acid (mRNA) expression analysis was used to
identify genes over-expressed in the malignant tissue (head and neck squamous cell
carcinoma) compared with a range of normal organs and tissues
3. Identified HLA s were compared to gene expression data. Peptides over-
ted or selectively presented on tumor tissue, preferably encoded by selectively
expressed or over-expressed genes as detected in step 2 were considered suitable
TUMAP candidates for a multi-peptide vaccine.
4. Literature research was performed in order to identify additional evidence supporting
the relevance of the identified peptides as TUMAPs
. The relevance of over-expression at the mRNA level was confirmed by redetection of
selected TUMAPs from step 3 on tumor tissue and lack of (or infrequent) ion on
healthy tissues.
6. In order to assess, whether an induction of in vivo T-cell responses by the ed
peptides may be feasible, in vitro immunogenicity assays were performed using human
T cells from healthy donors as well as from head and neck squamous cell carcinoma
In an aspect, the es are pre-screened for immunogenicity before being included in
the warehouse. By way of example, and not limitation, the immunogenicity of the
peptides included in the warehouse is determined by a method comprising in vitro T-cell
priming through repeated stimulations of CD8+ T cells from healthy donors with artificial
antigen presenting cells loaded with peptide/MHC complexes and anti-CD28 antibody.
This method is preferred for rare cancers and patients with a rare expression profile. In
contrast to multi-peptide cocktails with a fixed composition as currently developed, the
warehouse allows a icantly higher matching of the actual expression of antigens in
the tumor with the e. Selected single or combinations of several “off-the-shelf”
peptides will be used for each patient in a multitarget approach. In theory, an approach
based on selection of e.g. 5 different antigenic peptides from a library of 50 would
y lead to approximately 17 n le drug product (DP) compositions.
In an aspect, the peptides are selected for inclusion in the vaccine based on their
suitability for the individual patient based on the method according to the present
invention as described herein, or as below.
The HLA phenotype, riptomic and omic data is gathered from the patient’s
tumor material, and blood samples to identify the most suitable es for each patient
ning “warehouse” and patient-unique (i.e. mutated) TUMAPs. Those peptides will
be chosen, which are selectively or over-expressed in the ts’ tumor and, where
possible, show strong in vitro immunogenicity if tested with the patients’ individual
PBMCs.
Preferably, the peptides included in the vaccine are identified by a method comprising:
(a) identifying tumor-associated es (TUMAPs) presented by a tumor sample from
the dual patient; (b) comparing the peptides identified in (a) with a warehouse
(database) of peptides as described above; and (c) selecting at least one peptide from
the warehouse (database) that correlates with a tumor-associated peptide fied in
the patient. For example, the TUMAPs presented by the tumor sample are identified by:
(a1) comparing expression data from the tumor sample to expression data from a
sample of normal tissue corresponding to the tissue type of the tumor sample to identify
proteins that are over-expressed or aberrantly expressed in the tumor sample; and (a2)
correlating the expression data with sequences of MHC ligands bound to MHC class I
and/or class II molecules in the tumor sample to identify MHC ligands derived from
proteins over-expressed or aberrantly expressed by the tumor. ably, the
sequences of MHC ligands are identified by eluting bound peptides from MHC
molecules isolated from the tumor sample, and sequencing the eluted ligands.
Preferably, the tumor sample and the normal tissue are obtained from the same patient.
In on to, or as an alternative to, selecting peptides using a warehousing (database)
model, TUMAPs may be identified in the patient de novo, and then included in the
vaccine. As one example, candidate TUMAPs may be identified in the patient by (a1)
comparing expression data from the tumor sample to expression data from a sample of
normal tissue corresponding to the tissue type of the tumor sample to identify proteins
that are over-expressed or aberrantly expressed in the tumor sample; and (a2)
correlating the expression data with sequences of MHC ligands bound to MHC class I
and/or class II molecules in the tumor sample to identify MHC ligands derived from
proteins over-expressed or aberrantly sed by the tumor. As another example,
proteins may be identified containing mutations that are unique to the tumor sample
relative to normal corresponding tissue from the individual patient, and TUMAPs can be
identified that specifically target the mutation. For example, the genome of the tumor
and of corresponding normal tissue can be sequenced by whole genome sequencing:
For discovery of non-synonymous mutations in the protein-coding s of genes,
genomic DNA and RNA are extracted from tumor tissues and normal non-mutated
genomic germline DNA is extracted from peripheral blood clear cells (PBMCs).
The applied NGS approach is confined to the re-sequencing of n coding regions
(exome re-sequencing). For this purpose, exonic DNA from human samples is captured
using vendor-supplied target enrichment kits, followed by sequencing with e.g. a
HiSeq2000 ina). Additionally, tumor mRNA is sequenced for direct quantification of
gene expression and validation that mutated genes are expressed in the patients’
tumors. The resultant millions of sequence reads are processed through software
algorithms. The output list contains mutations and gene expression. Tumor-specific
somatic mutations are determined by ison with the PBMC-derived germline
variations and prioritized. The de novo identified peptides can then be tested for
immunogenicity as described above for the warehouse, and ate TUMAPs
possessing suitable immunogenicity are selected for inclusion in the e.
In one exemplary embodiment, the peptides included in the e are fied by: (a)
identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the
individual patient by the method as described above; (b) comparing the peptides
identified in a) with a warehouse of peptides that have been eened for
immunogenicity and over tation in tumors as compared to corresponding normal
tissue; (c) selecting at least one peptide from the warehouse that correlates with a
tumor-associated peptide identified in the patient; and (d) optionally, selecting at least
one peptide identified de novo in (a) confirming its immunogenicity.
In one exemplary embodiment, the es included in the vaccine are identified by: (a)
identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the
individual patient; and (b) selecting at least one peptide identified de novo in (a) and
confirming its immunogenicity.
Once the peptides for a personalized peptide based vaccine are ed, the vaccine is
produced. The vaccine preferably is a liquid formulation consisting of the individual
peptides dissolved in between 20-40% DMSO, preferably about 30-35% DMSO, such
as about 33% DMSO.
Each peptide to be included into a product is ved in DMSO. The concentration of
the single e solutions has to be chosen depending on the number of peptides to
be included into the product. The single peptide-DMSO solutions are mixed in equal
parts to achieve a solution containing all peptides to be included in the product with a
concentration of ~2.5 mg/ml per peptide. The mixed solution is then diluted 1:3 with
water for injection to achieve a concentration of 0.826 mg/ml per peptide in 33% DMSO.
The d solution is filtered through a 0.22 pm sterile filter. The final bulk solution is
obtained.
Final bulk on is filled into vials and stored at -20°C until use. One vial contains 700
pL solution, containing 0.578 mg of each peptide. Of this, 500 pL (approx. 400 pg per
peptide) will be applied for intradermal injection.
In addition to being useful for treating cancer, the peptides of the present ion are
also useful as diagnostics. Since the peptides were generated from head and neck
squamous cell oma cells and since it was determined that these es are not
or at lower levels present in normal tissues, these peptides can be used to diagnose the
presence Of a cancer.
The presence of d peptides on tissue biopsies in blood samples can assist a
pathologist in diagnosis of cancer. Detection of certain peptides by means of antibodies,
mass spectrometry or other methods known in the art can tell the pathologist that the
tissue sample is malignant or inflamed or generally diseased, or can be used as a
biomarker for head and neck squamous cell carcinoma. Presence of groups of peptides
can enable classification or sub-classification of diseased tissues.
The ion of peptides on diseased tissue specimen can enable the decision about
the benefit of therapies involving the immune system, especially if T-lymphocytes are
known or expected to be involved in the mechanism of action. Loss of MHC expression
is a well described mechanism by which infected of malignant cells escape immuno-
llance. Thus, ce of peptides shows that this mechanism is not exploited by
the analyzed cells.
The es of the present invention might be used to analyze lymphocyte ses
against those peptides such as T cell responses or antibody responses against the
peptide or the peptide complexed to MHC molecules. These lymphocyte ses can
be used as prognostic s for decision on further therapy steps. These responses
can also be used as surrogate response markers in immunotherapy approaches aiming
to induce lymphocyte responses by ent means, e.g. vaccination of protein, nucleic
acids, autologous materials, adoptive transfer of lymphocytes. In gene y settings,
lymphocyte responses against peptides can be considered in the assessment of side
effects. Monitoring of lymphocyte responses might also be a valuable tool for follow-up
examinations of transplantation therapies, e.g. for the detection of graft versus host and
host versus graft diseases.
The present ion will now be described in the following examples which describe
preferred embodiments thereof, and with reference to the accompanying figures,
nevertheless, without being limited thereto. For the purposes of the present invention,
all nces as cited herein are orated by reference in their entireties.
FIGURES
Figure 1A through 1D show the over-presentation of various peptides in normal tissues
(white bars) and head and neck squamous cell carcinoma (black bars). Figure 1A)
Gene symbols: KRT6C, KRT6A, KRT6B, Peptide: GLAGGFGGPGFPV (SEQ ID NO.:
1); Tissues from left to right: 6 adipose s, 8 adrenal glands, 1 bile duct, 24 blood
cells, 15 blood vessels, 1O bone marrows, 15 brains, 7 breasts, 11 esophagi, 2 eyes, 6
gallbladders, 16 hearts, 17 kidneys, 27 large intestines, 24 livers, 49 lungs, 7 lymph
nodes, 12 nen/es, 5 ovaries, 15 ases, 6 yroid glands, 3 peritoneums, 7
pituitary , 1O placentas, 3 pleuras, 11 tes, 9 skeletal muscles, 11 skins, 16
small intestines, 13 spleens, 9 stomachs, 8 testes, 3 thymi, 8 thyroid glands, 18
tracheas, 7 ureters, 8 urinary bladders, 6 uteri, 12 head-and-necks, 17 HNSCC. Figure
1B) Gene symbols: KRT6C, KRT6A, KRT6B, Peptide: SLYGLGGSKRISI (SEQ ID NO.:
3); Tissues from left to right: 6 adipose tissues, 8 adrenal glands, 1 bile duct, 24 blood
cells, 15 blood s, 1O bone marrows, 15 brains, 7 breasts, 11 esophagi, 2 eyes, 6
gallbladders, 16 , 17 kidneys, 27 large intestines, 24 livers, 49 lungs, 7 lymph
nodes, 12 nen/es, 5 ovaries, 15 pancreases, 6 yroid glands, 3 peritoneums, 7
pituitary glands, 1O placentas, 3 pleuras, 11 prostates, 9 skeletal muscles, 11 skins, 16
small ines, 13 spleens, 9 stomachs, 8 testes, 3 thymi, 8 thyroid , 18
tracheas, 7 ureters, 8 urinary bladders, 6 uteri, 12 head-and-necks, 17 HNSCC. Figure
) Gene symbol: KRT5, Peptide: STASAITPSV (SEQ ID NO.: 9); Tissues from left to
right: 6 adipose tissues, 8 adrenal , 1 bile duct, 24 blood cells, 15 blood vessels,
1O bone marrows, 15 brains, 7 breasts, 11 esophagi, 2 eyes, 6 gallbladders, 16 hearts,
17 kidneys, 27 large intestines, 24 livers, 49 lungs, 7 lymph nodes, 12 nerves, 5 ovaries,
ases, 6 parathyroid glands, 3 peritoneums, 7 pituitary glands, 1O placentas, 3
pleuras, 11 tes, 9 skeletal muscles, 11 skins, 16 small intestines, 13 spleens, 9
stomachs, 8 testes, 3 thymi, 8 thyroid glands, 18 tracheas, 7 ureters, 8 urinary bladders,
6 uteri, 12 head-and-necks, 17 HNSCC. Figure 1D) Gene symbol: SLC25A3, Peptide:
FVAGYIAGV (SEQ ID NO.: 61); Tissues from left to right: 3 cell lines (2 kidney, 1
pancreas), 7 normal tissues (1 adrenal gland, 1 colon, 2 lymph nodes, 1 ta, 2
spleens), 36 cancer tissues (5 leukocytic leukemia cancers, 3 brain cancers, 2 breast
cancers, 1 esophageal cancer, 1 adder cancer, 5 head-and-neck cancers, 1
kidney cancer, 1 liver cancer, 8 lung cancers, 4 lymph node s, 3 ovarian cancers,
WO 37085
2 stomach cancers). Figures 1E to 10 show the over-presentation of various peptides in
different cancer s (black dots). Upper part: Median MS signal intensities from
technical replicate measurements are d as dots for single HLA-A*02 positive
normal (grey dots) and tumor samples (black dots) on which the peptide was ed.
Tumor and normal samples are grouped according to organ of origin, and box-and-
whisker plots represent median, 25th and 75th tile (box), and minimum and
maximum (whiskers) of normalized signal intensities over multiple samples. Normal
organs are ordered according to risk categories (blood cells, blood vessels, brain, liver,
lung: high risk, grey dots; reproductive organs, breast, prostate: low risk, grey dots; all
other organs: medium risk; grey dots). Lower part: The relative peptide detection
frequency in every organ is shown as spine plot. Numbers below the panel indicate
number of samples on which the peptide was detected out of the total number of
samples analyzed for each organ (N = 526 for normal samples, N = 562 for tumor
samples). If the peptide has been detected on a sample but could not be quantified for
technical reasons, the sample is included in this representation of detection frequency,
but no dot is shown in the upper part of the figure. Tissues (from left to right): Normal
samples: blood cells; bloodvess (blood vessels); brain; heart; liver; lung; adipose
(adipose tissue); adren.gl. (adrenal gland); bile duct; bladder; BM (bone marrow);
cartilage; esoph (esophagus); eye; gallb (gallbladder); eck; kidney; int
(large intestine); LN (lymph node); nerve; pancreas; parathyr (parathyroid gland); perit
(peritoneum); pituit (pituitary); pleura; skel.mus (skeletal muscle); skin; int (small
intestine); spleen; stomach; thyroid; trachea; ureter; breast; ovary; placenta; prostate;
testis; thymus; uterus. Tumor samples: AML: acute myeloid leukemia; BRCA: breast
; CCC: cholangiocellular carcinoma; CLL: c lymphocytic leukemia; CRC:
ctal cancer; GBC: gallbladder ; GBM: glioblastoma; GC: gastric cancer;
GEJC: stomach cardia esophagus, cancer; HCC: hepatocellular carcinoma; HNSCC:
head-and-neck cancer; MEL: melanoma; NHL: non-hodgkin lymphoma; NSCLC: non-
small cell lung cancer; 00: ovarian cancer; OSCAR: esophageal cancer; PACA:
pancreatic cancer; PRCA: prostate ; RCC: renal cell carcinoma; SCLC: small cell
lung cancer; UBC: urinary bladder carcinoma; UEC: uterine and endometrial .
Figure 1E) Gene symbols: KRTBC, KRT6A, KRT1, KRTBB, KRT75, KRT5, Peptide:
PVCPPGGIQEV (SEQ ID NO.: 2), Figure 1F) Gene symbol: PKP1, Peptide:
SMLNNIINL (SEQ ID NO.: 15), Figure 1G) Gene symbol: PRKDC, Peptide:
GLIEWLENTV (SEQ ID NO.: 45), Figure 1H) Gene symbol: , ATP5G1,
ATP5G3, Peptide: AILGFALSEA (SEQ ID NO.: 57), Figure 1|) Gene symbol: ITGB4,
Peptide: SLSDIQPCL (SEQ ID NO.: 58), Figure 1J) Gene symbol: KRT5, Peptide:
ALMDEINFMKM (SEQ ID NO.: 63), Figure 1K) Gene symbol: ESRP2, Peptide:
ALASAPTSV (SEQ ID NO.: 75), Figure 1L) Gene : PARP9, Peptide:
ILFDEVLTFA (SEQ ID NO.: 76), Figure 1M) Gene : MCM4, Peptide:
QLLQYWNL (SEQ ID NO.: 83), Figure 1N) Gene symbol: FHAD1, Peptide:
QLIEKITQV (SEQ ID NO.: 85), Figure 10) Gene symbol: PLEC, Peptide: ALPEPSPAA
(SEQ ID NO.: 87), Figure 1P) Gene : G3BP1, Peptide: TLNDGWVQV (SEQ ID
NO.: 90), Figure 1Q) Gene symbol: ODC1, Peptide: MLFENMGAYTV (SEQ ID NO.:
Figures 2A through C show exemplary expression profiles of source genes of the
present invention that are highly over-expressed or exclusively expressed in head and
neck squamous cell carcinoma in a panel of normal tissues (white bars) and 15 head
and neck squamous cell carcinoma samples (black bars). Figure 2A) Gene symbol:
PGLYRP4, Peptide: AIYEGVGWNV (SEQ ID NO.: 33); Figure 2B) Gene : PAPL,
Peptide: KLLPGVQYV (SEQ ID NO.: 38); Figure 20) Gene symbols: LGALS7,
LGALS7B, e: RLVEVGGDVQL (SEQ ID NO.: 53).
Figure 3 shows exemplary immunogenicity data: flow cytometry results after peptide-
specific multimer staining.
Figure 4 shows exemplary results of peptide-specific in vitro CD8+ T cell responses of a
healthy HLA-A*02+ donor. CD8+ T cells were primed using artificial APCs coated with
anti-CD28 mAb and HLA-A*02 in complex with Seq ID NO.: 17 peptide (A, left ,
Seq ID NO.: 28 peptide (B, left panel) and Seq ID NO.: 29 peptide (C, left panel),
tively. After three cycles of stimulation, the ion of peptide-reactive cells was
performed by 2D er staining with A*O2/Seq ID NO.: 17 (A), A*O2/Seq ID NO.: 28
(B) or A*02/Seq ID NO.: 29 (C). Right panels (A, B and C) show control staining of cells
ated with irrelevant A*02/peptide complexes. Viable t cells were gated for
CD8+ lymphocytes. n gates helped excluding false-positive events detected with
multimers specific for ent peptides. Frequencies of specific multimer+ cells among
CD8+ lymphocytes are indicated.
EXAMPLES
EXAMPLE 1
Identification and guantitation of tumor associated peptides presented on the cell
Tissue samples
Patients’ tumor tissues were obtained from: Asterand (Detroit, MI, USA & Royston,
Herts, UK); ProteoGenex Inc. (Culver City, CA, USA). Normal tissues were obtained
from Asterand (Detroit, MI, USA & Royston, Herts, UK); Bio-Options Inc. (Brea, CA,
USA); BioServe (Beltsville, MD, USA); l BioScience Inc. (Rockville, MD, USA);
Geneticist Inc. (Glendale, CA, USA); Kyoto Prefectural University of Medicine (KPUM)
(Kyoto, Japan); ProteoGenex Inc. (Culver City, CA, USA); Tissue Solutions Ltd
(Glasgow, UK); University Hospital Geneva (Geneva, Switzerland); University Hospital
Heidelberg (Heidelberg, Germany); University Hospital Ttibingen (Ttibingen, Germany).
Written ed consents of all patients had been given before surgery or autopsy.
Tissues were shock-frozen immediately after excision and stored until isolation of
TUMAPs at -70°C or below.
Isolation of HLA peptides from tissue samples
HLA peptide pools from shock-frozen tissue samples were obtained by immune
precipitation from solid tissues according to a slightly ed protocol (Falk et al.,
1991; Seeger et al., 1999) using the HLA-A*02—specific antibody 887.2, the HLA-A, -B, -
ific antibody WES/32, CNBr—activated sepharose, acid ent, and
ultrafiltration.
Mass spectrometm analyses
The HLA peptide pools as obtained were separated according to their hydrophobicity by
ed-phase chromatography (nanoAcquity UPLC system, Waters) and the eluting
peptides were analyzed in LTQ- velos and fusion hybrid mass spectrometers
(ThermoElectron) equipped with an ESI . Peptide pools were loaded directly onto
the analytical silica micro-capillary column (75 um id. x 250 mm) packed with 1.7
pm C18 reversed-phase al (Waters) ng a flow rate of 400 nL per minute.
Subsequently, the peptides were separated using a two-step 180 minute-binary nt
from 10% to 33% B at a flow rate of 300 nL per minute. The gradient was composed of
Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A
gold coated glass ary (PicoTip, New Objective) was used for introduction into the
nanoESl source. The LTQ-Orbitrap mass spectrometers were ed in the data-
dependent mode using a TOP5 strategy. In brief, a scan cycle was initiated with a full
scan of high mass accuracy in the Orbitrap (R = 30 000), which was followed by MS/MS
scans also in the Orbitrap (R = 7500) on the 5 most abundant precursor ions with
dynamic exclusion of usly selected ions. Tandem mass spectra were interpreted
by SEQUEST and additional manual control. The identified peptide sequence was
assured by comparison of the generated l peptide fragmentation pattern with the
fragmentation pattern of a synthetic sequence-identical reference peptide.
Label-free relative LC-MS quantitation was performed by ion counting i.e. by extraction
and analysis of LC-MS features (Mueller et al., 2007). The method assumes that the
peptide’s LC-MS signal area ates with its abundance in the sample. Extracted
features were further processed by charge state deconvolution and retention time
alignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MS features were
cross-referenced with the sequence fication results to combine quantitative data of
different samples and tissues to e presentation profiles. The quantitative data
were normalized in a two-tier fashion according to central tendency to account for
variation within technical and biological replicates. Thus, each identified peptide can be
associated with quantitative data allowing relative quantification between samples and
tissues. In addition, all quantitative data acquired for peptide candidates was inspected
WO 37085
manually to assure data consistency and to verify the accuracy of the automated
analysis. For each peptide, a presentation e was calculated showing the mean
sample presentation as well as replicate variations. The profiles juxtapose head and
neck squamous cell carcinoma samples to a baseline of normal tissue samples.
Presentation profiles of exemplary over-presented peptides are shown in Figure 1.
Presentation scores for exemplary peptides are shown in Table 8.
Table 8: Presentation scores. The table lists es that are very highly over-
presented on tumors compared to a panel of normal tissues (+++), highly over-
presented on tumors compared to a panel of normal tissues (++) or over-presented on
tumors compared to a panel of normal tissues (+).The panel of normal tissues
considered relevant for comparison with tumors consisted of: adipose tissue, adrenal
gland, bile duct, blood cells, blood , bone marrow, brain, esophagus, eye,
gallbladder, head-and-neck, heart, kidney, large intestine, liver, lung, lymph node,
nerve, pancreas, parathyroid gland, peritoneum, pituitary, pleura, skeletal muscle, skin,
small intestine, spleen, stomach, thymus, thyroid gland, a, ureter, urinary r.
SEQ ID
No ce Peptide Presentation
1 GLAGGFGGPGFPV +++
2 PVCPPGGIQEV +++
3 SLYGLGGSKRISI +++
4 lLDlNDNPPV +++
VCPPGGIQEV +++
6 ALYDAELSQM +++
7 ALEEANADLEV +++
8 AQLNIGNVLPV +++
9 STASAITPSV +++
PPKA +++
11 VLFSSPPVI +++
12 TLTDEINFL +++
13 SLVSYLDKV +++
14 RIMEGIPTV +++
SMLNNIINL +
16 ALKDSVQRA +++
17 SIWPALTQV +++
19 ALAKLLPLL +++
SEQ ID
No Sequence e Presentation
YLINEIDRIRA +++
21 FLHEPFSSV +++
22 KLPEPCPSTV +++
23 SLPESGLLSV +++
24 LLIAINPQV +++
SLCPPGGIQEV +++
26 TLVDENQSWYL +++
27 YLAEPQWAV +++
28 AVDPVSGSLYV +++
29 RLLPDLDEV +++
3O TLASLGYAW +++
31 LLV +++
32 AIHEV +++
33 AIYEGVGWNV +++
34 ALDTFSVQV +++
ALVGDVILTV +++
36 GLWSSIFSL +++
37 FQL +++
38 KLLPGVQYV +++
39 LLPEDDTRDNV +++
40 LLTPLNLQI +++
41 RLNGEGVGQVNISV +++
42 ALYTSGHLL +++
43 AVLGGKLYV +++
44 GLGDDSFPI +++
45 GLIEWLENTV +++
46 GLISSIEAQL +++
47 QLLEGELETL +++
48 YLLDYPNNL +++
49 YLWEAHTNI +++
5O ALSNWHKV +++
51 FLIPSIIFA +++
52 LLFTGLVSGV +++
53 RLVEVGGDVQL +++
54 RLSGEGVGPV +++
55 VLNVGVAEV +++
56 FLQLETEQV +++
58 SLSDIQPCL +++
60 SLGNFKDDLL +++
SEQ ID
No Sequence Peptide Presentation
61 FVAGYIAGV +++
62 ILSSACYTV +++
63 ALMDEINFMKM ++
67 WQL +
69 WMESMTYL +
70 LTA +++
71 SLFPYWLI +++
72 SLDGNPLAV +++
73 YIDPYKLLPL +++
74 SLTSFLISL +++
75 ALASAPTSV +++
78 VLYGDVEEL +++
79 GLHQDFPSVVL +
81 VLAENPDIFAV +++
82 NPPV +++
83 QLLQYVYNL +++
84 ALMAGCIQEA +++
85 QLIEKITQV +++
86 SLQERQVFL +++
88 LMAPAPSTV ++
90 TLNDGWVQV +
91 MLFENMGAYTV +
EXAMPLE 2
Expression profiling of genes encoding the peptides of the invention
Over-presentation or ic presentation of a peptide on tumor cells compared to
normal cells is sufficient for its usefulness in therapy, and some peptides are
tumor-specific despite their source protein occurring also in normal tissues. Still, mRNA
expression profiling adds an additional level of safety in selection of peptide targets for
immunotherapies. Especially for therapeutic options with high safety risks, such as
affinity-matured TCRs, the ideal target peptide will be derived from a protein that is
unique to the tumor and not found on normal tissues.
RNA s and preparation
Surgically removed tissue specimens were provided as indicated above (see Example
1) after written informed consent had been obtained from each patient. Tumor tissue
specimens were snap-frozen immediately after surgery and later homogenized with
mortar and pestle under liquid nitrogen. Total RNA was prepared from these s
using TRl Reagent (Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy
(QIAGEN, Hilden, Germany); both methods were performed according to the
manufacturer's protocol.
Total RNA from healthy human tissues for RNASeq experiments was obtained from:
Asterand (Detroit, MI, USA & Royston, Herts, UK); BioCat GmbH lberg,
Germany); tions lnc. (Brea, CA, USA); BioServe (Beltsville, MD, USA); Capital
BioScience lnc. (Rockville, MD, USA); Geneticist lnc. (Glendale, CA, USA); lstituto
ale Tumori "Pascale" (Naples, Italy); ProteoGenex lnc. (Culver City, CA, USA);
University Hospital Heidelberg (Heidelberg, Germany). Total RNA from tumortissues for
RNASeq experiments was obtained from: Asterand (Detroit, MI, USA & Royston, Herts,
UK); ProteoGenex lnc. (Culver City, CA, USA).
Quality and quantity of all RNA samples were ed on an t 2100 Bioanalyzer
(Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).
RNASeg experiments
Gene expression analysis of - tumor and normal tissue RNA samples was performed by
next generation sequencing (RNASeq) by CeGaT (Ttibingen, y). Briefly,
sequencing libraries are prepared using the lllumina HiSeq v4 reagent kit ing to
the provider’s protocol (lllumina Inc, San Diego, CA, USA), which includes RNA
fragmentation, cDNA conversion and addition of sequencing adaptors. Libraries derived
from multiple samples are mixed equimolar and sequenced on the lllumina HiSeq 2500
sequencer according to the cturer’s instructions, generating 50 bp single end
reads. Processed reads are mapped to the human genome (GRCh38) using the STAR
software. Expression data are provided on ript level as RPKM (Reads Per
se per n mapped reads, ted by the software Cufflinks) and on exon
WO 37085
level (total reads, generated by the software Bedtools), based on annotations of the
ensembl sequence database (Ensembl77). Exon reads are normalized for exon length
and alignment size to obtain RPKM values.
Exemplary sion profiles of source genes of the present invention that are highly
over-expressed or exclusively expressed in head and neck squamous cell carcinoma
are shown in Figure 2. Expression scores for further exemplary genes are shown in
Table 9.
Table 9: Expression scores. The table lists peptides from genes that are very highly
over-expressed in tumors compared to a panel of normal tissues (+++), highly overexpressed
in tumors ed to a panel of normal tissues (++) or over-expressed in
tumors ed to a panel of normal tissues (+). The ne for this score was
calculated from measurements of the following relevant normal tissues: adipose tissue,
adrenal gland, artery, bile duct, blood cells, bone marrow, brain, cartilage, colon,
esophagus, eye, gallbladder, head-and-neck and salivary gland, heart, kidney, liver,
lung, lymph node, pancreas, parathyroid gland, peripheral nerve, peritoneum, pituitary,
pleura, rectum, skeletal muscle, skin, small intestine, , h, thyroid gland,
trachea, ureter, urinary bladder, and vein. In case expression data for several s
of the same tissue type were available, the arithmetic mean of all respective samples
was used for the calculation.
SEQ ID Gene
ZO Sequence Expression
OVCDO‘l-POONA GLAGGFGGPGFPV +++
PVCPPGGIQEV +++
SLYGLGGSKRISI +++
lLDlNDNPPV +++
VCPPGGIQEV +++
LSQM +++
ALEEANADLEV +++
STASAITPSV +++
SEQ ID Gene
No Sequence sion
12 TLTDEINFL +++
14 RIMEGIPTV +++
SMLNNIINL +++
19 PLL +++
YLINEIDRIRA ++
21 FLHEPFSSV +++
24 LLIAINPQV +++
26 TLVDENQSWYL +++
27 YLAEPQWAV +
33 AIYEGVGWNV +++
34 ALDTFSVQV ++
ALVGDVILTV +
36 GLWSSIFSL +++
38 KLLPGVQYV +++
39 TRDNV +++
40 LLTPLNLQI +++
41 RLNGEGVGQVNISV +++
49 YLWEAHTNI +
51 FLIPSIIFA +++
53 RLVEVGGDVQL +++
54 RLSGEGVGPV +++
59 YLQNEVFGL +++
60 SLGNFKDDLL +++
62 ILSSACYTV +++
63 ALMDEINFMKM +++
82 VLDINDNPPV +++
91 MLFENMGAYTV ++
EXAMPLE 3
In vitro immunogenicity for MHC class I presented peptides
In order to obtain information regarding the immunogenicity of the TUMAPs of the
present invention, the ors performed investigations using an in vitro T-cell priming
assay based on repeated stimulations of CD8+ T cells with artificial antigen presenting
cells (aAPCs) loaded with peptide/MHC complexes and anti-CD28 antibody. This way
the inventors could show genicity for HLA-A*0201 restricted TUMAPs of the
invention, demonstrating that these peptides are T-cell epitopes against which CD8+
sor T cells exist in humans (Table 10).
In vitro priming of CD8+ T cells
In order to perform in vitro stimulations by cial antigen presenting cells loaded with
peptide-MHC complex (pMHC) and anti-CD28 antibody, the ors first isolated
CD8+ T cells from fresh HLA-A*02 leukapheresis products via positive selection using
CD8 microbeads (Miltenyi Biotech, ch-Gladbach, Germany) of healthy donors
obtained from the University clinics Mannheim, Germany, after informed consent.
PBMCs and isolated CD8+ lymphocytes were incubated in T-cell medium (TCM) until
use consisting of RPMl-Glutamax (lnvitrogen, Karlsruhe, Germany) supplemented with
% heat inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/ml
Penicillin/100 ug/ml Streptomycin ex, Cologne, Germany), 1 mM sodium
pyruvate (CC Pro, Oberdorla, Germany), 20 pg/ml ycin (Cambrex). 2.5 ng/ml IL-
7 (PromoCell, Heidelberg, Germany) and 10 U/ml lL-2 (Novartis Pharma, Ntirnberg,
y) were also added to the TCM at this step.
Generation of pMHC/anti-CD28 coated beads, T-cell ations and readout was
performed in a highly defined in vitro system using four different pMHC molecules per
stimulation condition and 8 different pMHC molecules per readout condition.
The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung et al., 1987)
was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommended
by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.6 pm diameter
streptavidin coated polystyrene particles (Bangs Laboratories, Illinois, USA).
pMHC used for positive and negative control stimulations were A*0201/MLA-001
(peptide ELAGIGILTV (SEQ ID NO. 157) from modified Melan-A/MART-1) and
A*0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO. 158), respectively.
800.000 beads / 200 pl were coated in l plates in the presence of 4 x 12.5 ng
different biotin-pMHC, washed and 600 ng biotin anti-CD28 were added subsequently in
a volume of 200 pl. ations were initiated in 96-well plates by ubating 1x106
CD8+ T cells with 2x105 washed coated beads in 200 pl TCM supplemented with 5
ng/ml IL-12 (PromoCell) for 3 days at 37°C. Half of the medium was then exchanged by
fresh TCM supplemented with 80 U/ml IL-2 and ting was ued for 4 days at
37°C. This stimulation cycle was performed for a total of three times. For the pMHC
multimer readout using 8 different pMHC molecules per condition, a two-dimensional
combinatorial coding approach was used as previously described sen et al.,
2012) with minor modifications encompassing coupling to 5 different fluorochromes.
Finally, eric analyses were performed by ng the cells with ead near IR
dye (lnvitrogen, Karlsruhe, Germany), CD8-FITC antibody clone 8K1 (BD, Heidelberg,
y) and fluorescent pMHC multimers. For analysis, a BD LSRII SORP cytometer
equipped with appropriate lasers and filters was used. Peptide specific cells were
calculated as percentage of total CD8+ cells. Evaluation of multimeric analysis was
done using the FlowJo software (Tree Star, Oregon, USA). In vitro g of specific
multimer+ CD8+ lymphocytes was detected by comparing to negative control
stimulations. Immunogenicity for a given antigen was detected if at least one evaluable
in vitro stimulated well of one healthy donor was found to contain a specific CD8+ T-cell
line after in vitro stimulation (i.e. this well contained at least 1% of specific er+
among CD8+ T-cells and the percentage of specific multimer+ cells was at least 10x the
median of the negative control stimulations).
In vitro immunogenicity for head and neck sguamous cell carcinoma peptides
For tested HLA class I peptides, in vitro immunogenicity could be demonstrated by
generation of peptide specific T-cell lines. Exemplary flow try results after
TUMAP-specific multimer staining for 2 peptides of the invention are shown in Figure 3
together with corresponding ve controls. Additional exemplary flow cytometry
results after TUMAP-specific multimer staining for 3 peptides of the invention are shown
in Figure 4 together with ponding negative controls. Results for 17 peptides from
the invention are summarized in Table 10A. Additional results for 17 peptides from the
invention are summarized in Table 108.
Table 10A: in vitro immunogenicity of HLA class I peptides of the invention
Exemplary s of in vitro immunogenicity experiments conducted by the applicant for
the es of the invention. <20 % = +; 20 % - 49 % = ++; 50 % - 69 %= +++; >= 70 %
= ++++
Seq ID No Peptide Code Sequence Wells Donors
98 RAD54B-001 SLYKGLLSV ++ ++++
101 6-001 ESIKL + ++++
105 KRT-010 STYGGGLSV + ++++
108 KRT5-001 SLYNLGGSKRISI + ++++
109 IGFZBP3-001 KIQEILTQV + +++
113 PKP1-002 NLMASQPQL +++ ++++
114 TP6-001 VLVPYEPPQV + ++++
1 18 KRT-006 TLLQEQGTKTV + ++
123 GJB5-001 LLSGDLIFL ++ ++++
127 FHL2—001 SLFGKKYIL ++ ++++
135 DNMT3B-001 GLFSQHFNL + ++
137 LOG-002 GLAPFLLNAV + ++++
143 FAP-003 YVYQNNIYL + ++
145 TMEM222— LLYGKYVSV ++ ++++
Seq ID No Peptide Code Sequence Wells Donors
147 DNMT1-OO1 ILMDPSPEYA +++ ++++
150 NLRP2-001 ILAEEPIYIRV +++ ++++
154 BDH1-001 KMWEELPEW + ++++
Table 10B: In vitro immunogenicity of HLA class I peptides of the ion
Exemplary results of in vitro immunogenicity experiments conducted by the ant for
HLA-A*02 restricted peptides of the invention. Results of in vitro immunogenicity
experiments are indicated. Percentage of positive wells and donors (among evaluable)
are summarized as indicated <20 % = +; 20 % - 49 % = ++; 50 % - 69 %= +++; >= 70
%= ++++
SEQ ID No Sequence Wells positive [%]
1 GLAGGFGGPGFPV +
3 SLYGLGGSKRISI +
8 NVLPV +
TLWPATPPKA +
11 PVI ++
12 TLTDEINFL +
13 SLVSYLDKV ++
16 ALKDSVQRA +
17 SIWPALTQV ++++
18 YLYPDLSRL +
19 ALAKLLPLL ++
YLINEIDRIRA +
26 TLVDENQSWYL ++
28 AVDPVSGSLYV +++
29 RLLPDLDEV ++
TLASLGYAW +++
82 VLDINDNPPV +
EXAMPLE 4
Synthesis of peptides
All peptides were synthesized using standard and well-established solid phase peptide
synthesis using the trategy. Identity and purity of each dual peptide have
WO 37085 2017/071347
been determined by mass spectrometry and analytical RP-HPLC. The peptides were
obtained as white to off-white Iyophilizes (trifluoro acetate salt) in purities of >50%. All
TUMAPs are preferably administered as trifluoro-acetate salts or acetate salts, other
salt-forms are also possible.
EXAMPLE 5
MHC Binding Assays
Candidate peptides for T cell based therapies according to the t invention were
further tested for their MHC binding capacity (affinity). The individual peptide-MHC
complexes were produced by UV-ligand exchange, where a UV-sensitive peptide is
d upon adiation, and exchanged with the peptide of interest as analyzed.
Only peptide candidates that can effectively bind and stabilize the peptide-receptive
MHC les prevent dissociation of the MHC complexes. To determine the yield of
the exchange reaction, an ELISA was performed based on the detection of the light
chain (02m) of stabilized MHC xes. The assay was performed as lly
described in Rodenko et al. (Rodenko et al., 2006).
96 well MAXISorp plates (NUNC) were coated over night with 2ug/ml streptavidin in
PBS at room temperature, washed 4x and blocked for1h at 37°C in 2% BSA containing
blocking buffer. Refolded HLA-A*02:01/MLA-001 monomers served as standards,
covering the range of 15-500 ng/ml. Peptide-MHC rs of the UV-exchange
reaction were diluted 100-fold in blocking buffer. Samples were incubated for 1h at
37°C, washed four times, ted with 2ug/ml HRP conjugated anti-02m for 1h at
37°C, washed again and detected with TMB solution that is stopped with NH2804.
Absorption was measured at 450nm. Candidate peptides that show a high ge
yield (preferably higher than 50%, most preferred higher than 75%) are generally
preferred for a generation and production of antibodies or fragments thereof, and/or T
cell receptors or fragments thereof, as they show sufficient avidity to the MHC
molecules and prevent dissociation of the MHC complexes.
Table 11: MHC class I binding scores. Binding of ass | restricted peptides to
HLA-A*O2:O1 was ranged by peptide ge yield: >10% = +; >20% = ++; >50 = +++;
> 75% = ++++
SEQ ID No Sequence Peptide exchange
1 GLAGGFGGPGFPV ++++
2 PVCPPGGIQEV +++
3 SLYGLGGSKRISI +++
4 ILDINDNPPV +++
VCPPGGIQEV +++
6 ALYDAELSQM +++
7 ALEEANADLEV +++
8 NVLPV ++++
9 STASAITPSV ++
TLWPATPPKA +++
11 VLFSSPPVI ++++
12 TLTDEINFL ++++
13 SLVSYLDKV ++++
14 RIMEGIPTV ++++
SMLNNIINL +++
16 ALKDSVQRA +++
17 SIWPALTQV ++++
18 YLYPDLSRL ++++
19 ALAKLLPLL ++++
YLINEIDRIRA ++++
21 FLHEPFSSV ++++
22 KLPEPCPSTV +++
23 SLPESGLLSV +++
24 LLIAINPQV ++++
SLCPPGGIQEV ++++
26 QSWYL +++
27 YLAEPQWAV ++++
28 AVDPVSGSLW ++++
29 RLLPDLDEV ++++
TLASLGYAW +++
31 HLATVKLLV ++++
32 IQDAEGAIHEV ++++
33 AIYEGVGWNV ++++
34 ALDTFSVQV ++++
ALVGDVILTV ++++
36 GLWSSIFSL ++++
SEQ ID No Sequence Peptide exchange
37 ILLEDVFQL ++++
38 QYV ++++
39 LLPEDDTRDNV +++
40 LLTPLNLQI +++
41 RLNGEGVGQVNISV ++
42 ALYTSGHLL ++++
43 AVLGGKLYV ++++
44 GLGDDSFPI ++++
45 GLIEWLENTV ++++
46 GLISSIEAQL ++++
47 QLLEGELETL +++
48 YLLDYPNNL +++
49 YLWEAHTNI ++++
50 ALSNVVHKV ++++
51 FLIPSIIFA ++++
52 LLFTGLVSGV +++
53 RLVEVGGDVQL ++++
54 RLSGEGVGPV +++
55 VLNVGVAEV +++
56 FLQLETEQV ++++
57 AILGFALSEA ++++
58 SLSDIQPCL +++
59 YLQNEVFGL +++
60 SLGNFKDDLL +++
61 FVAGYIAGV ++++
62 ILSSACYTV ++++
63 ALMDEINFMKM ++++
64 KILEJLFVJL +++
65 PVLL ++++
66 AEL ++++
67 AQLNLIWQL ++++
68 KILEMDDPRA ++
69 YVMESMTYL ++++
70 FLFPAFLTA ++++
71 SLFPYWLI ++++
72 SLDGNPLAV ++++
73 YIDPYKLLPL +++
74 SLTSFLISL +++
75 ALASAPTSV ++++
76 ILFDEVLTFA ++++
SEQ ID No ce Peptide exchange
77 MPI ++
78 VLYGDVEEL +++
79 GLHQDFPSVVL +++
80 GLYGIKDDVFL ++++
81 VLAENPDIFAV +++
82 VLDINDNPPV +++
83 QLLQYWNL ++++
84 ALMAGCIQEA ++++
85 QLIEKITQV +++
86 SLQERQVFL +++
87 ALPEPSPAA +++
88 LMAPAPSTV +++
89 VLDEGLTSV ++++
90 TLNDGVVVQV ++++
91 MLFENMGAYTV ++++
Reference List
Abdel-Ghany, M. et 211., J Biol Chem 276 : 25438-25446
Abdelmagid, S. A. et 211., J Cell Biochem. 112 (2011): 1084-1092
Adhik21ry, G. et 211., PLoS.One. 8 (2013): e84324
Agui21r, R. C. et 211., J Biol Chem 280 (2005): 33756-33765
Ahmed, N. et 211., Biol Chem 397 (2016): 1265-1276
Ai, R. et 211., Gene Expr. 11 (2003): 35-45
Ais21, Y. et 211., Int.J Hem21tol. 82 (2005): 266-269
Aiz21w21, S. et 211., J Oral Sci. 56 (2014): 209-214
Akbari, M. R. et 211., Hum.Genet. 129 (2011): 573-582
Akht21r, Ali M. et 211., Proc.N21tl.Ac21d.Sci.U.S.A 112 : 748
Alberg21ri21, A. et 211., Int.J DeV.Bi0155 (2011): 811-822
Allison, J. P. et 211., Science 270 : 932-933
Alr21Wi, S. J. et 211., Anticancer Res 26 (2006): 107-119
Ammendol21, M. et 211., Biomed.Res Int. 2014 (2014): 154702
Andersen, R. S. et 211., N21t.Protoc. 7 (2012): 891-902
Andersson, L., Cold Spring H21rb.Symp.Qu21nt.Biol 74 (2009): 5
Andersson, L. et 211., Transcription. I (2010): 144-148
Annib211di, A. et 211., PLoS.One. 6 : e29024
Apostolopoulou, M. et 211., PLoS.One. 7 (2012): e33289
App21y, V. et 211., Eur.J Immunol. 36 : 1805-1814
Arif, Q. et 211., Arch.P21thol.L21b Med. 139 (2015): 978-980
Att211121h, A. M. et 211., Tumour.Biol 36 (2015): 7667-7674
B2121k, J. P. et 211., J Clin Pathol. 59 (2006): 1017-1028
Bachmann, S. B. et a1., Mol Cancer 13 (2014): 125
Baglo, Y. et a1., PLoS.One. 8 (2013): e65200
Bailey, C. M. et al., J Cell Physiol 209 (2006): 617-624
Balakrishnan, A. et a1., Genes ChromosomesCancer 45 (2006): 883-892
Baluchamy, S. et al., In Vitro Cell ol Anim 46 (2010): 718-725
Banchereau, J. et al., Cell 106 (2001): 271-274
Bao, L. et al., Cell BiolToxicol. 32 : 419-435
Bar-ShaVit, R. et a1., Methods Cell Biol 132 : 341-358
Barach, Y. S. et a1., Trends Mol.Med 17 (2011): 47-55
Barilli, A. et a1., J Leukoc.Biol 90 (2011): 293-303
Barry, G. S. et a1., Oncotarget. 7 (2016): 18953-18964
Bauml, J. M. et 211., Ther.AdV.Med.Oncol 8 : 168-175
Bausch, D. et a1., Clin Cancer Res 17 (2011): 302-309
Beatty, G. et al., J Immunol 166 (2001): 2276-2282
Beggs, J. D., Nature 275 (1978): 104-109
Benjamini, Y. et a1., l of the Royal Statistical Society.Series B (Methodological), Vol.57
(1995): 289-300
Benzon, B. et a1., Prostate Cancer Prostatic.Dis. (2016)
Binai, N. A. et a1., Endocrine. 44 (2013): 496-503
Blanckaert, V. et a1., Int.J Oncol 46 (2015): 2649-2655
Bongiovanni, L. et a1., Vet.Dermatol. 25 (2014): 138-140
is, N. et a1., EXp.Onc0128 (2006): 187-193
Bottino, C. et a1., Front Immunol. 5 (2014): 56
Bouameur, J. E. et a1., J Invest Dermatol. 134 (2014): 885-894
Boulter, J. M. et a1., Protein Eng 16 (2003): 707-711
Boyero, L. et a1., Int.J Med Sci. 10 (2013): 1166-1173
Braumuller, H. et al., Nature (2013)
Brendle, A. et a1., Carcinogenesis 29 (2008): 1394-1399
Broderick, P. et a1., Cancer Res 69 (2009): 6633-6641
Brosens, R. P. et a1., J Pathol. 221 (2010): 411-424
Brossart, P. et al., Blood 90 (1997): 1594-1599
Bruckdorfer, T. et a1., Curr.Pharm.Biotechnol. 5 (2004): 29-43
Bruna, F. et a1., Stem Cell Res 18 (2017): 5-13
Bryan, R. T., Philos.Trans.R Soc.Lond B Biol Sci. 370 (2015): 20140042
Bryan, R. T. et al., J Urol. 184 (2010): 423-431
Bu, W. et a1., ne 30 (2011): 4399-4409
Bustin, S. A. et a1., DNA Cell Biol 20 (2001): 331-338
Buttner, S. et a1., EMBO J 30 (2011): 2779-2792
Cada, Z. et a1., Histol.Histopathol. 24 (2009): 41-48
a, R. et a1., J Cell Sci. 126 (2013): 1969-1980
Camicia, R. et a1., Mol.Cancer 14 : 207
Campione, E. et a1., Drug Des Devel.Ther. 9 (2015): 5843-5850
Camps, J. et a1., Cancer Res 73 (2013): 2003-2013
Canto, 1. et a1., Mini.ReV Med Chem 12 (2012): 804-811
Card, K. F. et a1., Cancer l Immunother. 53 (2004): 7
, J. B. et a1., Nat Commun. 5 (2014): 3756
WO 37085
Chang, H. H. et al., Cancer 117 (2011): 353-360
Chanock, S. J. et a1., Hum.Irnmunol. 65 (2004): 1211-1223
Chanthammachat, P. et a1., Arch.Oral Biol 58 (2013): 1677-1685
Chen, J. et a1., Int.J Clin EXp.Pathol. 8 (2015): 2026-2032
Chen, L. et a1., Oncotarget. (2016)
Chen, Q. et a1., PLoS.One. 9 (2014): e88386
Chien, A. J. et 211., Breast Cancer Res Treat. 155 (2016): 521-530
Choi, J. R. et a1., Ann.Occup.Environ.Med 28 (2016): 13
Choi, Y. K. et a1., Cancer Genomics Proteomics. 10 (2013): 265-275
Chowdhury, R. et a1., Nature 510 (2014): 422-426
Chuang, J. J. et a1., l.Appl.Pharmacol. 279 (2014): 0
Chung, T. K. et a1., Int.J Cancer 137 (2015): 776-783
Cipolat, S. et a1., E1ife.3 (2014): e01888
Clark, D. L. et al., J Anim Sci. 93 (2015): 2546-2558
Cohen, C. J. et a1., J M01 Recognit. 16 ): 324-332
Cohen, C. J. et a1., J Immunol 170 (2003b): 4349-4361
Cohen, S. N. et a1., Proc.Nat1.Acad.Sci.U.S.A 69 (1972): 2110-2114
Coligan, J. E. et a1., Current Protocols in Protein Science (1995)
Colombetti, S. et a1., J Immunol. 176 : 2730-2738
Corsaro, A. et a1., Oncotarget. 7 (2016): 38638-38657
D'Asti, E. et a1., Thromb.Hemost. 40 : 284-295
Das, M. et a1., PLoS.One. 8 : e69607
Das, M. et a1., Tumour.Biol 36 (2015): 9987-9994
David, G. et a1., Oncogene 25 (2006): 7354-7360
Davies, E. L. et a1., Eur.J Cancer 35 (1999): 902-907
Delgado, A. P. et al., Cancer Genomics Proteomics. 11 (2014): 201-213
Deng, M. et a1., J Biol Chem 284 (2009): 7875-7888
Deng, W. et a1., Ce11PhysiolBiochem. 35 (2015): 688
Deng, Y. et a1., Cancer Invest 31 (2013): 97-102
Dengjel, J. et a1., Clin Cancer Res 12 (2006): 4163-4170
Denkberg, G. et al., J Immunol 171 : 2197-2207
to, D. et al., Nat Genet. 42 (2010): 910-914
Dewar, R. et a1., Arch.Pathol.Lab Med 135 (2011): 422-429
do Prado, R. F. et a1., Oral Surg.Oral Med Oral Pathol.Oral Radiol.Endod. 104 (2007): e40-e44
Dorn, J. et a1., Oncol Lett. 9 (2015): 418-424
, S. et a1., Appl.Immunohistochem.Mol.Morphol. 22 (2014): 537-542
Dou, N. et a1., Am.J Cancer Res 6 (2016): 2641-2650
Drucker, K. L. et a1., BMC.Cancer 15 (2015): 565
Du, L. et a1., Cancer Res 73 (2013): 2682-2694
Dubash, A. D. et a1., J Cell Biol 202 (2013): 653-666
Duggan, M. A., Gan To Kagaku Ryoho 29 Suppl 1 (2002): 176-193
Economopoulou, P. et a1., Ann.Trans1.Med. 4 (2016): 173
Eichler, T. E. et a1., Kidney Int. 90 (2016): 568-579
El-Rifai, W. et al., Cancer Res 62 (2002): 826
E1ste, A. P. et a1., J Mol.Histol. 41 (2010): 89-99
Epp, N. et a1., J Cell Biol 177 (2007): 173-182
Er, T. K. et al., J Mol.Med.(Berl) (2016)
Esteban-Jurado, C. et a1., Eur.J Hum.Genet. 24 (2016): 1501-1505
Ettl, T. et a1., Clin EXp.Med (2016)
Evangelista, M. T. et al., J Cutan.Pathol. 42 (2015): 824-831
Falk, K. et 211., Nature 351 (1991): 290-296
Fan, J. et a1., Clin Cancer Res 17 (2011): 2908-2918
Fang, W. K. et a1., Asian Pac.J Cancer PreV. 15 (2014): 871-876
Fang, W. Y. et a1., Acta Biochim.Biophys.Sin.(Shanghai) 37 (2005): 541-546
Fauci, J. M. et a1., Gynec01.Onc01 127 (2012): 420-425
Montange, M. et a1., Int.J Oncol 35 (2009): 1395-1407
Fijneman, R. J. et a1., Clin Cancer Res 18 (2012): 624
Fong, L. et a1., Proc.Natl.Acad.Sci.U.S.A 98 : 8809-8814
French, J. et a1., Histochem.J 34 (2002): 1
Frohwitter, G. et a1., Oncol Lett. 12 (2016): 107-113
Funakoshi-Tago, M., Yakugaku Zasshi 132 : 1267-1272
Furstenberger, G. et a1., Prostaglandins Other Lipid . 82 (2007): 4
Gabrilovich, D. I. et a1., Nat Med. 2 (1996): 1096-1103
Galoian, K. et a1., Mol.Clin Oncol 3 (2015): 171-178
Gandhi, C. R. et a1., Gastroenterology 148 (2015): 379-391
Gao, W. et a1., BMC.Cancer 15 (2015): 367
Gao, Y. et a1., Di Yi.Jun.Yi.Da.Xue.Xue.Bao. 23 (2003): 885-887
Gao, Y. B. et al., Nat Genet. 46 (2014): 1097-1102
Gattinoni, L. et a1., Nat ReV.Irnmunol 6 : 383-393
Gazda, H. T. et a1., Hum.Mutat. 33 (2012): 1037-1044
Ge, W. et al., Nat Chem Biol 8 (2012): 960-962
Gelfand, R. et a1., Int.J 0 : 49-65
Gemmill, R. M. et a1., Cancer Lett. 300 (2011): 66-78
Giese1er, F. et al., Cell Commun.Signal. 11 (2013): 86
Giguere, A. et al., Cancer Genet.Cytogenet. 202 : 94-100
anatic, S. et a1., Proc Nat1.Acad.Sci.U.S.A 100 (2003): 8862-8867
Godkin, A. et a1., Int.Immun01 9 (1997): 1
Gomez-Morales, M. et a1., Histopathology 63 : 103-113
Gorski, J. J. et a1., Breast Cancer Res Treat. 122 (2010): 721-731
Green, M. R. et al., Molecular Cloning, A Laboratory Manual 4th (2012)
Greenfield, E. A., Antibodies: A Laboratory Manual 2nd (2014)
Grin, A. et a1., Hum.Pathol. 46 (2015): 541-548
Grosset, A. A. et a1., BMC.Cancer 14 (2014): 801
Grosset, A. A. et a1., PLoS.One. 11 (2016): e0166731
Gruber, A. D. et al., Cancer Res 59 (1999): 5488-5491
Gupta, S. K. et a1., Innate.1mmun. 19 (2013): 86-97
Haass, N. K. et a1., Pigment Cell Res 18 (2005): 150-159
Hammam, O. et al., J Soc.Parasitol. 44 (2014): 733-740
Harris, T. M. et a1., Arch.Pathol.Lab Med. 139 (2015): 494-507
Hatina, J. et a1., Neoplasma 59 (2012): 728-736
Hatta, M. et a1., J Obstet.Gynaecol.Res 30 (2004): 53-58
Hayes, D. C. et a1., Anticancer Res 26 (2006): 1567-1575
He, C. S. et al., Cell l Biochem. 40 (2016): 1221-1229
He, X. et al., Int.J Biol Macromol. 72 : 089
Heidenreich, B. et al., Curr.Opin.Genet.DeV. 24 (2014): 30-37
Heikinheimo, K. et al., J Dent.Res 86 (2007): 544-549
heimo, K. et al., J Dent.Res 94 (2015): 101-111
Herold-Mende, C. et al., Cell Tissue Res 306 (2001): 399-408
Higareda-Almaraz, J. C. et 211., BMC.Cancer 16 (2016): 680
Hoadley, K. A. eta1., PLOS.Med 13 (2016): e1002174
Honrado, E. et al., Crit Rev Oncol Hematol. 59 (2006): 27-39
Horiguchi, K. et al., Oncogene 31 (2012): 3190-3201
Hu, J. et al., Int.J Clin EXp.Pathol. 8 (2015): 9182-9188
Huang, Y. P. et al., icine.(Taipei) 6 (2016): 3
Huang, Y. Z. et al., Sci.Rep. 4 (2014): 4570
Huber, A. R. et al., BMC.Gastroenterol. 15 (2015): 80
Hwang, M. L. et al., J Immunol. 179 (2007): 5829-5838
Hwang, Y. S. et al., J Cancer Prev. 20 (2015): 121-128
Ida-Yonemochi, H. et al., Mod.Pathol. 25 (2012): 784-794
Iino, I. et al., Cancer Sci. 104 (2013): 624-630
Inamura, K. et al., Lung Cancer 103 (2017): 44-51
Ioana, M. et al., J Gastrointestin.Liver Dis. 19 (2010): 155-159
Iorns, E. et al., Breast Cancer Res Treat. 135 (2012): 79-91
Ishii, H. eta1., J Biol Chem 289 (2014): 27386-27399
Ishimi, Y. eta1., J Biochem. 157 (2015): 561-569
Janakiram, M. et al., Discov Med 14 (2012): 229-236
Janakiram, M. et al., Immunotherapy 8 (2016): 809-819
Jiang, L. eta1., ne. 9 (2014): e94187
Jiang, M. M. et al., uo Shi Yan.Xue.Ye.Xue.Za Zhi. 21 (2013): 9
Jiang, R. et al., J Biol Chem 286 (2011): 9127-9135
Jiang, Y. et al., Oncol Lett. 10 (2015): 3826-3831
Johnson, R. H. et al., Oncotarget. (2015)
Joosse, S. A. et al., Clin Cancer Res 18 (2012): 993-1003
Jung, G. eta1., Proc Natl Acad Sci U S A 84 (1987): 615
Jurcic, V. et al., Histol.Histopathol. 30 (2015): 945-953
Juszczynski, P. eta1., Mol.Ce11 Biol 26 (2006): 5348-5359
, D. K. et al., Biochim.Biophys.Acta 1414 (1998): 75-84
Kan, T. et al., Oncology 70 (2006): 25-33
Kaplun, A. et al., Crit ReV ot.Gene Expr. 22 (2012): 249-258
Kasthuri, R. S. et al., J Clin Onc0127 (2009): 4834-4838
Katada, K. et al., J Proteomics. 75 (2012): 1803-1815
Katoh, M., Int.J Oncol 41 (2012): 1913-1918
Kawakami, K. et al., Int.J Oncol (2015)
Kaz, A. M. et al., Genes Chromosomes.Cancer 51 (2012): 384-393
Kedde, M. et al., Cell Cycle 7 (2008): 899-903
en, E. et al., Cancer Genet.Cytogenet. 149 (2004): 98-106
Kibbe, A. H., Handbook of Pharmaceutical Excipients rd (2000)
Kim, H. J. et al., Anticancer Res 33 (2013): 1555-1561
Kim, K. et a1., Int.J ctal Dis. 23 (2008a): 569-580
Kim, K. H. et a1., Nucleic Acids Res 43 (2015): 7462-7479
Kim, S. W. et al., Blood 111 (2008b): 1644-1653
Kim, T. W. et a1., Oncotarget. (2016)
Kim, Y. H. et a1., Ann.Surg.Oncol 18 (2011): 2338-2347
Kinyamu, H. K. et a1., Mol.Carcinog 47 (2008): 845-885
Kishikawa, T. et a1., Oncotarget. 6 (2015): 8339-8352
Kitchen, M. O. et a1., etics. 11 (2016): 237-246
Klawitter, J. et a1., Breast Cancer Res 12 (2010): R16
Knudsen, K. A. et al., J Cell m. 95 (2005): 488-496
Koba, S. et 211., Am.J Dermatopathol. 37 (2015): e31-e36
Kobos, R. et al., J Pathol. 229 (2013): 743-754
Koc, E. C. et a1., Mitochondrion. 24 : 113-121
Kocaturk, B. et a1., Thromb.Res 129 Suppl 1 (2012): S69-S75
Kocaturk, B. et al., J Thromb.Haemost. 11 Suppl 1 (2013): 285-293
Kohn, K. W. et a1., PLOS.One. 9 : e99269
Kolin, D. L. et a1., Biol Chem 395 (2014): 1087-1093
Koringa, P. G. et a1., Vet.Comp Oncol (2013)
Krepischi, A. C. et a1., Breast Cancer Res 14 : R24
Krieg, A. M., Nat ReV.Drug Discov. 5 (2006): 471-484
Kwok, H. F. et a1., Am.J Cancer Res 5 (2015): 52-71
Kwon, J. et a1., Int J Oncol43 (2013): 1523-1530
, M. et a1., PLOS.One. 10 (2015): e0131307
Labrie, M. et a1., rget. 5 (2014): 7705-7721
Lee, D. J. et al., Cancer Biol Ther. 10 (2010): 689-693
Lee, D. M. et a1., Environ.Toxicol.Pharmacol. 34 (2012): 858-868
Lee, J. Y. et a1., Carcinogenesis 30 (2009): 1528-1531
Lee, K. Y. et al., J Med. 35 (2004): 9
Leiserson, M. D. et a1., Genome Biol 16 (2015): 160
Leiserson, M. D. et a1., Genome Biol 17 (2016): 168
Leung, F. et al., Cancer Epidemiol.Biomarkers PreV. 25 (2016): 1333-1340
Leung, J. et a1., Immune.NetW. 14 (2014): 265-276
Lexander, H. et a1., Anal.Quant.Cytol.Histol. 27 (2005): 263-272
Li, J. et a1., Chin Med J (Engl.) 122 (2009): 486-495
Li, J. 2. et a1., Chin Med.J (Engl.) 121 (2008): 1882-1890
Li, L. et a1., Asian Pac.J Cancer PreV. 13 (2012a): 3265-3270
Li, T. et a1., EXp.Dermatol. 24 (2015): 342-348
Li, W. Q. et a1., Carcinogenesis 34 (2013): 1536-1542
Li, X. et a1., Oncogene 23 (2004): 1474-1480
Li, X. et a1., Biochem.Biophys.Res Commun. 419 (2012b): 148-153
Li, Y. et al., J Cell Physi01212 (2007): 675-681
Lian, M. et a1., PLoS.One. 8 (2013): e84854
Liddy, N. et al., Nat Med. 18 (2012): 980-987
Lim, L. C. et a1., Pathol.Oncol Res 22 (2016): 7
Lima, L. G. et a1., Biosci.Rep. 33 (2013)
Lin, C. S. et al., Cancer Lett. 368 (2015): 36-45
Lin, H. S. et a1., Arch.Otolaryngol.Head Neck Surg. 130 (2004): 311-316
Lion, M. et al., Cell Cycle 12 (2013): 1211-1224
Liu, C. L. et a1., Eur.ReV Med Pharmacol.Sci. 20 (2016): 4466-4473
Liu, D. Q. et a1., Sci.Rep. 5 (2015): 11955
Liu, J. et a1., J Biochem. 148 (2010): 659-667
Liu, Y. et a1., Oncol Rep. 18 (2007): 943-951
Ljunggren, H. G. et a1., J EXp.Med. 162 (1985): 1745-1759
Llorente, A. et al., J Cell Sci. 117 (2004): 5343-5351
Lo, W. Y. et a1., J Proteomics. 77 (2012): 154-166
Lonardo, F. et 211., Curr.Pharm.Des 16 (2010): 1877-1881
Longenecker, B. M. et a1., Ann N.Y.Acad.Sci. 690 : 276-291
Lonsdale, J., Nat.Genet. 45 (2013): 580-585
Loos, M. et a1., C1in DeV.Immunol. 2010 (2010): 683875
Low, K. C. et a1., Trends Biochem.Sci. 38 (2013): 426-434
Lu, J. J. et a1., Chin J Nat Med. 13 (201521): 673-679
Lu, Y. et a1., BMC.Mol.Biol 16 (2015b): 21
Lu, Y. et a1., PLOS.One. 8 (2013): e73866
, B. et a1., J Biol Chem 270 (1995): 11549-11554
Lucito, R. et a1., Cancer Biol Ther. 6 (2007): 1592-1599
Lukas, T. J. et a1., Proc.Nat1.Acad.Sci.U.S.A 78 (1981): 2791-2795
Lundblad, R. L., al Reagents for Protein Modification 3rd (2004)
Luo, D. et a1., Biochem.Biophys.Res Commun. (2016)
, N. et a1., Acta Oncol 39 (2000): 931-934
Vlaerki, S. et a1., J Cell Biol 187 (2009): 791-800
Vlan, Y. et a1., Tohoku J EXp.Med 234 (2014): 29-40
Vlange, A. et al., J Proteomics. 142 (2016): 114-121
Vlarech, I. et a1., World J Gastroenterol. 20 (2014): 8910-8920
Vlarioni, G. et a1., Acta Otolaryngol. 129 (2009): 0
Vlarkljung, E. et a1., PLoS.Biol 7 (2009): 56
Vlarshall, P. A. et al., J d Biochem.Mol.Biol 132 (2012): 147-159
Vlartinez, O. et a1., PLOS.One. 5 (2010): e10398
Vlasugi, Y. et a1., Lab Invest 95 : 308-319
Vlatin, S. F. et a1., Urol.Oncol 32 (2014): 309-316
moto, K. et a1., Biomed.Res 35 (2014): 201-206
Vlatsuzaka, K. et a1., Bull.Tokyo Dent.Coll. 45 (2004): 229-233
Vchoniels-Silvers, A. L. et a1., Clin Cancer Res 8 (2002): 1127-1138
Vlei, Z. Z. et a1., J Biol Chem 291 : 18176-18189
Vlelaiu, O. et a1., Res 771 (2015): 6-12
Vleschenmoser, K. et a1., In Vivo 27 (2013): 431-442
n, F. et a1., Cancer Res 67 (2007): 10910-10919
Vlessina, M. et al., Blood 123 (2014): 2378-2388
Vleziere, C. et a1., J Immunol 159 (1997): 3230-3237
Vlin, L. et a1., Histopathology 67 (2015): 677-688
Vlisago, N. et al., J Dermatol. 43 (2016): 439-442
Vlitchell, S. M. et a1., ncer 14 (2014): 54
Vllacki, M. et a1., PLOS.One. 9 (2014): e89247
VIorgan, P. R. et a1., Eur.J Cancer B Oral Oncol 30B (1994): 6
Vlorgan, R. A. et al., Science 314 (2006): 126-129
Vlori, M. et a1., Transplantation 64 (1997): 1017-1027
VIorris, L. G. et a1., Nat Genet. 45 (2013): 253-261
VIorris, M. R. et a1., Oncogene 30 (2011): 1390-1401
Vlortara, L. et a1., Clin Cancer Res. 12 (2006): 3435-3443
VloskVina, L. V. et a1., Arkh.Patol. 72 (2010): 58-61
Vlountzios, G. et a1., Ann.Onc0125 : 1889-1900
VIueller, L. N. et a1., J Proteome.Res 7 (2008): 51-61
VIueller, L. N. et a1., Proteomics. 7 (2007): 3470-3480
Vlumberg, D. et a1., Proc.Nat1.Acad.Sci.U.S.A 96 (1999): 8633-8638
VIuramatsu, T. et a1., Oral Oncol 39 (2003): 199-203
Vlussai, F. et al., Blood 125 (2015): 2386-2396
Vlyklebust, M. P. et a1., Br.J Cancer 106 (2012): 756-762
\aeem, A. S. et a1., Ce11Death.Differ. 22 (2015): 2123-2132
\agappan, A. et a1., BMC.Biochem. 14 (2013): 24
\agata, M. et a1., PLoS.One. 9 (2014): e93164
\arayanan, B. A., Curr.Cancer Drug Targets. 6 (2006): 711-727
wa, Y. et al., J Dermatol. 42 (2015): 445-452
\ational Cancer Institute, (52015), www.cancergov
\atsuga, K. et al., J Invest Dermatol. (2015)
\atsuga, K. et a1., J Invest Dermatol. 136 (2016): 99-106
\eumann, M. et al., Blood 121 : 4749-4752
\orth, J. P. et a1., Am.J Surg.Pathol. 39 : 1347-1356
\ovak, B. et a1., Naunyn Schmiedebergs Arch.Pharmacol. 384 : 583-602
\ygren, M. K. et a1., Front Biosci.(E1ite.Ed) 3 (2011): 989-993
Oeh1er, V. G. et a1., Blood 114 (2009): 3292-3298
Oh, H. R. et a1., Cell Oncol (Dordr.) 37 : 455-461
Oi, N. et a1., Oncogene 34 (2015): 2660-2671
Oikonomopoulou, K. et a1., Biol Chem 391 : 0
Ormanns, S. et a1., Br.J Cancer 113 (2015): 1460-1466
, T. et a1., Cancer Med 4 (2015): 5
Palacios, J. et a1., Pathobiology 75 : 85-94
Papagerakis, S. et a1., Hum.Pathol. 34 (2003): 565-572
Paparella, M. L. et al., J Oral Pathol.Med 44 (2015): 801-809
Paredes, J. et a1., Breast Cancer Res 9 (2007): 214
s, J. et a1., Biochim.Biophys.Acta 1826 (2012): 297-311
Park, J. Y. et a1., Oncotarget. 6 (2015a): 5342-5353
Park, Y. H. et a1., Int.J Cancer 136 (2015b): 1976-1984
a, P. M. et a1., Org.Biomol.Chem. 12 (2014): 1804-1811
Perrin, C. et a1., Am.J Dermatopathol. 33 (2011): 131-139
Persson, F. et a1., Cancer Lett. 260 (2008): 37-47
Pickering, C. R. et a1., Clin Cancer Res 20 (2014): 592
Pierce, A. et a1., Mol.Ce11Proteomics. 7 (2008): 853-863
Pigullo, S. et a1., Pediatr.Blood Cancer 52 (2009): 376-378
ro, J. et a1., nlme: Linear and Nonlinear Mixed Effects Models (http://CRAN.R-
proj g/packe=n1me) (2015)
Piura, B. et a1., Harefuah 144 (2005): 261-5, 303, 302
ski, M. et a1., Eur.J Immun0125 (1995): 1783-1787
Poligone, B. et 211., J Invest Dermatol. 135 (2015): 869-876
Polotskaia, A. et a1., Proc.Natl.Acad.Sci.U.S.A 112 (2015): E1220-E1229
Pondugula, S. et a1., M01.Ce11 Biol 29 (2009): 4891-4905
Porta, C. et a1., Virology 202 : 949-955
Preisz, K. et a1., OrV.Hetil. 148 (2007): 979-983
Probst, C. et a1., Clin Chim.Acta 410 (2009): 13-18
Qiu, S. et a1., Cancer Sci. (2016)
Qu, T. et a1., Mol.Med Rep. 14 (2016): 5041-5048
, T. et al., Cancer Res 71 (2011): 1356-1361
Ramakrishna, S. et a1., ne. 7 (2012): e37772
Ramakrishna, S. et al., J Biol Chem 286 (2011): 10505-10514
, D. et a1., Clin Nutr. 33 (2014): 14-22
Ramani, V. C. et a1., BMC.Cancer 8 (2008): 373
Ramena, G. et a1., PLoS.One. 11 : e0147489
Rammensee, H. et a1., Immunogenetics 50 (1999): 213-219
Rashid, R. et a1., 11 21 (2006): 249-260
Rastelli, F. et a1., Tumori 96 (2010): 875-888
Ratovitski, E. A., FEBS Lett. 587 (2013): 3581-3586
RefSeq, The NCBI handbook net], Chapter 18
, (2 002),
http://WWW.ncbi.n1m.nih.gov/books/NBK21091/
Remmelink, M. et a1., Histopathology 58 (2011): 543-556
Resende, C. et a1., Helicobacter. 16 Suppl 1 (2011): 38-44
Reyes, C. et a1., App1.Immunohistochem.Mo1.Morphol. 21 (2013): 283-286
Ribeiro, A. S. et a1., Front Oncol 4 (2014): 371
Riker, A. I. et a1., BMC.Med Genomics 1 (2008): 13
Rini, B. I. et a1., Cancer 107 (2006): 67-74
Rock, K. L. et a1., Science 249 (1990): 918-921
Rohan, S. et a1., Clin Cancer Res 12 (2006): 6937-6945
Rohrbeck, A. et a1., PLoS.One. 4 (2009): e7315
Rooney, M. S. et a1., Cell 160 (2015): 48-61
Rotmann, A. et a1., Biochem.J 395 (2006): 117-123
Rotty, J. D. et a1., J Cell Biol 197 (2012): 381-389
Ruf, W., Thromb.Res 130 Suppl 1 (2012): S84-S87
Ruf, W. et a1., J Thromb.Haemost. 9 Suppl 1 (2011): 306-315
Rui, X. et a1., Int.J Clin EXp.Pathol. 8 (2015): 5435-5442
Saaber, F. et a1., Pathol.Res Pract. 211 (2015): 208-213
Sabeti, S. et a1., Indian J Dermatol. 58 (2013): 331-336
Safadi, R. A. et a1., Oral Surg.Oral Med.Oral .Oral Radiol. 121 (2016): 402-411
Sager, R. et a1., Curr.Top.Microbiol.Immunol. 213 ( Pt 1) (1996): 51-64
Saiki, R. K. et a1., Science 239 : 487-491
Salas, S. et a1., Int.J Cancer 125 (2009): 0
Saletta, F. et a1., BBA.Clin 1 (2014): 59-77
Sanchez-Palencia, A. et al., Int.J Cancer 129 (2011): 355-364
Sasaki, Y. et al., Cancer BiolTher. 13 (2012): 1512-1521
Sato, T. et al., ne 33 : 2215-2224
Sauer, H. et al., Free Radic.Biol Med 27 : 283
Sawada, K. et al., J Oral Sci. 58 (2016): 325-331
Schmitt-Graeff, A. et al., Histopathology 51 (2007): 87-97
Schrader, C. H. et al., M01.Cancer 14 (2015): 107
Schulten, R. et al., Naunyn Schmiedebergs harmacol. 385 (2012): 969-979
Schumann, H. et al., Br.J Dermatol. 167 (2012): 929-936
Scola, N. et al., Br.J Dermatol. 167 : 591-597
Seal, S. et al., Cancer Res 63 (2003): 8596-8599
Sedda, S. et al., World J Gastroenterol. 20 (2014): 11977-11984
, F. H. et al., Immunogenetics 49 (1999): 571-576
Seishima, M. et al., Arch.Dermatol. 140 (2004): 1500-1503
Sellheyer, K., J Cutan.Pathol. 42 (2015): 90-101
Sharifi, N. et al., Prostate 67 (2007): 1
Shen, M. et al., Environ.Mol.Mutagen 50 (2009): 285-290
Shen, X. eta1., Tumour.Biol 36 (2015): 7133-7142
Sheng, S., Front Biosci. 9 (2004): 2733-2745
Sherman, F. et al., Laboratory Course Manual for Methods in Yeast Genetics (1986)
Shi, L. eta1., ncer 16 (2016): 815
Shim, J. H. et al., Cancer PreV.Res (Phila) 3 (2010): 670-679
Shimbo, T. et al., PLoS.One. 5 (2010): e10566
Shinmura, K. et al., Dis.Markers 2014 (2014): 619273
Shruthi, D. K. et al., J Oral Maxillofac.Pathol. 18 (2014): 365-371
Sidiropoulos, K. G. et al., Mol.Onc0110 (2016): 993-1007
Silveira, A. C. et al., Cancer Lett. 276 (2009): 32-37
Jasuja, H. et al., Cancer Immunol.Immunother. 53 (2004): 187-195
Sinha, N. et al., Oral Oncol 49 (2013): 854-862
Sivanathan, L. et al., Prostate 74 (2014): 537-546
Sizemore, G. M. eta1., J Biol Chem 289 (2014): 24102-24113
rth, R. J. et al., Int.J Oncol 36 (2010): 973-982
Slaga, T. J. et al., Prog.Clin Biol Res 391 (1995): 1-20
Small, E. J. et al., J Clin Oncol. 24 (2006): 094
Smith, K. T. et al., Mol.Cell Proteomics. 11 (2012): 1815-1828
Sobolik-Delmaire, T. et al., Cell Commun.Adhes. 14 (2007): 99-109
Solus, J. F. et al., Int.J Surg.Pathol. 24 (2016): 29-36
Somasekharan, S. P. et al., J Cell Biol 208 (2015): 913-929
Song, B. et al., EXp.Ther.Med 12 (2016): 2455-2468
Soreide, K. et al., J Pathol. 209 (2006): 6
Southgate, J. et al., Histol.Histopathol. 14 (1999): 657-664
Sturm, M. et al., BMC.Bioinformatics. 9 (2008): 163
Sun, B. C. et al., Zhonghua Yi.Xue.Za Zhi. 86 : 1808-1812
Sun, L. eta1., Mol.Med Rep. 12 (2015a): 4266-4272
Sun, N. K. et al., Oncotarget. 6 (2015b): 27065-27082
Sun, S. et al., Gene 584 (2016): 90-96
Suzuki, A. et al., Cancer Sci. 99 (2008): 986-994
Swatler, J. et a1., Postepy Hig.Med Dosw.(Online.) 70 (2016): 25-42
Swoboda, R. K. et al., Cancer Res 67 (2007): 3555-3559
Tai, G. et 211., PLoS.One. 8 (2013): e81167
Taintor, A. R. et a1., J Am.Acad.Dermatol. 56 (2007): S73-S76
Tamir, A. et al., J Ovarian.Res 7 (2014): 109
osenstein, K. et a1., PLoS.One. 8 (2013): e68907
Tang, B. et a1., rget. 6 (201521): 12723-12739
Tang, H. B. et a1., Zhonghua Yi.Xue.Za Zhi. 88 (2008): 1553-1556
Tang, X. H. et a1., Oncotarget. 6 (2015b): 24424-24435
Taniguchi, T. et al., Nat Med 9 (2003): 568-574
Taoka, Y. et a1., Biomed.Res 36 (2015): 253-261
Tauber, S. et a1., Mol.Cancer 9 (2010): 200
Teles, Alves, I et a1., Oncogene 34 (2015): 568-577
baum, T. et a1., J Investig.Dermatol.Symp.Proc. 1 (1996): 157-161
Teo, C. R. et al., Cell Signal. 28 (2016): 488
Terada, T., Int.J C1in EXp.Pathol. 5 (2012): 596-600
, R. et al., Cell M01 Life Sci. 62 (2005): 1755-1762
Tian, S. Y. et a1., Int.J C1in EXp.Pathol. 7 (2014): 3752-3762
Timar, J. et a1., C1in tastasis 27 : 371-387
Tomlinson, R. L. et a1., Mol.Biol Cell 19 (2008): 800
Tonoike, Y. et a1., BMC.Ce11 Biol 12 (2011): 41
Tran, E. et al., Science 344 (2014): 641-645
Trojandt, S. et a1., Humlmmunol. 77 (2016): 1223-1231
Tsuji, A. B. et a1., Biochem.Bi0phys.Res Commun. 333 (2005): 1370-1377
Tsutsui, M. et a1., Int.J Oncol 47 (2015): 867-874
Ueda, S. et al., Cancer Res 64 (2004): 5672-5676
Vadie, N. et a1., RNA.Biol 12 : 893-899
Vakrakou, A. et a1., Biol Chem 395 (2014): 1105-1117
Valletta, D. et a1., Carcinogenesis 35 (2014): 1407-1415
Vanaja, D. K. et a1., Cancer Res 63 : 3877-3882
Vasca, V. et a1., Oncol Lett. 8 (2014): 2501-2504
Vieira, A. F. et a1., Mol.Cancer 14 : 178
Vigneswaran, N. et a1., Oral ofac.Surg.Clin North Am. 26 (2014): 1
Vliet-Gregg, P. A. et a1., Virology 478 (2015): 50-60
Volkmer, J. P. et a1., Proc.Natl.Acad.Sci.U.S.A 109 (2012): 2078-2083
Walia, V. et a1., Cancer Res 69 (2009): 6624-6632
Walia, V. et a1., Oncogene 31 (2012): 2237-2246
Walter, S. et al., J Immunol 171 (2003): 4974-4978
Walter, S. et al., Nat Med. 18 (2012): 1254-1261
Wang, J. et a1., Br.J Dermatol. 153 (2005): 558-564
Wang, L. et al., J Cutan.Pathol. 42 (2015a): 361-367
Wang, L. et a1., Int.J Cancer 134 (2014a): 771
Wang, L. et a1., TumourBiol 37 (2016a): 14939-14947
Wang, M. et a1., EXp.Dermatol. 23 (2014b): 636-638
Wang, S. et a1., Cytokine 86 (2016b): 110-118
Wang, X. et al., Oncotarget. 7 (2016c): 22911-22927
Wang, X. et al., Proc.Nat1.Acad.Sci.U.S.A 110 (2013): 15997-16002
Wang, X. et al., Mol.Cell Biol 27 (2007): 3098-3108
Wang, X. et 211., Eur.J Pharmacol. 768 (2015b): 116-122
Wang, X. et al., Sci.Rep. 6 (2016d): 19006
Wang, X. et al., Int.J Biol Markers 29 (2014c): e150-e159
Wang, Z. S. et al., Oncotarget. 7 (2016e): 44266-44276
Ward, A. M. et al., RNA.Biol8 (2011): 1173-1186
be, T. et al., Cancer Cell Int. 10 (2010): 2
Wheler, J. J. et al., BMC.Cancer 15 (2015): 442
Willcox, B. E. et al., Protein Sci. 8 (1999): 2418-2423
Willers, I. M. et al., Biochim.Biophys.Acta 1807 (2011): 543-551
Williams, L. M. et al., Aquat.Toxicol. 180 (2016): 141-154
Willis, S. et al., Meta Gene 4 (2015): 129-141
w, S. et al., Mol.Cancer 12 (2013): 156
Witte, D. et al., J Clin Med 5 (2016)
Wojtalewicz, N. et al., PLoS.One. 9 (2014): e90461
Wojtukiewicz, M. Z. et al., Cancer Metastasis Rev 34 (2015): 775-796
Wong, M. P. et al., Pathology 40 : 611-616
World Health Organization, (2014), http. ://WWW.Who.int/en/
Wreesmann, V. B. et a1., ORL J Otorhinolaryngol.Re1at Spec. 69 (2007): 218-225
Wu, S. et al., Oncotarget. (2016)
Xi, Y. et al., Monoclon.Antib.Immunodiagn.lmmunother. 34 (2015): 346-353
Xie, C. eta1., Sci.Rep. 6 (2016a): 27528
Xie, X. et a1., Obesity.(Si1ver.Spring) 24 ): 389-397
Xin, Z. et al., Virchows Arch. 465 (2014): 35-47
Xu, C. eta1., PLoS.Genet. 9 (2013): e1003169
Xu, X. et a1., Proteomics. 10 (2010): 1374-1390
Xue, L. Y. et al., Zhonghua Zhong.Liu Za Zhi. 32 : 838-844
YadaV, R. eta1., J Neurochem. 133 (2015): 857-869
chi, T. et al., EXp.Dermatol. 22 (2013): 840-842
Yamazaki, K., Ultrastruct.Pathol. 31 (2007): 9
Yang, C. et al., Tumour.Biol (2015)
Yang, F. et al., Biomed.Rep. 4 (2016a): 6
Yang, H. Y. et al., J Proteomics. 75 ): 3639-3653
Yang, J. et a1., Curr.Opin.Onc0125 (2013): 398-406
Yang, L. et a1., Carcinogenesis 33 (2012b): 1863-1870
Yang, L. eta1., J Biol Chem 291 (2016b): 3905-3917
Ye, Z. eta1., Cell Physiol Biochem. 39 : 1568-1580
Yermachenko, A. et al., Gene 590 : 85-89
Yi, K. H. et al., ImmunolReV 229 (2009): 145-151
Yi, Y. et a1., Mol.Cytogenet. 2 (2009): 18
Yong, A. A. et al., Australas.J Dermatol. 54 (2013): 241-250
n Zhang, M. M. et al., J Cancer Res Ther. 9 (2013): 660-663
Yu, X. J. et a1., EBioMedicine 2 (2015a): 0
Yu, Y. et al., ACS Appl.Mater.Interfaces. 7 (2015b): 4401-4405
Yu, Y. et a1., PLoS.One. 8 (2013): e83943
Yun, C. W. et a1., Anticancer Res 36 (2016): 4449-4458
a, S. et a1., Cancer Res. 57 (1997): 4570-4577
Zdrojewicz, Z. et 211., Postepy d Dosw.(On1ine.) 68 (2014): 393-403
Zekri, A. R. et a1., Asian Pac.J Cancer PreV. 16 (2015): 3543-3549
Zhang, H. et a1., Oncotarget. 6 (2015): 17039-17053
Zhang, Q. et a1., Endocrinology 143 (2002): 4788-4796
Zhang, S. et a1., J M01.Histol. 45 (2014a): 283-292
Zhang, W. et a1., Tumori 100 (2014b): 338-345
Zhang, Y. et a1., PLoS.One. 7 (2012): e30188
Zhao, L. H. et a1., Genet.Mol.Res 14 (2015): 5417-5426
Zhao, L. J. et a1., Chin Med.J (Eng1.) 126 (2013): 4260-4264
Zhao, S. et a1., C1in Cancer Res 23 (2017): 9
Zheng, G. et a1., FEBS J 277 (2010): 4506-4518
Zhou, L. et a1., Int.J Cancer 135 (2014): 2329-2337
Zhou, P. et a1., Eur.J Cancer PreV. 21 (2012): 231-240
Zhou, X. et a1., Oncotarget. 7 (2016): 67196-67211
Zhu, X. et a1., J Dermatol. 34 (2007): 503-511
Zhu, Y. et a1., M01.Bi01 Ce1115 (2004): 81-90
Ziari, K. et a1., Biologicals 43 (2015): 181-185
Ziegler, A. et a1., Cancer Lett. 326 (2012): 1-7
Zimmermann, J. et a1., J Dtsch.Dermatol.Ges. 8 (2010): 598-606
Zubor, P. et a1., M01.Biol.Rep. 42 : 977-988
Claims (3)
1. A peptide comprising an amino acid sequence set forth in SEQ ID No. 3, or a variant sequence thereof which is at least 88% homologous to SEQ ID No. 3, wherein said variant binds to molecule(s) of the major histocompatibility complex (MHC) and/or induces T cells cross-reacting with said variant peptide; and a pharmaceutical acceptable salt thereof, wherein said peptide is not the full-length polypeptide.
2. The peptide or variant thereof according to claim 1, wherein said peptide or variant f has an l length up to 100, or up to 30, or up to 16 amino acids, or wherein the peptide consists or ts essentially of an amino acid sequence according to SEQ ID No. 3. 3. The peptide or variant thereof ing to claim 1 or claim 2, wherein said peptide is modified and/or includes non-peptide bonds, or wherein said peptide is part of a fusion protein, or part of a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 4. An antibody, or a soluble antibody, or a membrane-bound antibody, that specifically recognizes the e or variant thereof according to any one of claims 1 to 3, or recognizes the peptide or variant thereof according to any one of claims 1 or 2 when bound to an MHC molecule. 5. A T-cell receptor, or a soluble T-cell receptor, or a membrane-bound T-cell receptor, that is reactive with an HLA ligand, wherein said ligand has at least 75%, or at least 88% ty to an amino acid ce set forth in SEQ ID No. 3, or wherein said ligand has an amino acid sequence consisting of SEQ ID No. 6. The soluble T-cell receptor ing to claim 5y carrying a further effector function, an immune ating domain, or a toxin. 7. An aptamer that specifically recognizes the peptide or variant thereof according to any one of claims 1 to 3, or recognizes the peptide or variant thereof according to any one of claims 1 to 2 that is bound to an MHC molecule. 8. An isolated nucleic acid, encoding for the peptide or variant thereof according to any one of claims 1 to 3, the antibody according to claim 4, the TCR according to claim 5 or 6, or an aptamer according to claim 7, or an expression vector expressing said nucleic acid. 9. A recombinant host cell, or a recombinant antigen presenting cell, or a recombinant dendritic cell, or a recombinant T cell or a recombinant NK cell, comprising the peptide or variant according to any one of claims 1 to 3, or the nucleic acid or the expression vector according to claim 8, wherein the cell is not a cell within a human body. 10. The peptide or variant thereof according to any one of claims 1 to 3, the antibody according to claim 4, the TCR according to claim 5 or 6, the aptamer according to claim 7, the nucleic acid or the sion vector according to claim 8, or a cell ing to claim 9 for use in medicine. 11. A method for producing the peptide or variant thereof according to any one of claims 1 to 3, the antibody ing to claim 4, or the TCR according to claim 5 or 6, said method comprising culturing a cell according to claim 9 expressing the nucleic acid or the expression vector ing to claim 8, and isolating the peptide or variant thereof, the antibody, or the TCR from the cell or its culture medium. 12. An in vitro method for producing activated T lymphocytes, the method comprising contacting in vitro T cyte with antigen loaded human class I or II MHC les expressed on the surface of a suitable antigen-presenting cell or an cial construct ing an antigen-presenting cell for a period of time sufficient to activate said T lymphocyte in an antigen ic manner, wherein said n is a peptide according to any one of claims 1 or 2. 13. An activated T lymphocyte, produced by the method according to claim 12, that selectively recognizes a cell presenting a polypeptide comprising an amino acid sequence as given in claim 1 or claim 2. 14. Use of an effective number of activated T lymphocytes as defined in claim 13 in the manufacture of a medicament for killing target cells, which target cells present a polypeptide comprising an amino acid sequence according to any one of claims 1 or 2. 15. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of: a) a peptide of SEQ ID No. 3 or a salt thereof; b) a T-cell receptor reactive with a peptide according to a) and/or a complex of a peptide according to a) with an MHC molecule ; c) a fusion protein comprising a peptide according to a), and the N-terminal amino acids 1 to 80 of the HLA-DR antigen-associated invariant chain (Ii); d) an isolated nucleic acid ng for any one of a) to c) or an expression vector comprising said nucleic acid, e) a host cell comprising the nucleic acid or expression vector of d), wherein the host cell is not a cell inside a human body, f) an activated T-lymphocyte, obtained by a method comprising ting in vitro a T-lymphocyte with a e according to a) sed on the surface of a suitable antigen presenting cell for a period of time sufficient to activate said T-lymphocyte in an antigen specific manner; g) an antibody, or soluble T-cell receptor, ve to a peptide according to a) and/or a x of a peptide according to a) with a MHC molecule and/or a cell presenting a peptide according to a), h) a fusion protein comprising an antibody, or soluble T-cell receptor according to g), i) a fusion protein according to h) comprising an -activating domain or a toxin, j) an aptamer izing a e of SEQ ID No. 3 and/or a complex of a peptide of SEQ ID No. 3 with a MHC molecule, k) a conjugated or labelled peptide, or T-cell receptor, or dy, or fusion protein, or r according to any one of a) to c) or g) to j), the pharmaceutical composition further comprising one or more of: a ceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable stabilizer. 16. The pharmaceutical composition according to claim 15, n (i) the pharmaceutical composition further ses one or more adjuvants, and/or (ii) the pharmaceutical ition is a vaccine or a cellular therapeutic agent. 17. The pharmaceutical composition according to claim 16, wherein the one or more adjuvants are selected from: a) an eukin; b) an immunoadjuvant; c) IL-2; and/or d) IL-15. 18. Use of the peptide according to any one of claims 1 to 3, the antibody according to claim 4, the TCR according to claim 5 or 6, the activated T lymphocyte according to claim 13, the nucleic acid or the expression vector according to claim 8, or a cell according to claim 9, in the in vitro diagnosis of cancer, or in the manufacture of a medicament against cancer,. 19. The use according to claim 18, wherein the cancer is selected from the group of: head and neck us cell carcinoma, acute myelogenous leukemia, breast cancer, bile duct cancer, brain cancer, chronic lymphocytic leukemia, colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian , pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer, urinary bladder cancer, uterine cancer and other tumors that show an pression of a n from which a peptide ing to SEQ ID No. 3 is derived from. 20. A kit comprising: a) a container comprising a pharmaceutical composition comprising a peptide or the t according to any one of claims 1 to 3, the antibody according to claim 4, the TCR according to claim 5 or 6, the activated T lymphocyte according to claim 13, the nucleic acid or the expression vector according to claim 8, or a cell according to claim 9, in solution or in lyophilized form. 21. The kit according to claim 20, further comprising one or more of: b) a second container containing a diluent or reconstituting solution for the lyophilized formulation; c) at least one more peptide selected from the group consisting of: SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 4 to SEQ ID No. 156; d) instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation; e) a ; f) a diluent; g) a filter; h) a needle; i) a syringe; or j) an adjuvant. 22. The kit ing to claim 21, wherein the one or more peptides of c) are selected from the group consisting of: SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 4 to SEQ ID No. 91. 23. A method for producing a personalized anti-cancer vaccine or a compoundbased and/or ar therapy for an individual patient, said method comprising: a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from said individual patient; b) comparing the peptides as identified in a) with a warehouse of peptides that have been pre-screened for immunogenicity and/or resentation in tumors as compared to normal tissues; c) selecting at least one peptide from the use that matches a TUMAP identified in the patient; and d) manufacturing and/or formulating the personalized vaccine or ndbased or cellular therapy based on step c), wherein said warehouse comprises at least a peptide according to SEQ ID No. 24. The method according to claim 23, wherein said TUMAPs are identified based on the steps comprising: a1) comparing sion data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or ntly expressed in the tumor sample; and a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC s d from ns over-expressed or aberrantly expressed by the tumor. 25. The method according to claim 23 or 24, wherein the peptides included in the warehouse are identified based on the following steps: aa. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by highly parallel methods, comprising identify genes that pressed in a malignant tissue, compared with a normal tissue or tissues; ab. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step aa; and ac. Determining an induction of in vivo T-cell responses by the peptides as selected comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient; or ba. Identifying HLA ligands from said tumor sample using mass spectrometry; bb. Performing genome-wide messenger ribonucleic acid (mRNA) sion analysis by highly parallel methods, comprising identify genes that overexpressed in a malignant tissue, compared with a normal tissue or tissues; bc. ing the identified HLA ligands to said gene expression data; bd. Selecting peptides encoded by selectively expressed or over-expressed genes as ed in step bc; be. Re-detecting of selected TUMAPs from step bd on tumor tissue and lack of or infrequent detection on healthy tissues and confirming the relevance of overexpression at the mRNA level; and bf. ining an induction of in vivo T-cell responses by the peptides as ed comprising in vitro immunogenicity assays using human T cells from healthy donors or said patient. 26. The method according to claim 25, wherein the genome-wide messenger ribonucleic acid (mRNA) expression analysis at steps aa) and bb) is performed by microarrays or sequencing-based expression profiling. 27. The method according to any one of claims 22 to 26, further sing identifying at least one mutation that is unique to the tumor sample relative to normal corresponding tissue from the individual patient, and selecting a peptide that correlates with the mutation for inclusion in the vaccine or for the generation of cellular therapies. m.“ wwwz: a m. a“ & “fig,“ £m§w ,3 aw kgfifia gaggfifim gfigfifi gwax mgfimxma m z h mwgfiam £3 mw gxgfisfigggg E“ Qmwamfififi ”3E3? *fifiwégwmta €33 $2“ Mgafiwfism w mm ES,» 2., fiugfi ”mgfifi £3333 qgwgfix 3 «$3 n.“ Efixgwfig ”$wa Sazmfi ”323 .3. £§§ w “33% gamgwgsg 5.?me “3335 £53 9% ”figwgmw a amkfimwfififim mm w ”mafia?“ gmwafig 3, Eugwfimwfim m” gym»: “$33 ”3% m @3333 Emfiawmm a gmagaamm away: 2“ 33S§ 33$“ saggy a fiamgfi m w 353% 3 : 435,“ ”92 89%? a m: mg a £533 an?” ‘afiggfi “3&3 5 ”Egg 6% 93m: {figfifi afijfiwfi gaézgzwsmg magggag mum 932$ m H a,“ w @533 ghmafi gfigfiw “maugéfim “mgatgfi £23» fififixa m 3, m, ““33”? gag gfififiam mafigmsgmifia mm, msggfigégfi «gamwmfifi M.“ figag £33 wag” w «63%, mm ”wwgmw 33%
3. qfiwwwgfi gmgw ,3 a “gmfi ,3“ng $.33 M.“ gfimfia & fig figgfiyga «333% ”flywfis fig “33¢me Ammgni H fgwgmmfim mm m ‘mfiwagx £33m w. $333 $.23va “33 m @3333 ggaggmw “mmmxmwwflwfim w .3 w ‘ngaame *wggmc “33%“ 333% *mflmwmm» NH £53K @ m Egg: 3 ngawg ”mag“ ”$2 39%? m, m” 3% w aafimwfi gag” gauggfia xmfiwfi 3 ”$23?” fimm 93m: {$sz msggzvl fifiémnasaéa @3393 m m a w flmsmfii , ma gmfifiw mm ”Eggga §§$§§ $9»me 3&3“..me m ,«N m, Saga“ 33 gawwgéggfiag ma 3” gmgmwflwwxm “figggcwfiga $3“ fi 3 $3“? £3: gag hm .mfiggmm mafia mfivwvfia mm gapgfia mm £3 .33w .3 Wigwam»: fififia Eafififiga 3 “£33 a 3 figmwmfifi $333 fig», w £3 *ifiugfimww “mgggga “335% a m.“ «w £§§¥3 amév gammfiw m. .fiwmgg Emfig £th m $3333 «flywwfim afiamfim w gagging» wmwim: ,3 vfififi wwgfiw *ammiawwa m a,” m ”wwmmmmu mafia: 3 xfifiwa m «méxfi we: ggfim ”gig a“ mg m gaging «3&3 gawcwgma mugfiwu UH 3% 8%: Egan méaaév} fifiézezaragma wwzaa i§i§él§zz§a§§p§i;§3§§a§égagggéaifixiééaiyziiziiiczéiaaiisiiiziiggsi;§%iz§%§§§z§z§§l§z¥i§_5a;§§z§§a¥§§§iiga§as}:g335§§2§§§§a§<§.§§§.32 §§§ $33 mam égfigg Agwmfim mgag» N fiafiafi “mfiggmg Egfifimfi N w w, gmhggu Kawag $33 £335. 39:3 M Egamagn» mtmggfifi $3me “$330. a $35, ‘wgwfi figgfi gaggnfix Eafiwa “33““ q 3 ffigg $33» $523 gag $3,.“ m, mgfigfi m, ‘wngg m. ”$353 gym agé figuggg a a fififixfi $553 éfifiqi aééaészzgigiiiiiqgiiii ”Egg: g wgfix wummmmw «gawk; gfifié a vmfiugg» m, Q “32 , 3mm” my ”whwwcg “3% 533$ m5 3 .3 §§235.§M mafimm awmfig mgm, 333% guy: $3 93m: gm {33m wfiifififi} wag-3mm wzma E5322 §£2€2 932; 32222: i‘ 333?: 3922‘: .333 £3213 53222 22.22 gvaw 22222) *Ezsvasa E: L22: 3i} £225.59 M323322 25.25 12-2321 23:22) 23122 51%? Wynn 212.221 $338 $1232?) 3:22;: 825 3:: {222.222 3345:) 8E25§ 38:1 get} :33} GEN} T23 22222) a 33:2 22222 g 3222;; ,,,,, 222:2...................523253 22,2222.“ swam 232;: mafia; 22,213 52:52: {3:29 322122523223 “252 (iii) 2: 22212332122; E20 m 5% 735.2222) gags g ......................................................... 1W???................. 52.29”” 21 2223122 23.523 g 2292;22222 25L{3 g 22:23qu 22222:: E (32222QO 1129 :2: gamma gm) g 222;”3122232 2:22:22: 5 222222 2222:: g 2322222122235 12:3 '3 Eemajd 2230 & 5522212: 9213 2%;{1’221823 3:523 522223322222 23:£3 x : 9222} (:3 N7 32% * Earéfimg 2:222) ‘31: 22mm 12.22:: w 253%?ng §L2) > 2224225 .553 LU 222 £223 (3 33 £22) g yafigtmw {52,} g v29 x2522 Q” E 2222mm 12,22) :1. a E222292222§ 2.223 (.3 N 3:; $222322? 63% ::> g . 32529225232 ............... 22,2122“, CL C) $221 E3522 21.3 E 2222:: $2222 «5) 222324: £2.20 E Q : 32; 025% ”‘5: (j 9: 222222202222 92223 1E 3.: 1.24 <12 gamwmq {322,222 Figure a, m § § [mun fizaflwv} 2209332133923 9222191233 Magma; 2232:3335: WO 37085 33?: 9 E 5%} Wgm £3 m 3§73§ @336 313%! £236 223% 13539 ‘S’ZNé 38 if?! EVBSCE £2 £5? 1:30 22.50 313515} ”am: 1332::952$: “239% 3;, M1! WWQEMH “95: M}: 393'»: 33393 3333?) 8561 3:} 3mm 53393 $255.58 Est: 9913 $33 394253 31:? j: if {1* g 3:333 2150 g $333 3 m .......................................................... ‘3???.................. 325%.. , Efiifijéfifi 15 1:3 Efimfiq: 33.55 35:39:53; 333mg fi gzazsma 3 3;;{3 ‘Efi vaumegd 3:3 33;) g @9520 ~G€34 33350 , ........................................................ gig???................. 2:133 39233;: ‘gg‘g PKPE 1:23am}; 6 LED mesanmtmn $2959qu {1:53 3541:13me 1 £33} 3393:3221 a we :u;”;}§w’$ {13.31} 1311513 3:31.59 :nw my; f’wticfie 1; m} émam We 31mm} gm Eva} 3:53) égmmd gm 3:333an 33} a a) GMQU 39 iii) 333:9g- umom 313:9:333:23 'gzm 5% PMmy???” 9 L! 1 Egaww£1358 fiéasa 3; 35g} T§ $13.39P 5% ; wsgmsa 3; m: 15 a 33:59a3% 3356 E ggé‘uagm 33;sz v a NO ‘23ij ID ~§ 333933: E gym {32m 55* gsmatfififim 5—; {if} 1F Pepfide SEQ (I {gtmtmm 333m Figure § 35» [53am } uofiawasam aagwiaa ’3 Mamba}; namalasp £33111 igzsé a: fins33:1 Sifi 332a £2ifi yam _6Effi Pagevgw sasa »£Lsa if}? :30 £333 Q 3133» Qéi£ “mm 535a 33w izaga W533224» 1:: W W 9:33 ”as: 41339 $56 . 3?} ‘38:) {Samar £933 i “am 733%} ask magma: muayata "I Law 3525;) ? 3" ........................................................ “‘3?qu i .. .. [3333323 fiaqwal mama: nmwntaam ' ufivmms g @3532: wrwems gnu: “gags i’emém "await: igmifi 3,13,:in Emmma E sigmaasm ;_am;su (A*02) ’ i553 gufafimg 253%??pr 1:11;?5 GUEWLENTV 3A3 27431353 @fiezguw ’Aafima 45 Madman; ES}? 91:6 gfimag}? w i NO Pepfide fD arm: aaésq SEQ High asaagmagq T E swmm 16 a» Figure {5mm Masggqsy; {sagmwasaigg 39539133 E Maar‘ébaj; gamma? Cancer 0 $3153“: {£19k mmcs mamas: Law Mega fiTWGG-fi 33:32am gggagr}................. $319933 prewnsafiw g; qwmms @3365 213:”iwws Pemide was 133; gamagd éemwmfi (A332) , affix: 'éauws xaaaggaag (15395 FALSEA $5353 535943132} Mk 53% Jafifififi 57 12329 93% AILG Msdiam {$133}??? NO: euomwxnua;wma’»watunbiA¢»&¥Isv§iw-ka‘t»¢xaakv¥:a~»rnwnn~ .-*...u‘x,...; ........ Pepfide: ID rim sswmagsz 1H SEQ @4833; summit: :9 {3&5 3 Figure <3 {sigma Aseniqsfi magzmuasaxg 83:12:93 ! Awaahm; uamamfi 33?} Eflk 1 32$: 5 E 3; 333 Fags;Egygga 3:33;; «we VS‘v‘é s :59 §¥3§Q £ {:1 ’ 39 E351 WW D‘EDSN 292352 "MN {325%} ‘339? 4:1 is??? WWW-W 233m“ {$1553A {5&7 33% 3:33 kg; iv gr; gm WWW;W$D 8E5? 3:333 9558 311:) §Epzizs 33:3 5}: £559 g 313:} § was [Law3 :51. .............................. ,,,,,,,,,,,,,,,,,,,,,,,,,,,, my................... €23,233“ Esmam @593 maxim} #750 45mm mm fi 9319591113 E; g 3‘ {3 :1 mamas i 2 £3 i might: imamaes ”3 €639 .............. ~1???%9................. €5.59.” my; :3“? mm; Esta; Wm: 53 E 5:: fim awmms 5;; Egg} § naggfig “gm guywzwa mm mm: 2 we Emu! “2323 am Pemiae 333mm {may :smsd 95:3 magi % gig asngwc} é 3:3 swawé game amaz: gag; 53’? 2:59 (A*92) £31 35 9 g 1236 £57.} ii??? SLSDIQPCL 35%} § 2 {5%} g :53? 58 g @5123 ......................................................... may o s NO gait; $2355 ID ~35; LE » [035:3 E £53fi§¢9$§ 9 E 5% (am, fizsazpamc; $3239 1| Pepfide SEQ, a» 2% ea 3 as
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016115974.3 | 2016-08-26 | ||
US62/379,864 | 2016-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ791720A true NZ791720A (en) | 2022-08-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10130693B2 (en) | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
US20160250307A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
AU2018250464A1 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
US11123370B2 (en) | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
US20220339272A1 (en) | Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
NZ791720A (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
NZ791721A (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |